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Hepatocyte transplantation has been used to treat liver disease.  The availability of cells for these 
procedures is quite limited.  hESCs and hiPSCs may be a useful source of hepatocytes for basic 
research and transplantation if efficient and effective differentiation protocols were developed 
and problems with tumorigenicity could be overcome.  Recent evidence suggests that the cell of 
origin may affect hiPSC differentiation. Thus, hiPSCs generated from hepatocytes may 
differentiate back to hepatocytes more efficiently than hiPSCs from other cell types. We 
examined the efficiency of reprogramming adult and fetal human hepatocytes.  The present 
studies report the generation of 40 hiPSC lines from primary human hepatocytes under feeder-
free conditions (37 from fetal hepatocytes, 2 from normal adult hepatocytes and 1 from adult 
hepatocytes of a patient with Crigler-Najjar Syndrome, Type-1).  All lines were confirmed 
reprogrammed and expressed markers of pluripotency by gene expression, flow cytometry, 
immunofluorescence, and teratoma formation. Fetal hepatocytes were reprogrammed at a 
frequency over 50-fold higher than adult hepatocytes. Adult hepatocytes were only 
reprogrammed with 6 factors, while fetal hepatocytes could be reprogrammed with 3 or 4 factors. 
The increased reprogramming efficiency of fetal cells was not due to increased transduction 
efficiency or vector toxicity.  
We also report the transplantation and differentiation of human fetal hepatocyte-derived 
iPSCs. We show preliminary data that undifferentiated cells can engraft in mouse livers of FRG 
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and NOD/SCID mice. Engraftment was based on human DNA presence in liver tissue. 
Furthermore we differentiated these cells to definitive endoderm and transplanted them to FRG 
mice. Human DNA and human albumin were present in mouse livers and mouse serum 
respectively. Finally, full hepatic differentiation was performed, although we show limited 
results in terms of the cells’ ability to express liver specific genes and perform liver-specific 
metabolism. Taken together, these studies confirm that hiPSCs can be generated from adult and 
fetal hepatocytes, including those with genetic diseases, and differentiated back to the hepatocyte 
lineage. Fetal hepatocytes reprogram much more efficiently than adult, although both could serve 
as useful sources of hiPSC-derived hepatocytes for basic research or transplantation if an 
efficient hepatic differentiation protocol could be developed. 
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 1 
1.0  INTRODUCTION 
1.1 GENERAL LIVER BACKGROUND 
The liver is one of the largest, most complex organs in the human body and is essential for life. It 
is located below the diaphragm within the abdominal pelvic region of the abdomen and weighs 
approximately 1500-1800 grams. It is made up of a spongy mass of wedge-shaped lobes [1]. 
Functions of the liver include, but are not limited to: processing of carbohydrates, fats, and 
proteins, vitamin storage, detoxification of substances in the blood, metabolism, protein 
synthesis, glycogen storage, decomposition of red blood cells, plasma protein synthesis, clotting 
factor synthesis, hormone production, bile production and it regulates high volume biochemical 
reactions (synthesis and breakdown) of complex molecules necessary for normal physiology and 
homeostasis [1, 2]. 
The liver receives blood inflow from the portal vein and hepatic artery. This arterial and 
venous blood mix together and travel through the specialized liver sinusoids perfusing the entire 
organ with blood that eventually will drain into the hepatic vein. The hepatic sinusoids perfuse 
the liver with both oxygen-rich blood from the hepatic artery and venous blood from the portal 
vein. The portal vein inflow blood has already circulated through the gut, pancreas, spleen and 
other associated organs and is enriched with toxins and other substances needed to be handled by 
the specialized cells of the liver for normal body physiology to occur. 
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The different lobes of the human liver consist of parenchymal cells known as hepatocytes 
and various non-parenchymal cells. Hepatocytes make up 80% of the total liver volume whereas 
non-parenchymal cells only make up 6.5%; however 40% of the cells within the liver are of the 
non-parenchymal type [2]. The walls of the hepatic sinusoid are lined by the following non-
parenchymal cells: sinusoidal endothelial cells (SECs), Kupffer cells (KCs), hepatic stellate cells 
(HSCs) and intrahepatic lymphocytes (IHLs) such as pit cells. Under both normal and 
pathological conditions there is cross-talk between both hepatocytes and their non-parenchymal 
cell counterparts through paracrine effects that influence cell behavior and function within the 
liver microenvironment [2]. 
SECs line the specialized hepatic sinusoid and their major function is to filter the blood 
that perfuses the entire liver. SECs have specialized fenestrations that allow free diffusion of 
blood to the surfaces of hepatocytes allowing the parenchymal cells to perform their various 
functions to maintain normal body physiology [2]. 
KCs are liver tissue specific macrophages that have strong endocytic and phagocytic 
abilities. They secrete potent mediators of the inflammatory response and therefore play an 
important role in early phase liver inflammation and innate immune defense [2].  
HSCs are characterized by their intracytoplasmic fat droplets and well-branched 
cytoplasmic processes. Under normal liver conditions HSCs store vitamin A, control turnover of 
liver ECM and regulate sinusoidal contractility and therefore sinusoidal blood flow. When liver 
damage occurs quiescent HSCs transform to myofibroblast-like cells that play a major role in the 
development of liver fibrosis and eventually cirrhosis [2]. 
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1.2 ORTHOTOPIC LIVER TRANSPLANTATION 
The first experimental trials of auxiliary liver transplantation occurred in homotransplantation 
canine models in 1956 by Goodrich and colleagues [3]. These successful trials laid the 
groundwork for the first clinical liver transplant in humans to be performed by Thomas E. Starzl 
in 1963 at the University of Pittsburgh [4]. The report described orthotopic liver transplant 
(OLT) in 3 patients, one of which died on the operating table (patient 1) and the other two 
survived 22 and 7.5 days respectively with their grafts (patients 2 and 3). Patient 1 was a 3 year 
old white male with congenital biliary atresia, patients 2 was a 48 year old African American 
male with Laenne’s cirrhosis and a primary hepatoma and patient 3 was a 67 year old white male 
with progressive jaundice and an intrahepatic duct cell carcinoma. Long term survival in these 
studies was limited by the lack of an effective immunosuppressive drug. In 1983 the 
development of immunosuppressive drug azathioprine allowed OLT to become an established 
treatment for hepatic failure [5]. The introduction of cyclosporine and FK506 a few years later 
further solidified the procedure in the medical community [5]. Table 1 summarizes the liver 
diseases currently treated by OLT in the United States. 
 
Table 1. Summary of the Liver Diseases Currently Treated by OLT 
Table adapted from the OPTN/SRTR 2010 Annual Data Report [6]. 
 
Liver Diseases Treated by OLT 
Non-cholestatic Cirrhosis 
Cholestatic Liver Disease/Cirrhosis 
Biliary Atresia 
Acute Hepatic Necrosis 
 4 
Metabolic Diseases: 
Wilson’s Disease, Hemochromatosis-Hemosiderosis, Tyrosinemia, Primary Oxalosis, 
Glycogen Storage Diseases, Hyperlipidemia, Crigler-Najjar Syndrome, Carbamoyl Phosphate 
Synthase Type-1 Deficiency, Ornithine Transcarbamylase Deficiency, Clotting Factor 
Deficiencies, Familial Hypercholesterolemia, Infantile Refsum’s Disease, Progressive 
Familial Intrahepatic Cholestasis, Argininosuccinate Lyase Deficiency, Citrullinemia 
Malignant Neoplasms 
Other: 
Cystic Fibrosis, Budd-Chiari Syndrome, Neonatal Hepatitis, Congenital Hepatic 
Fibrosis, Graft vs. Host Disease, Chronic or Acute Liver Failure, Benign Tumor 
 
 
Since the initial 3 OLT surgeries, there has been significant advancement in surgical 
techniques, immunosuppression and overall patient management to the point where OLT is a 
routine procedure, albeit with the potential complications and risks associated with a whole 
organ transplant. Currently, the only curative therapy for acute and chronic liver failure and 
inborn errors in metabolism is OLT. There are three different types of OLT surgeries practiced in 
the United States today: whole liver, reduced liver and liver segment [1]. Whole liver transplants 
involve removing a patient’s entire liver and replacing it with a whole liver from an organ donor, 
first performed in 1963 [4]. Since the liver is known to regenerate in vivo, surgeons speculated 
that smaller patients could be transplanted with organs that could be tailored made in size to the 
patients and have the graft grow with patients as they grow. This observation led to the 
establishment of the following two liver transplant techniques. Reduced liver transplants are 
performed when the surgeon makes a donor liver smaller for the recipient, first performed in 
1984 [7]. And finally liver segment transplants are surgeries that allow one cadaveric donor liver 
to transplant two patients, first performed in 1989 and 1990 [8, 9]. Liver segment transplants can 
also occur with living donor donations as well. Since partial transplantation of the liver to treat 
patients is possible it seems likely that cell transplantation may also be possible, if issues with 
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engraftment, proliferation of the graft, immunosuppression and patient management are 
overcome. Cells can be given to patients with liver failure to allow for metabolic support and 
potential liver failure reversal. Cells can also be given to patients with inborn errors in 
metabolism because transplanted cells will be competent in the enzyme or protein that is 
deficient in the patient with the metabolic disorder. 
1.3 CELL TRANSPLANT AS A POTENTIAL THERAPY – REASONS FOR 
DEVELOPMENT 
An important question that needs to be answered is whether or not cell transplant, either primary-
cell or stem cell-based, is a viable therapy to treat liver disease.  The need for cellular transplant 
to become a viable therapy to treat liver diseases is obvious. According to the most recent annual 
report performed by the Organ Procurement and Transplantation Network (OPTN) and the 
Scientific Registry of Transplant Recipients (SRTR), in 2009 there were almost 26,000 people 
on the liver transplant waiting list and only a total of 6,320 OLTs performed (Figure 1) [6]. This 
resulted in 1,723 deaths on the waitlist and 15,682 people on the waitlist at year’s end (Figure1) 
[6]. 
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Figure 1. Orthotopic Liver Transplant Data, 2000-2009 
Number of total patients on the liver transplant waitlist (blue), number of patients on waitlist at year end 
(red), number of patient deaths on waitlist (green) and total patients transplanted (purple) from 2000-2009. 
Reproduced from the OPTN/SRTR Annual Report. 
 
 
Over the course of the past 10 years of collated data, one can see a trend that is 
continuing. The total number of patients requiring a transplant is staying stagnant and so is the 
number of total transplants being performed. This is due to the lack of donor livers available for 
transplant. In order to transplant more patients an alternative source of liver tissue is necessary. 
When a surgeon performs an OLT there is one donor liver for one patient (in most cases). If 
cellular transplant can be used to treat patients there can be 1 donor for many recipients, 
depending on the number of cells necessary to treat the patient and the overall viable cell yield 
from the isolation. Furthermore, one can increase the amount of tissue used for transplant if cells 
can be isolated from liver tissues that are normally discarded. Therefore one can identify liver 
diseases that can be managed or cured by cellular transplant and treat those patients with cells 
and leave the whole organ transplants solely for diseases that can only be treated by OLT. This 
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would greatly reduce the burden on the liver transplant waiting list and allow surgeons to 
decrease the number of patients on the waitlist while increasing the number of total transplants 
performed. Also, if cell transplant can be shown to manage patient symptoms for certain 
underlying liver pathologies requiring an OLT, these patients can be given cells as a “bridge to 
transplant” and be sustained until an organ becomes available for OLT. This procedure would 
reduce the number of deaths on the transplant waitlist. Moreover, with the emerging fields of 
human adult stem cell, human embryonic stem cell (hESC) and human induced pluripotent stem 
cell (hiPSC) research there is the possibility of alternative cell sources to treat liver diseases, 
which would further reduce the burden on the liver transplant waiting list. 
Although OLT is a routine procedure, it still is a major surgery with a high incidence of 
surgical complications (graft vs. host disease, ischemia/reperfusion injury, graft failure, etc.). 
Furthermore the expenses associated with the surgery and therapies to maintain the graft for the 
life of a patient are extremely high. To compound issues further, there are limited donors and the 
timing of the transplant is critical. In contrast, cell transplantation is less invasive and less costly 
with fewer complications and risks associated with the procedure. Moreover, cryopreserved cells 
can be made available on demand from cell banks with cell expansion possible to treat a greater 
number of patients with the same amount of donor tissue. New cell sources for liver tissue to 
transplant are also becoming a reality with the discovery of different stem cells (hESCs, hiPSCs 
and adult stem cells) and the ability to turn these cells into hepatocyte-like cells. These 
alternative cell sources would solve the problem of the shortage of donor liver tissue to isolate 
primary hepatocytes from. Taken together this information shows the need to investigate if 
cellular transplantation to treat different liver diseases is possible. Table 2 summarizes the 
benefits of cell transplantation over OLT. 
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Table 2. Benefits of Cell Transplantation over OLT 
Adapted from Dhawan et al. [5]. 
 
OLT Cell Tx 
One or two patients maximum per one 
donor liver 
Multiple patients can be treated from one donor 
liver 
Major surgery Less invasive surgery compared to OLT 
Organs have to be immediately 
transplanted 
Hepatocytes can be cryopreserved for long term 
storage and transplantation on demand 
Graft failure is life threatening Graft failure reverts patient to pre-transplantation 
state; not immediately life threatening 
Native liver removed Native liver remains, allowing for its potential 
recovery 
Curative treatment, but requires patient to 
be on life-long immunosuppression (in 
most cases) 
Patients can be potentially weaned off 
immunosuppression if methods become available 
 
1.4 PRIMARY HEPATOCYTE TRANSPLANT RESEARCH – FROM TISSUES TO 
CELLS IN ANIMAL MODELS 
In 1964 investigators performed the first heterotopic partial autotransplantation of pieces of rat 
livers [10]. This crude liver graft was demonstrated to have structure and function when 
transplanted to the kidney capsule or subcutaneous space. This idea of transplanting pieces of 
liver was further solidified to be viable when sliced rat liver tissue was autologously transplanted 
into rats subcutaneously [11]. These autografts were approximately 1/10 of the original size and 
found alive in subcutaneous tissue 1 year after transplant. Partial hepatectomy was performed on 
the rats prior to transplantation to see if this would increase the size of the graft, however this did 
not lead to an increase at the end of the 1 year study.  Therefore if pieces of liver can be 
transplanted and shown to have function why can’t cells be transplanted and function as well? 
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Two important studies that paved the way for hepatocyte transplants becoming a potential 
reality to treat liver diseases occurred in the pancreas and diabetes field. In 1967 a method for the 
isolation of intact islet of Langerhans from rat pancreas was reported [12] and then in 1972 these 
rat islets were transplanted into diabetic rats [13]. This cell transplant improved blood glucose 
levels though intraperitoneal or subcutaneous injection of the cells, thus demonstrating that 
transplanted cells can function within a recipient. Now a procedure to isolate viable hepatocytes 
needed to be discovered in order for the hepatocyte transplant field to push forward. This was 
accomplished in 1969 by Berry and Friend, who described a high-yield preparation of isolated 
rat liver parenchymal cells using a collagenase perfusion method [14]. Since then this procedure 
has been refined and optimized with human tissue. Gramignoli and colleagues have developed a 
purified tissue dissociation enzyme mixture for the isolation of human hepatocytes where the 
isolated cells can be used in a clinical transplantation setting [15]. 
Now that it is possible to isolate highly viable and functioning human hepatocytes, 
researchers need to demonstrate that the isolated cells can be transplanted into liver metabolic 
disease animal models and function enough to improve blood chemistries and overall symptoms 
associated with disease. In 1970 cells from a clonal strain of a rat hepatoma were transplanted 
subcutaneously into Gunn rats that are deficient in the UGT1A1 enzyme [16]. This enzyme 
deficiency causes animals to become hyperbilirubinemic and subsequently jaundiced. The Gunn 
rat models CN-1 in humans, which is characterized by the inability to metabolize bilirubin. 
Bilirubin forms in the blood serum through the metabolism of heme oxygenases released by the 
breakdown of hemoglobin in old erythrocytes or any other cells that contain hemoproteins. 
Patients suffering from this disorder experience altered senses, incoordination, slurring of 
speech, weakness, brain damage and possible coma due to high amounts of unconjugated 
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bilirubin in the blood serum. Although the cells transplanted were not hepatocytes, they had been 
previously shown to metabolize bilirubin in vitro [17] and were readily available. This was the 
first report to demonstrate transplanted cells can provide metabolic support, in this case helping 
to reduce bilirubin levels in rats modeling a known human metabolic disease. Matas and 
colleagues further developed this research in the CN-1 rat model by transplanting mechanically 
isolated liver fragments and demonstrating that they too reduce bilirubin levels in blood serum 
[18]. Finally in 1977 the first actual hepatocyte transplant occurred when investigators took 
isolated rat hepatocytes and transplanted them via the portal vein into the Gunn rat [19]. They 
were able to show correction of hyperbilirubinemia. More specifically, they observed a 21% 
decrease in bilirubin levels at day 10 with a maximum reduction of 35% at day 28. An important 
caveat of this experiment was the usage of immunosuppression through the administration of 
cyclophosphamide, which allowed the graft to stabilize within the recipient. 
Further evidence that cell transplantation can be used to treat metabolic disease occurred 
when cryopreserved human hepatocytes were attached to collagen-coated microcarriers and 
injected IP into athymic-UGT1A1 deficient Gunn rats and athymic-analbuminemic Nagase rats 
[20]. These Nagase rats are deficient in albumin synthesis. Animals were made athymic in order 
to be deficient in T-cells to help with stabilization of the graft. Cells formed aggregates on the 
surface of the pancreas. Gunn rats excreted bilirubin glucuronides (conjugated bilirubins) in bile 
for 30 days and overall serum bilirubin levels were reduced. Nagase rats had plasma albumin 
levels increased from a low of 0.024 mg/ml to a high of 4.8 mg/ml 8 days post transplant and 
remained near this high level for the duration of the 30 day experiment. This study was one of 
the first to demonstrate that human cells have the ability to engraft after transplant and function 
metabolically. More importantly this study demonstrated that when you transplant 1-2% liver 
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mass you get a 15 fold increase in albumin and when you transplant 2-4% you elevate it 60%. 1-
2% engraftment does not equal 1-2% increase in albumin synthesis. Therefore a large amount of 
cellular engraftment is not needed to get a large effect and reversal of pathology and symptoms. 
This observation is extremely important because it demonstrates that a large supply of viable 
hepatocytes is unnecessary if issues with engraftment and graft stability can be overcome. 
A study performed on the Eizai hyperbilirubinemic rat, which models the human Dubin-
Johnson Syndrome, demonstrated that transplanted fully competent rat hepatocytes can engraft 
and successfully integrate with the hepato-biliary system. These rats have impaired canalicular 
excretory transport of organic anions, bile acid glucuronides and sulfate conjugates therefore 
causing conjugated hyperbilirubinemia. Animals were treated with intraportal injections of wild 
type rat hepatocytes along with a 68% partial hepatectomy to promote hepatic proliferation in 
vivo. This therapy resulted in reduction of serum bilirubin level and bile excretion became 
possible demonstrated by biliary transport of indocyanine and sulfobromophthalein into bile. 
Furthermore it shows that hepatic transport of bile acid conjugates can be restored by hepatocyte 
transplant. Additionally, it is a second report that showed only a transplant of 1-2% of liver mass 
results in a 50% reduction in bilirubin levels. It appears that one does not need large engraftment 
to make a major physiological impact within the transplant recipient. 
Multi-locational allogenic hepatocyte transplant for the treatment of ascorbic acid 
deficiency in rats was shown to be possible [21]. Cells were transplanted in the portal vein, 
spleen omentum and mesentery. Ascorbic acid was found in the serum of recipients up to 3 
months after transplant. This report demonstrates that transplanted hepatocytes do not need to 
engraft into the liver architecture to provide metabolic support. 
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Further evidence that hepatocyte transplant is a viable method to treat liver metabolic 
disease occurred when investigators corrected a mouse model of progressive familial intrahepatic 
cholestasis type-3 (PFIC-3) [22]. Patients that have PFIC-3 have a mutation in the MDR3 gene 
that encodes the hepatocanalicular phospholipid translocator that results in the absence of 
phospholipids in the bile. This absence causes chronic bile salt-induced damage to hepatocytes 
and bile duct epithelium. The mdr2-knockout mouse is the animal model for the human disease. 
Transplanted mdr2-competent hepatocytes repopulated the liver and were shown to restore 
phospholipid secretion and diminish liver pathology. More importantly, liver engraftment was 
shown to be enhanced by administering a high cholate diet to further intensify the liver damage. 
The thought here is that enhancing liver damage will give the transplanted cells more room to 
engraft in the liver. However, the animals given a high cholate diet developed multiple hepatic 
tumors and biliary phospholipid secretion decreased, most likely due to the diet causing 
enhanced pathology. Animals fed the control diet had slower repopulation; however these 
transplant recipients were still able to completely abrogate pathology without tumor formation. 
Overall, these data demonstrate that hepatocyte transplantation could be useful to treat PFIC in 
humans. 
Reduction of serum cholesterol in Watanabe rabbits has also been accomplished by 
porcine hepatocyte transplant [23]. This is the animal model for the human homozygous familial 
hypercholesterolemia, an LDL-receptor defect. Investigators demonstrated that the transplanted 
cells initially localize within the hepatic sinusoids and can over time migrate out of vessels and 
integrate into the parenchyma. These engrafted cells provided functional LDL receptors to lower 
serum cholesterol by 30-60% for the 100 day study. This report determined that they 
transplanted 10% of liver mass, which resulted in 1-5% survival of hepatocytes. Therefore 0.1-
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0.5% of liver mass corrects cholesterol by 30-60%, thus one does not need large engraftment to 
correct disease phenotype. 
Wilson’s disease was corrected by hepatocyte transplant in a rat model [24]. Long-Evans 
Cinnamon rats have excessive accumulation of copper within hepatocytes and therefore, are a 
good model of human Wilson’s disease. These animals have the atp7b gene mutation, an ATP-
dependent copper transporter, which results in copper cytotoxicity and decreased biliary 
excretion of copper. The investigators pretreated all rat recipients with retrorsine to inhibit 
proliferation of native hepatocytes and gave the animals a partial hepatectomy to promote liver 
repopulation. The liver was shown to have repopulation of transplanted rat cells. This 
repopulation was <25% at 6 weeks, 26-40% at 4 months and 74-100% at 6 months and longer. 
The highly repopulated animals restored biliary copper excretion and lowered intrahepatic 
copper levels. Furthermore the liver histology was completely normal compared to extensive 
damage in non-transplanted animals. Wilson’s disease was also shown to be reversed using 
hepatocyte transplant as an early intervention to treat the underlying disease pathologies [25]. 
Rat hepatocytes were transplanted into the same rat modeled mentioned previously via 
intrasplenic injections. 71% of the transplanted animals became highly repopulated. Copper 
levels were virtually normal in 60% of these animals and the remaining 40% had substantially 
less copper compared to control non-transplanted animals. There were positive changes in 
ceruloplasmin levels; bile copper excretion capacity and liver histology were maintained as 
expected with the decreases in liver copper levels. This report demonstrated the efficacy of cell 
transplant to treat inborn errors in metabolism at an early age before extensive liver damage 
occurs. 
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Rat hepatocytes have been shown to engraft, survive and proliferate in rat livers that have 
CCl4 and phenobarbital-induced cirrhosis [26]. This demonstrates that cell transplant is a viable 
option to treat liver failure and cirrhosis. This was further corroborated when rat hepatocytes 
were shown to rescue rats with D-galactosamine-induced acute liver failure [27]. Intrasplenic 
injections of cells and liver cell culture supernatants were shown to lead to a survival rate of 
47.1% and 42.9% respectively. Injections were performed 20-28 hours after poisoning. These 
reports demonstrated that hepatocytes themselves, and the soluble factors that they release, 
improve survival of the recipient either through engrafting within the liver to provide metabolic 
support or by stimulating liver regeneration of the recipient’s native cells or both 
Cell transplant has also been shown to treat chronic liver failure as well. A rat model of 
CCl4 and phenobarbital-induced chronic liver failure utilized intrasplenic injection of rat 
hepatocytes to treat the disease [28]. The rats in this model display irreversible liver cirrhosis. 
Animals receiving the cells showed significant improvements in liver function and prolonged 
survival compare to non-transplanted controls. These data further demonstrated the utility of 
hepatocyte transplant to treat liver disease. 
Hepatocytes have been shown to provide metabolic support, in a glucose-related 
function,  when transplanted to rats that have received a 90% hepatectomy [29]. Rat hepatocytes 
were attached to collagen coated microcarriers and were transplanted IP 3 days prior to surgery. 
Non-transplanted animals died within 48 hours from hypoglycemia. Rats that received cells had 
significantly higher blood glucose levels and 40% of them survived longer than 28 days. All 
control rats died within 5 days. When cells were injected IP immediately after the surgery all rats 
became hypoglycemic and died within 48 hours, suggesting that engraftment is required for the 
transplanted hepatocytes to provide metabolic support and improve survival.  
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Primary mouse hepatocyte transplantation improved the phenotype and extended survival 
in a murine model of intermediate maple syrup urine disease [30, 31]. This was also true in a 
mouse model of tyrosinemia type-1 [32]. Table 3 summarizes some of the hepatocyte transplants 
that have been performed to treat different liver diseases within relevant animal models. This 
table includes the disease treated, transplant site, donor cell species and recipient species. 
 
 
 
 
Table 3. Hepatocyte Transplants Performed in Relevant Liver Disease Animal Models 
Table summarizes some of the hepatocyte transplants that have been performed in relevant liver disease animal 
models. Information includes disease treated, transplant site, donor cell species, recipient species and reference of 
paper according to first author last name. 
 
Disease Treated TX Site Donor 
Species 
Recipient 
Species 
References 
CN-1 SubQ Rat Rat Rugstad et 
al.[17], Matas et 
al. [18] 
CN-1 Portal vein Rat Rat Groth et al. [19] 
CN-1 IP Human Rat Moscioni et al. 
[20] 
Analbuminemia IP Human Rat Moscioni et al. 
[20] 
Dubin Johnson 
Syndrome 
Portal Vein Rat Rat Hamaguchi et al. 
[33] 
Ascorbic Acid 
Deficiency 
Portal vein, 
spleen, 
omentum, 
mesentery 
Rat Rat Nakazawa et al. 
[21] 
PFIC (type 3) Spleen Mice Mice De Vree et al. 
[22] 
Homozygous familial 
Hypercholesterolemia 
Portal vein Porcine Rabbit Gunsalus et al. 
[23] 
Wilson’s Disease Spleen Rat Rat Irani et al. [24], 
Malhi et al. [25] 
Maple Syrup Urine 
Disease 
Direct Liver Mouse Mouse Skvorak et al. 
[30], Skvorak et 
al. [31] 
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Tyrosinemia Type-1 Spleen Human Mouse Azuma et al. [32] 
Acute Liver Failure Spleen Rat Rat Gagandeep et al. 
[26], 
Baumgartner et 
al. [27] 
Chronic Liver Failure Spleen Rat Rat Kobayashi et al. 
[28] 
Acute Liver 
Insufficiency 
IP Rat Rat Demetriou et 
al.[29] 
 
1.5 INTEGRATION AND INTERACTION OF TRANSPLANTED CELLS WITHIN 
RECIPIENT 
The integration and interaction of transplanted hepatocytes in the host has been determined in a 
rat model [34]. When cells are transplanted via the portal vein they reach the distal portal spaces 
and sinusoids within 1 hour after injection. During this process they occlude the portal vein flow 
and thus increase the portal pressure and cause initial damage of the recipient liver. This was 
inferred from increases in AST, ALT and LDH 1-2 hours after transplant. The cells then traverse 
the endothelial barrier through mechanical disruption. The transplanted cells lose their 
membrane-bound gap junctions facilitated by connexin-32 down-regulation during the migration 
through the sinusoids. Integration of the graft in the liver parenchyma and bile canalicular 
activity requires up to 5 days and is associated with connexin-32 up-regulation. MMP-2 degrades 
the ECM in close proximity to donor cells, which allows space for cell proliferation of the graft. 
Cells that remain in the portal vein are removed by polymorphonuclear leukocytes and 
macrophages. 
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Primary hepatocytes have been transplanted via many different avenues. These include: 
peritoneal cavity, omentum, mesentery, spleen, portal vein, kidney capsule and lung. Table 3 
summarizes some of the animal models of liver disease that have been corrected by hepatocyte 
transplant. 
1.6 METHODS TO INCREASE REPOPULATION – GIVING DONOR CELLS 
PROLIFERATIVE ADVANTAGE 
There have been many studies that have investigated ways to increase repopulation of the 
recipient liver with donor hepatocytes. Methods to increase repopulation include: genetic 
manipulation of the recipient through delivery of a virus expressing urokinase plasminogen 
activator to breakdown the ECM and give the transplanted cells more space to engraft [32], 
growth factor administration in concordance with cell transplantation (VEGF) to help increase 
migration past endothelial cells [35], pretreatment with partial hepatectomy to stimulate 
expression of soluble factors in the body that lead to liver regeneration, pretreatment with 
retrorsine which inhibits proliferation of the native hepatocytes through alkylation of DNA 
without extensive toxicity and allows transplanted cells to be the only cells that can proliferate, 
pretreatment with CCl4 or radiation to damage the host liver to allow transplanted cells to have a 
growth advantage over native cells, administration of vasodilators to promote migration through 
liver sinusoids, immunosuppression [19], preconditioning with radiation and ischemia-
reperfusion [36] to damage native cells and promote proliferation of transplanted cells through 
oxidative DNA damage and finally hepatic stimulatory substances obtained from regenerating 
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porcine livers [37]. Table 4 summarizes some of the methods to increase donor cell repopulation 
and the species of the donor and recipient. 
 
Table 4. Methods to Increase Cellular Engraftment in Relevant Animal Models 
Table summarizes some of the methods to increase cellular engraftment in relevant liver disease animal models. 
Information includes method to increase engraftment, donor cell species, recipient species and reference of paper 
according to first author last name. 
 
Method to Increase 
Engraftment 
Donor 
Species 
Recipient 
Species 
References 
Removal of thymus Human Rat Moscioni et al. [20] 
Partial hepatectomy Rat Rat Hamaguchi et al. [33], Irani et 
al. [24] 
Retrorsine Rat Rat Irani et al. [24] 
CCl4 Rat Rat Gagandeep et al. [26] 
Phenobarbital Rat Rat Gagandeep et al. [26] 
D-galactosamine Rat Rat Baumgartner et al. [27] 
uPA expressing virus Human Mouse Azuma et al. [32] 
Immunosuppression Mouse Mouse Groth et al. [19] 
Radiation Rat Rat Malhi et al. [36] 
Ischemia/Reperfusion Rat Rat Malhi et al. [36] 
Hepatic Stimulatory 
Substances 
Rat Rat Jiang et al. [37] 
 
 
Some liver-based inborn errors in metabolism may provide a built in selective growth 
advantage of donor cells that may make the liver more susceptible to donor hepatocyte 
engraftment and repopulation. This is due to the nature of the disease and the associated 
hepatocellular damage to native cells. These diseases include: tyrosinemia, progressive familial 
cholestasis type 2 and 3, Wilson’s disease and alpha-1-antitrypsin disease. 
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1.7 HEPATOCYTE TRANSPLANTS IN HUMANS – THE CLINICAL EXPERIENCE 
Hepatocyte transplantation was transitioned to the clinic to see if patients would respond to this 
new therapy after showing promise in various liver-based metabolic disease and liver failure 
animal models. Intraportal injection is the preferred method of delivery for clinical hepatocyte 
transplantation; however alternative sites include the spleen, pancreas, peritoneal cavity and 
subrenal capsule [5]. Transplantation of cells through the portal vein has shown to lead to portal 
hypertension and formation of hepatocytes thrombi; however this can be minimized by limiting 
the number of cells per infusion and the rate at which the cells are delivered. To increase the total 
number of cells given to a patient multiple infusions of cells can be performed [5]. 
Initially researchers believed transplantation of cells would not be as immunogenic as 
OLT; however this is not the case. There is no consensus as to what is the best 
immunosuppressive protocol but most transplants follow the protocol used for OLT, which 
includes combination of tacrolimius (with or without steroids) and monoclonal antibodies, such 
as interleukin 2 receptor antibodies [5]. 
In animals, engraftment of the transplanted cells can be assessed rather easily by making 
sure the transplanted cells have a unique reporter protein the recipient liver does not and 
identifying the transplanted cells by ICC, in situ hybridization, real time RT-PCR or flow 
cytometry. In humans, it is more difficult to assess engraftment. Indirect evidence includes 
positive changes in the symptoms of the patients and changes in enzyme activity. For example 
patients with urea cycle disorders show extended decreases in serum ammonia levels and 
patients with CN-1 show extended decreases in serum bilirubin levels after hepatocyte 
transplant. Direct evidence includes the identification of donor sex chromosomes or HLA 
antigens in cases of donor-recipient sex mismatch or HLA mismatch. In patients that fit this 
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category who receive eventual OLT, livers can be obtained to perform ICC, in situ hybridization 
or real time RT-PCR to test for the presence of donor-derived cells. 
Theoretically, all patients that are afflicted by liver-based metabolic disorders resulting 
from a mutation within an important metabolic protein can benefit from hepatocyte transplant. 
Transplanted cells will be genetically competent in whatever protein is mutated within the 
patient and when they repopulate the recipient liver they will provide metabolic support that 
results in the symptoms of the disease being alleviated. The indication for hepatocyte 
transplantation is currently based on severity of disease or quality of life, with the aim being to 
avoid or postpone liver transplantation whether due to genetic defects or acute or chronic liver 
failure [5]. The following paragraphs will describe all reports of clinical hepatocyte transplants 
that have occurred worldwide since 1993. Most transplants have been performed with adult 
hepatocytes, however some have been performed with hepatocytes isolated from livers of 
aborted fetuses. The first report of adult hepatocyte transplant occurred when Mito and 
colleagues treated 9 patients with cirrhosis and 1 patient with chronic active hepatitis [38]. 
Autotransplantation of cells from cirrhotic individuals took place. Investigators reported the 
presence of cells in the spleens of 8 patients up to 11 months post transplant. One patient’s 
ascites resolved.  
CN-1 is characterized by patients who experience hyperbilirubinemia caused by a 
mutation in the UDP-glucuronosyltransferase 1A1 (UGT1A1) gene. This gene encodes a protein 
that is responsible for glucuronidating bilirubin found in the serum, which allows for the 
excretion of the molecule through the bile. If it is not excreted and builds up to high enough 
levels in the serum, bilirubin can cross the blood-brain barrier and cause brain damage. Therefore 
it needs to be removed from the blood. Bilirubin is formed from the breakdown of hemoproteins, 
 21 
such as hemoglobin. Bilirubin is water insoluble and therefore cannot be cleared from the body 
unless it becomes water soluble. This is accomplished by hepatocytes that express the UGT1A1 
enzyme. This enzyme is responsible for glucuronidating bilirubin (conjugated bilirubin). 
Glucuronidation of the propionic acid carboxyls of bilirubin disrupts hydrogen bonding and 
makes the molecule water soluble and rapidly excretable in the bile. The only current therapy 
available for patients is phototherapy. This therapy has patients sit underneath bilirubin lamps 
that emit a blue light (420-470 nm). This light can penetrate the skin and help convert bilirubin to 
its conjugated form so it can be excreted in the urine and feces. This therapy becomes less and 
less effective as the patients become older as their surface area to body mass ratio decreases. 
Currently the only curative treatment for CN-1 is OLT. However, since 1998, 10 patients ranging 
from 1 to 11 years have been treated with 15 million to 7.5 billion hepatocytes (1 patient 
received CD326+ fetal hepatocytes) [39-46]. Patients saw a 20-50% reduction in serum bilirubin, 
increased the amount of conjugated bilirubin and decreased their phototherapy. Only 1 of 10 
patients did not benefit from the transplant. However no patients saw complete reversal. This 
resulted in patients either receiving OLTs or remaining on the OLT wait list at the end of all 
studies. 
Familial hypercholesterolemia (FH) is characterized by patients with abnormally high 
levels of low density lipoprotein (LDL) in their blood serum. Patients generally have mutations 
in the LDLR gene that encodes the LDL receptor protein. LDLR is responsible for removing 
LDL from the circulation. Heterozygous FH can lead to early onset cardiovascular disease 
around the age of 30 to 40 and can be treated with statins, bile acid sequestrants or other 
hypolipidemic agents. On the other hand, homozygous FH can cause severe cardiovascular 
disease in early childhood and often does not respond to conventional therapies and may have to 
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be treated with LDL apheresis or eventual OLT. In 1995 Grossman and colleagues transplanted 5 
patients from the ages of 7 to 41 with 1 to 3.2 billion hepatocytes [47]. Researchers saw up to a 
20% reduction in LDL in 3 patients. The other 2 patients did not respond to therapy. 
Factor VII deficiency is a disorder caused by the absence of this coagulation factor, 
which is one of the critical components of the coagulation cascade that results in the clotting of 
blood. Patients that have this deficiency have a mutation within the factor VII protein that makes 
it non-functional. Only homozygotes or compound heterozygotes (2 different mutations within 
the gene) develop hemorrhagic syndrome, heterozygotes are asymptomatic. Patients develop 
intracerebral hemorrhages, hemarthroses, cutaeneous-mucosal hemorrhages or hemorrhages 
provoked by a surgical intervention. Severity of disease depends on type of mutation within the 
factor VII gene [48]. In 2004 Dhawan et al. transplanted 1 3-month old patient and 1 35-month 
old patient with 1.1 and 2.2 billion cells respectively [49]. The doctors saw a 70% reduction in 
factor VII requirements after 6 months; however both patients eventually received an OLT. 
Glycogen storage disease is characterized by a defect in the processing of glycogen. This 
inborn error in metabolism results from a mutation in one of the enzymes responsible for the 
breakdown of glycogen causing impaired protein activity. One type of glycogen storage disease 
is caused by a mutation in the G6Pase gene, which is responsible for the process of glycogen 
degradation and gluconeogensis in the liver. This mutation prevents the production of free 
glucose molecules and leads to hypoglycemia, abnormal blood sugar levels between meals 
without constant feedings, the buildup of lactate, uric acids and triglycerides, hepatomegaly, 
developmental delay and seizures leading to impaired breathing, coma and death. Patients with 
this disorder must adhere to a strict dietary regimen with constant feeding every one to four 
hours. Children often have a nasogastric feeding tube placed on them for the use of a continuous 
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feeding pump; this is especially true at night. The strict diet is so the body does not receive 
glucose. If it does, the body will store the glucose as glycogen, which will end up building up in 
high amounts in hepatocytes because it cannot be broken down. This hyper-glycogen state can 
cause hepatomegaly and eventual liver damage. OLT is the only known curative treatment. 
Severity of the disease depends on what gene is mutated and the type of mutation. Two patients 
have been treated for glycogen storage disease with hepatocyte transplant [50, 51]. Patients were 
18 and 47 years old and received 6 and 2 billion cells respectively. They were able to be put on a 
normal diet and their fasting time increased after transplantation. The 18 year old had normal 
G6Pase activity up to 7 months after transplant. 
Infantile Refsum’s disease is characterized by mutations in genes that encode peroxins, 
which are important proteins for normal peroxisome assembly and function, therefore making 
this disease a peroxisome biogenesis disorder. The most common mutations for the disease occur 
in the PEX1, PEX3, PEX6, PEX12 and PEX26 genes and severity of the disease depends on 
what gene is mutated and where the mutation is within the gene. As a result of mutation, these 
proteins become less active or completely inactive altogether. Since one of the major functions 
of the peroxisome is the catabolism of very long chain and branched chain fatty acids, non 
functioning PEX genes lead to the accumulation of these lipids within cells and tissues. 
Abnormal peroxisome biogenesis can lead to a reduction of myelin in the central nervous system 
(CNS) leading to abnormal CNS function and development as well as hepatomegaly, eventually 
causing liver damage. There is currently no standard treatment for this disease. In 2003 a four 
year old female received 2 billion hepatocytes to treat her underlying Infantile Refsum’s disease 
[52]. She saw a 40% reduction in pipecholic acid at 18 months post transplant, thus 
demonstrating indirect evidence of hepatocyte engraftment and function. 
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Progressive familial intrahepatic cholestasis (PFIC) is a disease characterized by defects 
in genes that encode proteins of biliary epithelial transporters. These defects cause problems in 
the export of bile out of hepatocytes and eventually lead to progressive cholestasis that presents 
in early childhood. This leads to eventual hepatic failure and need for OLT. Specifically PFIC-2 
is caused by mutation in the bile salt export pump (BSEP) that results in the retention of bile salts 
within hepatocytes causing hepatocelluar damage through cholestasis. 2 patients with PFIC-2 
were transplanted in 2006 to treat their underlying disease [42]. These patients were 16 and 32 
months old and were transplanted with 400 million and 200 million cells respectively. Both of 
these patients showed no biochemical benefit from the transplantation and the disease-state 
progressed eventually resulting in cirrhosis that called for OLT. 
Biliary atresia is a congenital or acquired disease associated with the common bile duct 
between the liver and the small intestine being blocked or absent leading to progressive 
cholestasis and conjugated hyperbilirubinemia. The acquired type most often occurs due to an 
underlying autoimmune disease, this being one of the main causes of rejection after OLT. As 
mentioned earlier, patients have progressive cholestasis with conjugated hyperbilirubinemia, 
which causes classical liver failure symptoms: jaundice, malabsorption with developmental 
delays, fat-soluble vitamin deficiencies, and hyperlipidemia eventually causing cirrhosis and 
liver failure. Since the bilirubin is conjugated it cannot gross the blood brain barrier, thus brain 
damage caused by kernicterus is not a concern. The cause of congenital biliary atresia is 
unknown and the only curative treatment is OLT. In 2008, 1 1-year old patient was treated for 
biliary atresia by the transplantation of 12 million CD326+ fetal hepatocytes. The patient saw a 
3-fold reduction in total bilirubin and an 8-fold reduction in conjugated bilirubin. Furthermore, 
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ALT levels decreased and hepatobiliary scintigraphy showed an increase in liver cell function at 
2 months. 
Ornithine Transcarbamylase (OTC) deficiency is a urea cycle disorder characterized by a 
mutation in the OTC gene that encodes the OTC protein essential for the clearance of ammonia 
from the blood. Ammonia appears in the blood as a normal toxic breakdown product of the 
body’s use of protein and amino acids. Therefore patients that have a mutation within their OTC 
gene have low functioning or completely non-functioning OTC enzyme activity leading to 
hyperammonemia and a buildup of orotic acid. The buildup of orotic acid is due to increasing 
concentration of carbamoyl phosphate entering the pyrimidine synthesis pathway; if the urea 
cycle was working properly carbamoyl phosphate concentration would remain constant and thus 
would not enter this alternative biochemical pathway. Hyperammonemia, if left untreated, can 
cause seizures, loss of appetite, lack of energy, developmental delay, brain damage, irrational 
behavior, mood swings, coma or death. Management of OTC is done mainly through the 
administration of a low protein diet. The only curative treatment is OLT.  From 1997 to 2009 6 
patients with OTC have been treated for their disease by hepatocyte transplant [53-57]. Age of 
patients ranged from 6 hours to 5 years and they received anywhere from 600 million to 9 billion 
cells. All patients saw a decrease in serum ammonia levels associated with psychomotor 
improvement and an increase in protein tolerance administered by a normal diet. One patient was 
confirmed to have 0.5% normal liver OTC activity once his liver was explanted when death 
occurred at day 42 post transplant. Cause of death in this patient was not due to cell transplant. 
Some patients were also confirmed to have normal urinary orotic acid concentrations. All 
patients at the end of the various studies either received an OLT or were still on the OLT waiting 
list. 
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Argininosuccinate lyase (ASL) deficiency is a urea cycle disorder characterized by a 
mutation in the ASL gene that encodes the ASL protein essential for the clearance of ammonia 
from the blood. ASL deficiency leads to hyperammonemia with symptoms and consequences 
very similar to other urea cycle disorders. ASL is an enzyme that cleaves argininosuccinate to 
produce a molecule of fumarate and arginine in the urea cycle. A mutation in the ASL protein 
will lead to elevated levels of argininosuccinate resulting in argininosuccinic aciduria and 
clearance through the urine. Elevated argininosuccinate in the urine is a main symptom of 
disease. Although argininosuccinate contains two waste nitrogen molecules normally found in 
urea, patients still experience urea cycle disorder systems. OLT is the only curative treatment. 1 
42-month old patient was transplanted with 4.7 billion hepatocytes to treat the underlying ASL 
deficiency [58]. The patient saw a decrease in serum ammonia levels associated with 
psychomotor catch up. Although OLT was performed 18 months post cell transplant, donor cells 
were still detected in the liver. 
Carbamoyl phosphate synthetase (CPS) deficiency type-1 is a urea cycle disorder 
characterized by a mutation in the CPS gene that encodes the CPS protein essential for the 
clearance of ammonia from the blood. CPS-1 deficiency leads to hyperammonemia with 
symptoms and consequences very similar to other urea cycle disorders. CPS-1 is the enzyme that 
catalyzes the reaction of 2 molecules of ammonia and 2 molecules of bicarbonate to form 
carbamoyl phosphate. This is the initial reaction in the urea cycle to clear waste nitrogen from 
the body through the production of urea. Thus patients with mutation in the CPS-1 gene have 
inactive CPS-1 enzyme activity resulting in ammonia accumulation in the serum. OLT is the 
only curative treatment. In 2009, 1 2.5-month old patient was treated for CPS-1 by the 
transplantation of 1.4 billion hepatocytes [54]. The patient saw a decrease in serum ammonia 
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levels and an increase in urea production for 11 months. At the end of the study the patient was 
still on the OLT waiting list.  
Citrullinemia is a urea cycle disorder characterized by a mutation in the argininosuccinate 
synthetase (ASS) gene that encodes the ASS protein essential for the clearance of ammonia from 
the blood. Citrullinemia leads to hyperammonemia with symptoms and consequences very 
similar to other urea cycle disorders. ASS is the enzyme that catalyzes the reaction of citrulline 
and aspartate to form argininosuccinate. Thus patients with mutation in the ASS gene have 
inactive enzyme activity resulting in ammonia accumulation in the serum. OLT is the only 
curative treatment. In 2009, 1 36-month old patient was treated for citrullinemia by the 
transplantation of 1.5 billion hepatocytes [54]. The patient saw a return to normal ammonia 
blood serum levels as well as a 40% increase in urea production with an increase in protein 
intake due to dietary changes. 
Liver failure is the inability of the liver to perform its normal synthetic and metabolic 
function to maintain normal physiology and homeostasis and comes in two forms: acute and 
chronic. Acute liver failure (ALF) is defined as the rapid development of hepatocellular 
dysfunction and chronic liver failure usually occurs in the context of cirrhosis (liver fibrosis). 
Since 1993 the following types of liver failure have been treated by hepatocyte transplant: drug-
induced ALF (16 patients; 5 received fetal hepatocytes), viral-induced ALF (10 patients; 1 
received fetal hepatocytes), idiopathic ALF (4 patients), mushroom poisoning-induced ALF (1 
patient), post surgical ALF (1 patient) and ALF induced by acute fatty liver of pregnancy (1 
patient). Routes of hepatocytes transplant in these patients include intraperitoneal, intrasplenic 
and portal vein. Some patients died from their underlying disease, some survived until an organ 
became available for OLT and in rare instances some of the patient’s liver failure resolved.  
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Table 5 summarizes all current reports, to the knowledge of this investigator, of clinical 
hepatocyte transplants performed worldwide since 1993 broken down by disease. Table includes 
the specific reference where all data can be found along with the age of patient, total number of 
cells transplanted, the findings associated with the study and the outcomes of the patients. 
 
 
Table 5. Clinical Hepatocyte Transplants in Patients Worldwide 
Table summarizes all reports of clinical hepatocyte transplants performed worldwide since 1993 to treat various 
liver-based inborn errors of metabolism and acute liver failure. Table is broken down by each disease that has been 
treated. Cells transplanted are hepatocytes unless specified otherwise. PV = portal vein; IS = intrasplenic; IP = 
intraperitoneal. Adapted from Dhawan et al. [5]. 
 
Disease: CN-1 
Reference Age of Patient # Cells TX 
(X109) 
Findings Outcome 
Fox et al. [43] 10 years 7.5 ↓ 50% bilirubin, 
UGT1A1 activity 
in liver 
OLT after 4 
years 
Darwish et al. 
[41] 
8 years 7.5 ↓ 40% bilirubin 
for 6 months 
OLT after 
20 months 
Ambrosino et al. 
[40] 
9 years 7.5 ↓ 30% bilirubin 
for a few weeks 
OLT after 5 
months 
Dhawan et al. 
[42] 
18 months 
 
 
42 months 
4.3 
 
 
2.1 
↓ 40% bilirubin 
 
 
No clear benefit 
OLT after 8 
months 
 
NA 
Allen et al. [39] 8 years 1.4 ↓ 30% bilirubin, ↓ 
phototherapy 
OLT after 
11 months 
Lysy et al. [45] 9 years 
 
 
1 year 
6.1 
 
 
2.6 
↓ 35% bilirubin 
for 6 months 
 
↓25% bilirubin, ↓ 
phototherapy for 
4 months 
OLT 
waiting list 
 
 
OLT after 4 
months 
Khan et al. [44] 2 years 0.015 
 
CD326+ Fetal 
hepatocytes 
↓ 50% bilirubin, ↑ 
5-fold conjugated 
bilirubin 
NA 
Meyburg et al. 
[46] 
11 years 7.2 ↓ 20% bilirubin OLT 
waiting list 
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Disease: Familial Hypercholesterolemia 
Reference Age of Patient # Cells TX 
(X109) 
Findings Outcome 
Grossman et al. 
[47] 
Five total w/ages 
between 7 and 41 
years 
1.0-3.2 Up to ↓ 20% LDL 
in 3 patients 
NA 
 
Disease: Factor VII Deficiency 
Reference Age of Patient # Cells TX 
(X109) 
Findings Outcome 
Dhawan et al. 
[49] 
3 months 
 
 
 
35 months 
1.1 
 
 
 
2.2 
↓ 70% rFVII 
requirement for 6 
months 
 
↓ 70% rFVII 
requirement for 6 
months 
OLT after 7 
months 
 
 
OLT after 8 
months 
 
Disease: Glycogen Storage Disease Type-1 
Reference Age of Patient # Cells TX 
(X109) 
Findings Outcome 
Muraca et al. [51] 47 years 2.0 Normal diet, ↑ 
fasting time 
NA 
Lee et al. [50] 18 years 6.0 Normal G6Pase 
activity up to 7 
months 
NA 
 
Disease: Infantile Refsum’s Disease 
Reference Age of Patient # Cells TX 
(X109) 
Findings Outcome 
Sokal et al. [52] 4 years 2.0 ↓ 40% pipecholic 
acid after 18 
months 
NA 
 
Disease: Progressive Familial Intrahepatic Cholestasis Type-2 
Reference Age of Patient # Cells TX 
(X109) 
Findings Outcome 
Dhawan et al. 
[42] 
32 months 
 
 
 
0.2 
 
 
 
No benefit, 
cirrhosis 
established 
 
OLT after 5 
months 
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16 months 0.4 No benefit, 
cirrhosis 
established 
OLT after 
14 months 
 
Disease: Biliary Atresia 
Reference Age of Patient # Cells TX 
(X109) 
Findings Outcome 
Khan et al. [59] 1 year 0.012 
 
CD326+ Fetal 
hepatocytes 
↓ 3-fold total 
bilirubin, ↓ 8-fold 
conjugated 
bilirubin, ↓2.5-
fold ALT levels 
and hepatobiliary 
scintigraphy 
showed ↑ liver 
cell function at 2 
months 
NA 
 
Disease: Ornithine Transcarbamylase Deficiency 
Reference Age of Patient # Cells TX 
(X109) 
Findings Out
come 
Strom et al. [57] 5 years 1.0 ↓ NH3, 0.5% of 
normal liver OTC 
activity 
Death 42 
days after 
TX 
Horslen et al. [53] 10 hours 9.0 ↓ NH3, ↑ protein 
tolerance for a 
short period 
OLT after 6 
months 
Stephenne et al. 
[56] 
14 months 2.4 ↓ NH3, ↑ urea, 
psychomotor 
improvement 
OLT after 6 
months 
Puppi et al. [55] 1 day 1.6 ↓NH3, ↑ urea 
under normal 
protein diet 
APOLT 
after 7 
months 
Meyburg et al. 
[54] 
6 hours 
 
 
 
 
9 days 
0.6 
 
 
 
 
0.6 
↓ NH3, ↑ urea, 
normal urinary 
orotic acid 
excretion 
 
↓ NH3, ↑ protein 
intake, urinary 
ortoic acid normal 
at 6 months 
Death 4 
months after 
TX 
 
 
 
OLT 
waiting list 
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Disease: ASL Deficiency 
Reference Age of Patient # Cells TX 
(X109) 
Findings Outcome 
Stephenne et al. 
[58] 
42 months 4.7 ↓NH3, 
psychomotor 
catch-up, donor 
cells detected in 
liver 
OLT after 18 
months 
 
Disease: CPS-1 Deficiency 
Reference Age of Patient # Cells TX 
(X109) 
Findings Outcome 
Meyburg et al. 
[54] 
2.5 months 1.4 ↓ NH3, ↑ urea for 
11 months 
OLT waiting 
list 
 
Disease: Citrullinemia 
Reference Age of Patient # Cells TX 
(X109) 
Findings Outcome 
Meyburg et al. 
[54] 
36 months 1.5 Normal NH3, ↑ 
40% urea, ↑ 
protein intake 
NA 
 
Disease: Drug-induced Acute Liver Failure 
Reference Age of Patient # Cells TX 
(X109) 
Route of delivery Outcome 
Bilir et al. [60] 32 years 
 
 
35 years 
 
 
55 years 
1.3 
 
 
10 
 
 
39 
IS 
 
 
IS 
 
 
IS 
Death on day 
14 
 
Death on day 
20 
 
Death in 6 
hours 
Strom et al. [61] 13 years 
 
 
43 years 
1.0 
 
 
NA 
PV 
 
 
NA 
Death on day 
4 
 
Death on day 
35 
Fisher et al. [62] 27 years 
 
 
26 years 
 
0.03 
 
 
1.2 
 
IS 
 
 
IS 
 
OLT on day 
10 
 
OLT on day 
2 
 32 
 
21 years 
 
 
35 years 
 
 
35 years 
 
 
51 years 
 
0.94 
 
 
5.4 
 
 
3.7 
 
 
3.9 
 
IS 
 
 
PV 
 
 
PV 
 
 
PV 
 
Death on day 
1 
 
Death on day 
18 
 
Full recovery 
 
Death on day 
3 
Habibullah et al. 
[63] 
 
 
 
 
 
 
 
 
32 years 
 
 
29 years 
 
 
20 years 
 
 
20 years 
 
 
24 years 
 
0.06/kg 
 
 
0.06/kg 
 
 
0.06/kg 
 
 
0.06/kg 
 
 
0.06/kg 
 
Fetal Hepatocytes 
IP 
 
 
IP 
 
 
IP 
 
 
IP 
 
 
IP 
 
 
 
Death in 30 
hours 
 
Death in 37 
hours 
 
Death in 48 
hours 
 
Full recovery 
 
Full recovery 
 
Disease: Viral-induced Acute Liver Failure 
Reference Age of Patient # Cells TX 
(X109) 
Route of delivery Outcome 
Meyburg et al. 
[46] 
3 weeks 1.7 PV Death on day 
11 
Fisher et al.[62] 4 years 
 
 
54 years 
3.4 
 
 
6.6 
PV 
 
 
PV 
Death on day 
2 
 
Death on day 
7 
Bilir et al. [60] 29 years 
 
 
65 years 
10 
 
 
30 
PV and IS 
 
 
PV and IS 
Death in 18 
hours 
 
Death on day 
52 
Strom et al. [61] 28 years 
 
0.17 
 
IS 
 
OLT on day 
3 
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37 years 
 
 
43 years 
 
0.12 
 
 
0.73 
 
IS 
 
 
PV 
 
Death on day 
5 
 
OLT on day 
1 
Fisher et al. [64] 37 years 0.88 IS Full recovery 
Habibullah et al. 
[63] 
40 years 0.06/kg 
 
Fetal Hepatocytes 
IP Death in 13 
hours 
 
Disease: Idiopathic Acute Liver Failure 
Reference Age of Patient # Cells TX 
(X109) 
Route of delivery Outcome 
Fisher et al. [62] 3.5 months 
 
 
23 years 
 
 
 
48 years 
0.18 
 
 
0.44 
 
 
 
0.75 
PV 
 
 
IS 
 
 
 
PV 
OLT on day 
1 
 
OLT on day 
5 and death 
on day 13 
 
Death on day 
1 
Habibullah et al. 
[63] 
8 years 0.06/kg 
 
Fetal Hepatocytes 
IP Full recovery 
 
Disease: Mushroom-poisoning-induced Acute Liver Failure 
Reference Age of Patient # Cells TX 
(X109) 
Route of delivery Outcome 
Schneider et al. 
[65] 
64 years 4.9 PV Full recovery 
 
Disease: Postsurgical Acute Liver Failure 
Reference Age of Patient # Cells TX 
(X109) 
Route of delivery Outcome 
Strom et al. [61] 69 years 0.53 IS Death on day 
2 
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Disease: Acute Liver Failure Induced by Acute Fatty Liver of Pregnancy 
Reference Age of Patient # Cells TX 
(X109) 
Route of delivery Outcome 
Khan et al. [66] 26 years 0.3 
 
Fetal hepatocytes 
IP Full recovery 
 
 
It has been concluded that cell therapy shows promise in reversing clinical symptoms 
associated with liver failure and many metabolic diseases; however issues with cell source, size, 
viability, cryopreservation, engraftment, immunosuppression and family compliance with 
disease specific therapy need to be addressed. Moreover the lack of controlled trials during the 
clinical hepatocyte transplants performed to date makes it difficult to interpret findings and 
compare different studies. No patients to date have been completely cured of their disease; 
however cell transplant has shown the best outcomes in patients with liver-based inborn errors in 
metabolism. These patients demonstrate obvious positive effects on various disease specific 
symptoms. Cell-based therapy in some cases helped to reverse liver failure, however once again 
the lack of proper controls make it difficult to say patient’s liver failure was reversed due to 
hepatocyte transplant.  
Hepatocyte transplant has been shown to have potential to serve as a “bridge to 
transplant” for both metabolic liver-based diseases and liver failure therefore taking some of the 
burden off the OLT waiting list and allowing patients to survive longer until an organ for 
transplant becomes available.  
Current sources of hepatocytes for transplant are scarce and tissues that are available are 
livers that are unused or organs unsuitable for OLT. Livers not suitable for whole organ 
transplant include tissues with greater than 30% steatosis and extended cold ischemic times. This 
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fact demonstrates the limited supply of donor tissue that can provide high quality cells, thus 
leading to the transplantation of hepatocytes isolated from marginal livers. To compound issues, 
isolated primary adult human hepatocytes rarely, if ever, proliferate in vitro after cellular 
isolation. This means isolated cells cannot be expanded to treat more patients.  
Taken together, alternative cell sources and new methods to improve cell engraftment 
and liver repopulation need to be investigated in order to make cell-based therapeutics to treat 
liver diseases a regular clinical procedure. Alternative cell sources for transplant will increase the 
number of patients that can be treated and protocols to increase engraftment will allow for fewer 
cells to be delivered to patients and therefore more patients to be treated overall. Stem cells, 
specifically hESCs and hiPSCs, are an attractive cell source for hepatocyte transplant because 
they represent a potential constant and unlimited source of cells to transplant. They are easier to 
cryopreserve and smaller in size and thus easier to transplant. 
1.8 INTRODUCTION TO STEM CELLS 
The concept of one cell type that can give rise to all cells of the human body is very exciting to 
the medical and scientific world.  This totipotent cell could theoretically be used to make an 
unlimited amount of terminally differentiated cells.  These cells could be used for transplant to 
potentially correct a disease or stabilize a patient until an organ for transplant becomes available.  
These cells could also be used for in vitro drug discovery and screening.  Furthermore, if stem 
cells could be isolated from patients with genetic diseases, the cells could be differentiated to the 
cell type affected by the disease and used to model the disease and understand disease-related 
mechanisms.  Disease-specific cells could also be genetically corrected and then used for cell 
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transplantation to correct the phenotype.  Isolation, characterization, and propagation of 
pluripotent stem cells can come from embryonic sources, such as human embryonic stem cells 
(hESCs).  They can also come from somatic cells by forced expression of specific transcription 
factors, somatic cell nuclear transfer to an unfertilized oocyte, or fusion of a somatic cell with a 
hESC. 
1.9 HESC DERIVATION 
hESCs are derived from the inner cell mass of the blastocyst.  They have normal karyotypes, 
express high levels of telomerase activity, express cell surface markers that are found on primate 
ESCs, and maintain the developmental potential to form trophoblast and all 3 embryonic germ 
layers [67].  This was the first report of derivation and characterization of hESCs.  The next step 
in the research process would be to determine how to differentiate these cells to become cell 
types of terminally differentiated cells that can be used for transplant or in vitro analysis. 
1.10 ESC IN VITRO DIFFERENTIATION TO ENDODERM 
Researchers began determining ways to differentiate hESCs in vitro to desired cell types by 
exploiting observations made by developmental biologists during the study of normal embryonic 
development. Chemically defined culture conditions were determined by mimicking the same 
signaling events that occur during normal development. Therefore the first approach to 
generating functional hepatocytes from hESCs was to prime the cells to become endoderm, the 
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embryonic derivative from which hepatocytes are developed.  It has been shown that hESC 
differentiation toward hepatic endoderm requires activin A and Wnt3a signaling [68] as well as 
FGF signaling [69].  Furthermore, researchers have determined that activin A will only specify 
definitive endoderm from hESCs when phosphatidylinositol 3-kinase (PI3K) signaling is 
suppressed, thus establishing the PI3K inhibitor LY294002 as an important small molecule to 
use during endoderm differentiation [70]. PI3K signaling is usually active by insulin/IGF 
induction. It has been reported that inhibition of glycogen synthase kinase 3 (GSK-3) is also 
important in forming definite endoderm from hESCs [71]. Furthermore this group showed 
prolonged treatment with their novel GSK inhibitor generated a population of cells that displayed 
hepatoblast characteristics such as expression of α-fetoprotein and HNF4α, with further 
treatment leading to the generation of hepatocyte-like cells capable of producing albumin. Small 
molecules have also been demonstrated to direct hESCs to definitive endoderm at a higher 
efficiency than that achieved by activin A [72]. Finally, researchers have been able to establish 
endoderm progenitors through constitutive expression of SOX17 via a Cre-inducible expression 
vector [73].  These cell lines represent a constant source of endoderm that can be differentiated 
on demand to endoderm derivatives that could be used for cell transplant or in vitro analysis, 
such as hepatocytes. Some of the papers that have made important observations and 
advancements for in vitro endoderm formation are summarized in Table 6 [68-74]. 
 
Table 6. Formation of Endoderm from hESCs 
This table summarizes some of the important observations, advancements and protocols for in vitro 
formation of endoderm from hESCs. 
 
Reference Species Importance for in vitro Endoderm 
Formation 
Hay et al. [68] Human Activin A and Wnt3a signaling 
Morrison et al. [69] Mouse FGF signaling 
McLean et al. [70] Human PI3K inhibition 
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Bone et al. [71] Human GSK-3 inhibition 
Borowiak et al. [72] Mouse and 
Human 
Novel small molecules to induce endoderm 
Seguin et al. [73] Human Endoderm cell lines established by 
constitutive SOX17 expression 
D’Amour et al. [74] Human Activin A signaling and low serum 
 
 
It is important to note that these papers fail to address the issue of which protocol forms 
the definitive endoderm that is best suited to be differentiated toward the hepatocyte lineage that 
is both reproducible and efficient. 
1.11 ESC IN VITRO DIFFERENTIATION TO HEPATOCYTES 
The next step to generating stem cell-derived hepatocytes from hESCs is to form hepatic 
progenitors and then mature those progenitor cells to cells molecularly, functionally, and 
morphologically similar to primary hepatocytes.  Many protocols have been established using 
this stepwise approach with chemically defined media mimicking the molecular signaling events 
during normal embryonic development of the liver [75-84].  All of these protocols have varying 
degrees of success in terms of generating hESC-derived hepatocytes that have liver specific gene 
expression, protein expression, protein secretion, CYP450 metabolism and induction and 
glycogen storage comparable to primary human hepatocytes.  Mature hepatic function has yet to 
be accomplished through in vitro differentiation of hESCs, however it has been determined that 
HNF4α is essential for specification of hepatic progenitors from human pluripotent stem cells by 
establishing the expression network of transcription factors that control hepatocyte cell fate 
decisions [85]. Researchers were able to investigate each stage of the hepatic differentiation 
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process by depleting expression of various genes using shRNA technology and lentiviruses. 
Table 7 summarizes the various protocols that have been published regarding differentiation of 
hESCs to hepatocytes. 
 
Table 7. Various Reports of ESC Differentiation to Hepatocytes 
This table summarizes the various reports within the literature on the generation of ESC-derived hepatocytes from 
different species’ cells. Table includes the reference, species of cell used and a brief summary of the growth factors, 
cytokines and culture techniques used within each reference’s differentiation protocol. The forward slashes in the 
“summary of protocol” column denote a change in culture conditions consisting of a basal medium or growth factor 
change. 
 
Reference Species Summary of Protocol 
Agarwal et al. [75] Human ActA / FGF4, HGF / BSA, FGF4, HGF / 
FGF4, HGF, OSM, DEX 
Basma et al. [76] Human EB formation / ActA, FGF2 / HGF, DMSO 
/ DEX 
Bukong et al. [77] Human ActA, FGF2 / FGF4, BMP2, LY294002 / 
FGF10, RA, FGF4, HGF, EGF, SB431542 / 
FGF10, RA, FGF4, HGF, EGF, SB431542, 
OSM, DEX 
Cai et al. [78] Human ActA / FGF4, BMP2 / HGF / OSM, DEX 
Duan et al. [79] Human ActA / FGF4, HGF, BMP2, BMP4 / FGF4, 
HGF, BMP2, BMP4, DMSO / FGF4, HGF, 
OSM, DEX, DMSO 
Hay et al. [80] Human ActA, NaBut / ActA, NaBut / DMSO / 
HGF, OSM 
Medine et al. [81] Human ActA, Wnt3a / DMSO / HGF, OSM 
Sharma et al. [82] Human DMSO / NaBut / SNAP 
Touboul et al. [83] Human ActA, FGF2 / LY294002, ActA, BMP4, 
FGF2 / FGF10 / FGF10, RA, SB431542 / 
FGF4, HGF, EGF 
Tuleuova et al. [84] Mouse Use of various growth factor arrays and 
micropatterned co-cultures to induce hepatic 
differentiation 
 
 
A formidable issue holding back the use of hESCs for regenerative medicine and in vitro 
drug discovery is the ethical dilemma behind the formation of the various cell lines. The creation 
of each hESC line involves developing a fertilized egg to the pre-implantation blastocyst stage 
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and isolating the cells from the inner cell mass, which will eventually become the hESC line. 
Some believe this process to be destruction of a human life, therefore making this topic a huge 
political debate around the world. However, if an alternative pluripotent cell source were to 
become available that is identical to the proliferative and developmental potential of hESCs, 
there would no longer be an ethical issue. The discovery and creation of hiPSCs circumvents this 
ethical issue. 
1.12 PLURIPOTENCY AS A TWO-WAY STREET 
Mammalian embryogenesis begins with the fertilization of the female oocyte by a male sperm to 
form a single cell that contains the proper amount of genetic material. Successive cell divisions 
lead to the formation of the pre-implantation blastocyst that contains the outer trophectoderm and 
inner cell mass. Directed differentiation of the cells within the blastocyst to their appropriate cell 
type is coordinated by highly specific molecularly controlled signaling events that are spatially 
and temporally controlled. These observations indicate that development potential is controlled 
by manipulation of global DNA gene expression within the cell rather than direct genetic code 
alterations. 
One attempt to prove this observation experimentally, in mammalian cells, occurred 
when researchers successfully performed the first somatic cell nuclear transfer experiments in 
lambs [86]. Researchers transferred a somatic cell nucleus to an enucleated unfertilized egg and 
implanted the egg within a host uterus eventually leading to the birth of live lambs.  This 
experiment provided evidence that differentiation of a cell toward a somatic state is not 
accomplished by irreversible genetic manipulation.  A cell becomes specified not by changing its 
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DNA sequence, but by controlling the expression of certain genes through specific controls.  Cell 
differentiation and pluripotency was no longer seen as a one way road.  This somatic cell nuclear 
transfer approach has yet to be successfully accomplished in human cells. 
1.13 IPSC DERIVATION 
Since the successful somatic cell nuclear transfer experiments in lambs, researchers have 
determined ways to manipulate a cell’s developmental potential back to an embryonic-like state 
where, theoretically, developmental potential is at its highest.  One approach to generate 
pluripotent stem cells from somatic cells was discovered when mouse embryonic and adult 
fibroblasts were shown to be reprogrammed to an ESC-like state by forced transcription of 
Oct3/4, Sox2, c-Myc, and Klf4 by lentiviral induction [87].  These cells were similar to ESCs in 
morphology, growth properties, expression of ESC marker genes, teratoma formation and 
injection into a blastocyst yielded cells that contributed to multiple tissues during mouse 
development, including the germ line. Further characteristics of iPSCs include DNA 
demethylation of key pluripotency genes and regulators, endogenous expression of pluripotency 
genes and down-regulation of viral genes used to induce pluripotency.  These cells were coined 
“induced pluripotent stem cells” (iPSCs).  Generation of iPSCs was confirmed to be possible in 
adult human dermal fibroblasts a year later by the same method as was performed in mice [88] 
and by forced expression of a new set of 4 factors: Oct4, Sox2, Nanog, and Lin28 [89]. 
In order to make iPSC technology clinically relevant researchers needed to figure out 
how to induce pluripotency without viral DNA integration into the target cell genome, which can 
create unwanted mutations because DNA is randomly inserted and copy number cannot be 
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controlled.  Mouse fibroblasts and hepatocytes were shown to be successfully reprogrammed by 
using non integrating adenoviruses to deliver the reprogramming factors [90].  This observation 
demonstrated that reprogramming to pluripotency could be achieved through transient expression 
of viral genes.  Another report of using virus to generate hiPSCs occurred when researchers 
demonstrated that temperature-sensitive Sendai viral vectors can be used resulting in hiPSC free 
of transgenes [91]. Vector integration-free human iPSCs have been derived by using nonviral 
techniques such as episomes derived from the Epstein-Barr virus [92] and transient transfection 
of plasmid DNA encoding reprogramming factors [93]. Furthermore it has been demonstrated 
that a novel nonviral minicircle vector free of bacterial DNA can be used to induce pluripotency 
[94]. This report is important because it decreases the amount of vector being produced, as there 
is one vector containing all the genes necessary to form hiPSCs.  These five reports demonstrate 
that somatic cell reprogramming does not require transgene genomic integration or continued 
expression of exogenous DNA.  Other non-integrating methods used to generate hiPSCs include 
using mRNA transfection [95, 96] and direct delivery of reprogramming proteins [97]. 
Investigators have also reported being able to use a bacteriophage ΦC31 integrase to reprogram 
cells with only a single integration site with locations favoring intron regions, thus producing 
cells with undisturbed endogenous gene function [98]. It has also been shown that poly-β-amino 
esters can be used to transfect plasmids, although this technique still resulted in hiPSCs that 
contain transgenes, however it did not require the use of a virus to deliver the genes [99]. 
Researchers were able to induce pluripotency without the use of Oct4 under entirely feeder-free 
conditions, albeit still using integrating lentiviral vectors [100]. Finally, a report demonstrated 
that reprogramming can be achieved using Dox-inducible lentiviral vectors [101]. This report is 
important because it provides a platform for researchers to control when the reprogramming 
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process is initiated by viral gene expression. This allows for the characterization of the 
reprogramming process and screens to increase reprogramming efficiencies or replace individual 
factors used to induce pluripotency.  
The usage of the oncogenes c-Myc and Klf4 to induce pluripotency also had to be solved 
in order to make iPSCs more clinically relevant.  Recent studies have shown that reprogramming 
could be successful without using c-Myc and Klf4.  Human fetal gut mesentery-derived cells and 
human amnion using Oct4, Sox2, and Nanog [102, 103] and primary human fibroblasts using 
only Oct4 and Sox2 [104] were shown to be successfully reprogrammed to pluripotency.  It is 
important to point out that although iPSCs can be derived without the use of Klf4 or c-Myc the 
efficiency of reprogramming is drastically reduced. Table 8 summarizes the first reports of the 
different ways to induce pluripotency and if that method leads to transgene-free cells. 
 
 
 
Table 8. Methods to Generate iPSCs 
This table summarizes the first reports of different ways to induce pluripotency, species of cells that were used and 
if that method leads to transgene-free cells. 
 
Reference Species Method Transgene-free? 
Takashashi et al. [87] Mouse Lentivirus No 
Takahashi et al. [88], 
Yu et al. [89] 
Human Lentivirus No 
Stadtfeld et al. [90] Mouse Adenovirus Yes 
Ban et al. [91] Human Sendai Virus Yes 
Yu et al. [92] Human Episomal Yes 
Si-Tayeb et al. [93] Human Plasmid DNA Yes 
Jia et al. [94] Human Novel ‘minicircle’ 
DNA 
Yes 
Warren et al. [95], 
Yakubov et al. [96] 
Human mRNA transfection Yes 
Kim et al. [97] Human Protein transfection Yes 
Montserrat et al. [99] Human Poly-β-amino esters to 
transfect plasmids 
No 
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Ye et al. [98] Mouse and Human Bacteriophage ΦC31 
integrase 
No 
Hockemeyer et al. 
[101] 
Human Drug inducible 
lentivirus 
No 
Li et al. [102] and 
Zhao et al. [103] 
Human Lentivirus delivering 
only Oct4, Sox2 and 
Nanog 
No 
Huangfu et al. [104] Human Retrovirus delivering 
only Oct4 and Sox2 
along with valproic 
acid treatment 
No 
Montserrat et al. [100] Pig Lentivirus delivering 
only Sox2, Klf4 and 
c-Myc in feeder-free 
conditions 
No 
 
 
Since iPSC technology has the potential to be very useful in the regenerative medicine 
field as well as drug discovery research, investigators became interested in seeing which cell 
types of the body can be reprogrammed to pluripotency. This was important because researchers 
postulated that perhaps the cell of origin of the iPSC will influence developmental potentials due 
to retention of epigenetic memory of the parent cell. Researchers have confirmed iPSC induction 
in the following cell types: fetal lung fibroblasts, neonatal foreskin fibroblasts, mesenchymal 
stem cells and dermal fibroblasts taken from healthy patients [105], adult mouse liver and 
stomach cells [106], primary human adult hepatocytes [107], fetal gut mesentery-derived cells 
[102], human and mouse extra-embryonic cells [108], human mesenchymal cells from the 
umbilicial cord matrix and amniotic membrane [109], human amnion [103], juvenile human 
primary keratinocytes [110], mouse hematopoietic and myogenic cells [111], and mouse fetal 
hepatocytes [112, 113]. Table 9 summarizes the first reports of reprogramming of different 
somatic cell types and what species the iPSCs came from. 
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Table 9. Generation of iPSCs from Various Somatic Cell Sources 
Table 9 summarizes some of the first reports of iPSCs generated from various somatic cell sources and species. 
 
Reference Species Cell Type 
Park et al. [105] Human Fetal lung fibroblasts, 
neonatal skin fibroblasts, 
mesenchymal stem cells and 
dermal fibroblasts 
Aoi et al. [106] Mouse Adult mouse liver and 
stomach cells 
Liu et al. [107] Human Adult Hepatocytes 
Li et al. [102] Human Fetal gut mesentery-derived 
cells 
Nagata et al. [108] Human and Mouse Extra-embryonic cells 
Cai et al. [109] Human Mesenchymal cells from the 
umbilical cord matrix and 
amniotic membrane 
Zhao et al. [103] Human Amnion 
Aasen et al. [110] Human Keratinocytes 
Polo et al. [111] Mouse Hematopoietic and Myogenic 
cells 
Kleger et al. [112] and Lee et 
al. [113] 
Mouse Fetal Hepatocytes 
 
 
The observation that different somatic cells could be reverted back to an embryonic state 
was very important; however there were no data that indicated if cell source affected the 
differentiation potentials of the generated iPSCs. 
1.14 DISEASE-SPECIFIC IPSC GENERATION 
Now that iPSC technology has been well established, investigators are trying to generate disease-
specific iPSCs to study disease both in vitro and in vivo.  These disease specific iPSCs will allow 
investigators to have an unlimited supply of disease specific cells if the iPSCs can be 
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differentiated to the cell type affected by the disease. These differentiated cells can be used for 
disease modeling, drug discovery and autologous cell replacement therapies after genetic 
correction. This genetic correction is possible through the usage of genome modifying zinc-
finger nucleases (ZFNs) [114]. These ZFNs allow for more efficient and less time-consuming 
gene targeting. They generate site-specific double strand breaks, leading to insertions or 
deletions via DNA repair by the non-homologous end joining pathway. ZFNs have corrected 
genetic defects in hiPSCs from disease specific cells, specifically in those generated from 
patients with sickle cell anemia [115] and alpha-1-antitrypsin deficiency [116]. In short, disease 
specific iPSCs represent an invaluable opportunity to recapitulate both normal and pathologic 
human tissue formation in vitro, thereby enabling disease investigation and drug development. 
Some successful reports of generating disease-specific iPSCs include: adenosine 
deaminase deficiency-related severe combined immunodeficiency [117],  Shwachman-Bodian-
Diamond syndrome [117], Gaucher disease type III [117], muscular dystrophy [117, 118], 
Parkinson disease [117, 119], Huntington disease [117], juvenile-onset type 1 diabetes mellitus 
[117], down syndrome/trisomy 21 [117], carrier state of Lesch-Nyhan syndrome [117], spinal 
muscular atrophy [120], familial dysautonomia [121], lysosomal storage disorders [122], 
Timothy syndrome [123], Fanconi anemia [124], and sickle cell anemia [115].  iPSCs have also 
been generated from skin fibroblasts of an 82 year old woman diagnosed with amyotrophic 
lateral sclerosis and subsequently differentiated back into motor neurons [125].  This report 
demonstrates that iPSC technology can even be used to generate cells from patients who are in 
the latter stages of life.  
Finally, iPSCs have been generated from patients with many liver-based genetic inborn 
errors in metabolism. These diseases include: α1-antitrypsin deficiency [116, 126], familial 
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hypercholesterolemia [126], glycogen storage disease [126, 127], CN-1 [126, 127], tyrosinemia 
[126, 127], progressive familial hereditary cholestasis [127] and Wilson’s disease [128]. Table 
10 summarizes the various disease-specific iPSCs that have been generated. 
 
Table 10. Summary of Various Reports of Disease-specific iPSC Generation 
This table is a summary of the various diseases that have had iPSCs generated from patient-specific cells. 
 
Reference Species Disease 
Park et al. [117] Human adenosine deaminase deficiency-
related severe combined 
immunodeficiency,  Shwachman-
Bodian-Diamond syndrome, Gaucher 
disease type III, muscular dystrophy, 
Parkinson disease, Huntington disease, 
juvenile-onset type 1 diabetes 
mellitus, down syndrome/trisomy 21, 
carrier state of Lesch-Nyhan 
syndrome 
Kazuki et al. [118] Mouse and Human muscular dystrophy 
Soldner et al. [119] Human Parkinson’s disease (transgene-free) 
Ebert et al. [120] Human spinal muscular atrophy 
Lee et al. [121] Human familial dysautonomia 
Meng et al. [122] Mouse lysosomal storage disorders 
Pasca et al. [123] Human Timothy syndrome 
Raya et al. [124] Human Fanconi anemia 
Sebastiano et al. [115] Human sickle cell anemia 
Dimos et al. [125] Human Amyotrophic lateral sclerosis 
Rashid et al. [126] Human α1-antitrypsin deficiency, familial 
hypercholesterolemia, glycogen 
storage disease, CN-1, tyrosinemia 
Ghodsizadeh et al. [127] Human Tyrosinemia, glycogen storage 
disease, progressive familial 
hereditary cholestasis, CN-1 
Yusa et al. [116] Human α1-antitrypsin deficiency 
Zhang et al. [128] Human Wilson’s disease 
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1.15 INCREASING REPROGRAMMING EFFICIENCIES 
In order to make hiPSC technology clinically relevant for both in vitro diagnostics or cell 
transplantation for regenerative medicine purposes, hiPSCs need to be efficiently and 
reproducibly generated in a low-cost and non-labor intensive manner. Therefore investigators 
began determining ways to increase reprogramming efficiencies of somatic cell reprogramming. 
It is known that reprogramming is enhanced by p53 deficiency and that p21, a 
downstream target of p53, contributes to p53-dependent repression of iPSC formation. This led 
researchers to postulate that p53 targets may help to hold back cells from becoming 
reprogrammed. miR-34 microRNAs (miRNAs) are downstream targets of p53 that are induced 
during iPSC development. Researchers determined that miR-34 deficiency, in mice, significantly 
increases reprogramming efficiency, kinetics and iPSC generation [129]. Furthermore, unlike 
p53 deficiency, which enhances reprogramming at the expense of iPSC differentiation potential, 
miR-34 deficiency increases iPSC formation without compromising self renewal or 
differentiation. Therefore miR-34 inhibitors can be used to help increase the reprogramming 
efficiency and therefore decrease the time for establishing iPSC lines and increasing the amount 
of lines that can be selected for to determine the best line to differentiate to the desired cell type 
of choice. 
Transfection of somatic cells with protein-encoding RNA of reprogramming genes is an 
attractive method to produce clinically relevant iPSCs free of genomic modification. However 
this is a very low efficiency method and it can become labor intensive, resulting in few iPSC 
lines to select for the best ones that differentiate to the investigator’s cell type of choice. It has 
been determined that multiple rounds of RNA transfection trigger an innate immune response 
that leads to growth arrest and eventual cell death. Therefore researchers hypothesized that if 
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they desensitize cells to exogenous RNA with various siRNA cocktails targeting the innate 
immune response they can enable multiple rounds of RNA transfection without causing growth 
arrest and cell death. Specifically researchers used siRNA to knockdown interferon-β, Eif2ak2 
and Stat2 to rescue transfected cells from the innate immune response triggers by frequent RNA 
transfection [130]. Therefore reprogramming efficiency can be increased if siRNA cocktails are 
used to target these three genes during RNA-mediated reprogramming of somatic cells. 
It has also been determined that reprogramming efficiency can be enhanced through 
forcing the transcription of all six transcription factors, rather than just using the Yamanaka four 
or the Thomson four [131]. This was shown using lentiviruses, however it is likely that this 
concept would be applicable to all types of reprogramming methods. Moreover, using chemical 
compounds that inhibit the TGFβ and MEK-ERK pathways have increased reprogramming 
efficiency of human fibroblasts and decrease the time to cell line establishment [132]. This was 
determined because it is known that TGFβ and MEK-ERK pathway inhibitors promote 
mesenchymal to epithelial transition, which is important to the reprogramming process in 
fibroblasts. 
Other ways to increase the reprogramming process include: adding SV40 large T antigen 
(which inactivates p53) to either set of 4 reprogramming genes enhances colony formation up to 
70-fold higher with formation 1-2 weeks earlier [133], co-expressing RAR-γ and Lrh-1 with the 
Yamanaka factors [134], culturing cells being reprogrammed under hypoxic conditions [135], 
using UTF1 forced transcription with p53 siRNA along with the Yamanaka factors [136] and 
enrichment of the cell population for progenitor cells [112]. Table 11 summarizes the different 
strategies to increase reprogramming efficiencies and iPSC colony formation. 
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Table 11. Summary of the Different Strategies to Increase Reprogramming Efficiencies and hiPSC Colony 
Formation 
This table summarizes the various ways researchers have increased reprogramming efficiencies and hiPSC colony 
formation. Table includes the specific reference associated with the method and the species of cells used. Method 
described in table is what is included in addition to the usual forced transcription of the reprogramming genes. 
 
Reference Species Method 
Choi et al. [129] Mouse miR-34 deficiency 
Angel et al. [130] Human Innate immune suppression 
Liao et al. [131] Human Combination of six 
transcription factors 
Yoshida et al. [135] Mouse and Human Hypoxia 
Lin et al. [132] Human TGFβ and MEK-ERK 
pathway inhibition 
Mali et al. [133] Human Addition of SV40 large T 
antigen 
Wang et al. [134] Mouse and Human Co-expression of RAR-γ and 
Lrh-1 
Zhao et al. [136] Human Addition of UTF1 forced 
transcription and p53 siRNA 
Kleger et al. [112] Mouse Enrichment of the cell 
population for progenitor 
cells 
 
1.16  MECHANISMS OF REPROGRAMMING – A BRIEF OVERVIEW OF 
IMPORTANT PATHWAYS 
It is important to know the molecular mechanisms associated with the reprogramming process. 
This information will enable researchers to determine more efficient and reproducible ways to 
generate iPSCs. It will also help in assessing if iPSCs are safe to use in a clinical setting. This is 
based on what pathways are being manipulated and if this can potentially lead to complications if 
the cells are transplanted into a patient. Important pathways and events involved in the 
reprogramming process include: p53 and its various downstream targets [129, 133, 136], innate 
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immune response pathways and regulators [130], pathways downstream of hypoxia inducible 
factors [135], MEK-ERK and TGFβ pathways [132], retinoic acid signaling [134],  AID-
dependent DNA demethylation [137], downstream targets of the orphan nuclear receptor Esrrb 
[138], and up-regulation of epithelial cell adhesion molecule complex proteins [139]. 
Furthermore it has been determined that reprogramming factor stoichiometry influences the 
epigenetic state of resulting iPSCs [140]. Different epigenetic states of iPSCs influence the 
resulting pluripotency and developmental potential of generated iPSCs and can affect the 
tumorigenicity of cells when transplanted in vivo. Finally, through the use of high resolution 
time-lapsed imagining it was determined that successfully reprogrammed cells undergo a rapid 
shift in their proliferative rate that coincides with a reduction in cell size [141]. This observation 
suggests that part of the reprogramming process follow defined rather than stochastic steps. 
1.17 TRUE REPROGRAMMED IPSCS VS. REPROGRAMMING INTERMEDIATES 
Since generating iPSCs involves forced expression of transcription factors it is not surprising that 
there is variation among the developmental and growth potential of different clonally expanded 
colonies.  This is especially true since each generated iPSC line is genetically unique (depending 
on the method used to produce the cell line). Through the use of live cell imaging, observations 
were made that lead to the conclusion that true reprogrammed colonies express: TRA1-60, 
DNMT3B, and REX1 and are able to silence viral DNA [142].  It was also determined that 
partially reprogrammed intermediates are alkaline phosphatase positive as well as express SSEA-
4, GDF4, hTERT, and NANOG [142].  This information is very important because iPSCs that 
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have the greatest developmental potential need to be identified early in the generation process so 
inferior colonies are not expanded and used for differentiation. 
1.18 IPSC DEVELOPMENTAL POTENTIALS – DEMONSTRATING IPSCS ARE 
PLURIPOTENT 
True pluripotency is determined by the ability of a stem cell to be differentiated to all 3 germ 
layers. Therefore in order to claim iPSCs are pluripotent investigators needed to describe in vitro 
and in vivo methods to differentiate iPSCs to cell types of all 3 germ layers. Teratoma formation 
is the “gold standard” in vivo method researchers use to determine pluripotency. If injected iPSC 
lines form tumors consisting of cell types from all 3 germ layers then the cell line is fully 
reprogrammed and pluripotent. As for in vitro methods, investigators used prior studies 
performed on hESCs as a basis for differentiation. Researchers began to determine chemically 
defined culture conditions that model the signaling events known to occur in tissue specification 
during embryogenesis.  Reports have been generated where iPSCs were differentiated back 
toward ventral midbrain dopaminergic neurons [143], neurospheres [144], hematopoietic and 
endothelial cells [145], cardiomyocytes [146-148],  and insulin secreting islet-like clusters [149]. 
These reports of in vitro differentiation of iPSCs represent lineages from all 3 germ layers. In 
each instance iPSCs were derived from fibroblasts and differentiation to desired cell type was 
achieved, however phenotype observed in culture is not always 100% comparable to the level of 
a primary cell.  Thus in vitro differentiation needs to be optimized, either by a change in iPSC 
source or differentiation protocol. 
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1.19 IPSC IN VITRO DIFFERENTIATION TO HEPATOCYTES 
Many investigators are interested in using iPSCs for drug discovery and regenerative medicine 
applications to treat liver disease. Therefore, researchers are interested in determining the best in 
vitro protocol for the derivation of high quality hiPSC-derived hepatocytes that is efficient and 
reproducible. There have been many reports claiming differentiation of iPSCs to hepatocytes 
using chemically defined culture conditions that include using various growth factors and 
cytokines, plating techniques and transduction of key liver-specific transcription factors [126-
128, 150-155]. All of these reports use different gene expression characteristics and hepatocyte-
specific function tests to characterize their iPS-derived hepatocytes. The take home message 
from all of these reports is that in most function tests, these stem-cell derived hepatocytes were 
never on the same level as compared to a primary hepatocyte. In fact, iPS-derived hepatocytes 
showed only 0.3-10% activity when compared to primary hepatocytes in certain hepatocyte 
specific function tests [154].  Therefore, as mentioned earlier, there needs to be a change in iPSC 
source or differentiation protocol to produce iPSC-derived hepatocytes that can be used for drug 
discovery or regenerative medicine applications. Table 12 summarizes the various reports of 
iPSC differentiation to hepatocytes in various species’ cells with a brief summary of their novel 
differentiation protocol. 
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Table 12. Various Reports of iPSC Differentiation to Hepatocytes 
This table summarizes the various reports within the literature on the generation of iPSC-derived hepatocytes from 
different species’ cells. Table includes the reference, species of cell used and a brief summary of the growth factors, 
cytokines and transduction techniques used within each reference’s differentiation protocol. The forward slashes in 
the “summary of protocol” column denote a change in culture conditions consisting of a basal medium or growth 
factor change. 
 
Reference Species Summary of Protocol 
Asgari et al. [150] Human ActA / FGF4, HGF / OSM, DEX 
Chen et al. [151] Human ActA, Wnt3a, HGF / DMSO / OSM, 
DEX, ITS 
Sancho-Bru et al. [152] Mouse ActA, Wnt3a / BMP4, FGF2 / 
FGF1, FGF4, FGF8 / HGF, 
Follistatin 
Si-Tayeb et al. [153] Human ActA / BMP4, FGF2 / HGF / OSM 
Song et al. [154] Human ActA / BMP2, FGF4 / HGF, KGF / 
OSM, DEX / OSM, DEX, N2, B27 
Takayama et al. [155] Human ActA, FGF2, transduction w. 
HNF3β / BMP4, FGF4, transduction 
w. HNF3β and HNF1α / HGF, 
FGF1, FGF4, FGF10, transduction 
w. HNF3β and HNF1α / HGF, 
OSM, DEX 
Rashid et al. [126] Human ActA, FGF2, BMP4, LY294002 / 
ActA / HGF, OSM 
Ghodsizadeh et al. [127] Human EB Formation / ActA / DMSO HGF 
/ DEX 
Zhang et al. [128] Human ActA / FGF4, BMP2 / HGF, KGF / 
OSM, DEX / OSM, DEX, N2, B27 
 
 
1.20 IN VITRO AND IN VIVO DISEASE MODELING WITH IPSCS – AND GENETIC 
CORRECTION 
In vitro disease models currently rely on tumor cells lines and transformed derivatives of native 
tissue, which may not be the best approaches to model disease.  If disease specific hiPSCs can be 
created and subsequently differentiated back to the cell type affected by the disease then these 
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cells would represent a better in vitro disease model than currently available. A recent study 
generated disease specific iPSCs from patients with familial dysautonomia and differentiated the 
cells back to neural crest precursor cells that maintain disease phenotype [121].  These neural 
crest precursor cells were then treated with a candidate drug and shown to respond to the drug as 
expected, demonstrating iPSC technology’s utility in drug development. There was a report of a 
complete genetic correction of hiPSCs from a muscular dystrophy patient using human artificial 
chromosome technology to deliver a correct copy of the dystrophin gene [118]. These corrected 
hiPSCs were differentiated to muscle-like tissues that expressed dystrophin. hiPSCs have been 
generated from a patient with ALS and were successfully directed to differentiate into motor 
neurons, the cell type destroyed in ALS [125]. Patients suffering from sickle cell anemia have 
had hiPSCs generated from their cells and then had their genetic mutation corrected for using 
zinc finger nuclease technology [115]. ZFNs are a class of engineered DNA-binding proteins that 
facilitate targeted genome editing my creating a double-stranded break in DNA. This allows for 
homologous recombination and non-homologous end joining to allow for user specific gene 
edits. Fanconi anemia disease specific hiPSCs have been generated [124]. These disease specific 
hiPSCs were shown to be corrected for their defect and could give rise to hematopoietic 
progenitors of the myeloid and erythroid lineages that are phenotypically normal. Patients 
afflicted with Timothy syndrome have had hiPSCs generated from their somatic cells [123]. 
Neurons derived from these hiPSCs have given new insights into the cellular phenotypes 
associated with Timothy syndrome that would not have been possible with primary cells from 
these patients. This observation demonstrates the true power of disease modeling with hiPSC 
technology in how it can provide new targets to treat underlying disease pathologies. Other 
reports using iPSCs to model disease like the above examples include disease specific cells from 
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patients with: lysosomal storage disorders [122], spinal muscular atrophy [120] and Parkinson’s 
disease [119]. 
In terms of liver specific diseases, hiPSCs have been shown to be a powerful tool to 
model liver-based inborn errors in metabolism in vitro. The following diseases have been 
modeled in vitro using hiPSCs: CN-1, tyrosinemia, A1AT, FH, glycogen storage diseases, 
progressive familial hereditary cholestasis and Wilson’s disease [116, 126-128]. The resulting 
hiPSCs from A1AT, FH and glycogen storage diseases were found to recapitulate key 
pathological features of the diseases affecting the patients from with they were derived, such as 
aggregation of misfolded α1-antitrypsin in the endoplasmic reticulum, deficient LDL receptor-
mediated cholesterol uptake and glycogen accumulation [126]. Although this report 
demonstrates the differentiated disease cells recapitulate key disease phenotypes, investigators 
failed to show hiPSC-derived hepatocytes derived from normal patients have normal protein 
folding, cholesterol uptake and glycogen accumulation. Therefore an alternative explanation for 
the findings in this report is that the disease phenotypes are from a failure of the hiPSCs to 
differentiate properly to hepatocytes.  
The hiPSCs derived from a patient with A1AT were shown to be corrected for the point 
mutation in the A1AT gene that was responsible for the deficiency [116]. This genetic correction 
restored the structure and function of A1AT in subsequently derived liver cells in vitro. The 
Wilson’s disease specific hiPSCs were shown to be differentiated into hepatocyte-like cells that 
displayed abnormal cytoplasmic localization of mutated ATP7B and defective copper transport, 
as would be expected in Wilson’s disease primary hepatocytes [128]. More importantly, gene 
correction using a lentiviral vector that expresses the corrected ATP7B gene or treatment with 
the chaperone drug curcumin could reverse the functional defect within the hepatocyte in vitro. 
 57 
These observations demonstrate the power of disease specific hiPSCs to model and treat liver 
diseases with gene therapy and potential autologous cell replacement or new drug discovery by 
treatment of disease specific hiPSC-derived hepatocytes with new small molecules to reverse 
pathologies. 
Many in vivo disease models utilize transgenic or pharmaceutical/chemical based 
approaches that do not control for off target effects and some diseases do not have a relevant 
model.  A Fah(-/-)Rag2(-/-)Il2rg(-/-) mouse has been developed that allows for the robust 
expansion of human hepatocytes within the host liver [32].  This specialized knockout mouse can 
be repopulated with human hepatocytes up to 90%.  Primary cells have a limited life span in 
culture and metabolic disease hepatocytes are not readily available.  If iPSCs can be generated 
from patients with genetic metabolic diseases and differentiated back to a hepatocyte-like state, 
these cells could serve as an unlimited source of cells for research.  If these genetically defective 
hepatocytes can highly repopulate the mouse liver it is hypothesized that the animal would 
recapitulate a phenotype similar to what is seen in the human.  These mice that contain 
“humanized” livers would be superior animal models for metabolic disorders because the basis 
for disease in the animal is human cell-derived.  These mice could provide the microenvironment 
milieu to support the tissue’s physiological function within the context of the whole organism, 
enabling greater understanding of disease pathogenesis and providing a platform for preclinical 
testing of drug candidates. 
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1.21 IPSCS USED TO TREAT DISEASE – POTENTIAL AUTOLOGOUS AND 
ALLOGENIC CELL REPLACEMENT THERAPIES 
Using patient specific iPSCs, correcting them for their genetic defect, and differentiating them 
back to hepatocytes could be the answer to the immunosuppression and cell shortage problems 
associated with primary cell replacement therapies for liver-based diseases.  If patient specific 
hiPSCs cannot be corrected for their defect, cell replacement therapies can utilize hiPSCs from a 
genetically competent donor and the OLT immunosuppression protocol can be used. This would 
solve the cell shortage issue. The current issue with making hiPSCs relevant for cell replacement 
therapy involves getting hiPSC-derived hepatocytes to engraft into various liver disease mouse 
models. This engraftment issue of hiPSC-derived hepatocytes needs to be solved. However, it 
does appear engraftment of hESC-derived somatic cells is possible given the recent report of 
hESC-derived neural progenitors elicit a distinct neurogenesis and functional recovery in a rat 
spinal cord contusion injury model [156].  
Importantly, canine iPSCs were differentiated to endothelial cells and transplanted into a 
mouse hindlimb ischemia model and a mouse myocardial injury model [157]. These 
investigators reported engraftment of iPSC-derived endothelial cells 14 days following ligation 
of the femoral artery in the ischemia model along with significantly improved revascularization 
in mice receiving cells compared to mice receiving controls. iPSC-derived endothelial cells were 
also transplanted into the border zone of infracted mouse hearts. Engraftment was monitored and 
detectable at 42 days after infarction. Measurement of systolic function by echocardiography 
revealed improvement in cardiac contractility for animals receiving cells compared with animals 
receiving controls at 14 and 28 days post infarction. However their imaging technique revealed 
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progressive death of the donor cells following transplantation in the heart, hence there were no 
differences in systolic function between the transplanted animals and control animals at day 42. 
A third group has differentiated iPSCs derived from hepatocytes, fibroblasts and 
keratinocytes into iPSC-derived hepatocytes and shown that all 3 types of hiPSCs have ability to 
engraft into a mouse model of chemical-induced acute liver failure [158]. They infused the mice 
with 2 million hiPSC-derived hepatocytes intravenously. They found that these cells could 
engraft in the mouse liver with efficiency ranging from 8 to 15%, which was comparable to adult 
human primary hepatocytes (~11%). Furthermore their engrafted cells were deemed functional 
because they detected albumin, transferrin, +/-1-antritrypsin and fibrinogen in the serum of 
transplanted animals. These concentrations ranged from 8.1 to 1100 ng/ml. These results suggest 
that hiPSC-derived hepatocytes may be useful to treat patients with end-stage liver disease and 
also potentially patients suffering from liver-based inborn errors in metabolism. 
These observations show the promise of iPSC-derived cells to treat diseases but at the 
same time also display the current issue still holding back cellular therapies: long-term 
engraftment.  Taken together, these three reports show promise for hiPSC-derived cellular 
therapies in the future, especially if long term engraftment issues can be solved. 
1.22 PATIENT SPECIFIC IPSCS – WOULD THEY BE IMMUNOGENIC? 
One of the big promises from iPSC technology is that it would allow for the creation of patient 
specific cells that can be corrected for their defect and transplanted back to the patient 
autologously, without the need for immunosuppression. However it has recently been shown that 
syngeneic mouse iPSCs are immunogenic [159]. The following observations were made: ESCs 
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derived from C57BL/6 mice can efficiently form teratomas in C57BL/6 mice without any 
evidence of immune rejection and allogenic ESCs from 129/SvJ mice fail to form teratomas in 
C57BL/6 mice due to rapid rejection by recipients. C57BL/6 mouse embryonic fibroblasts were 
reprogrammed into iPSCs. In contrast to C57BL/6 ESCs, teratomas formed by C57BL/6 iPSCs 
were mostly immune-rejected by C57BL/6 recipients. The majority of teratomas formed by 
C57BL/6 iPSCs in C57BL/6 mice displayed T cell infiltration, and in a small fraction of 
recipients there was apparent tissue damage and regression. A global gene analysis was 
performed to find that C57BL/6 iPSC-derived teratomas had over expression of certain genes 
compared to C57BL/6 ESC-derived teratomas. These data indicate that in contrast to ESC 
derivatives, abnormal gene expression in cells differentiated from iPSCs can induce an immune 
response in syngeneic recipients. Therefore the immunogenicity of patient specific iPSCs should 
be evaluated before any clinical application for autologous cell therapy. The one downfall from 
this study was that the investigators did not take skin cells from a mouse, make iPSCs from 
them, and transplant them into the same mouse to see if the resulting teratoma had evidence of an 
immune response. This would be the definitive experiment to determine if patient-specific iPSCs 
will elicit and immune response. 
1.23 MAKING TRANSPLANTATION OF IPSCS CLINICALLY RELEVANT 
One of the biggest issues holding back the usage of hiPSCs (and hESCs) for cellular therapies is 
the fact that any undifferentiated cells within the differentiated cell population can lead to 
formation of teratomas and potential cancer metastasis. Therefore technology has to be 
developed to remove teratoma-forming cells from differentiated cultures. A group has recently 
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discovered a monoclonal antibody against SSEA-5, and separation based on SSEA-5 expression 
through FACS greatly reduced teratoma-formation potential of poorly differentiated hESC 
cultures [160]. To ensure complete removal of potential cancer causing cells, they identified 
other pluripotency surface makers such as CD9, CD30, CD50, CD90 and CD200. Moreover, 
when subjecting hESCs to the SSEA-5 antibody and antibodies to 2 of the above mentioned 
other markers, they completely removed teratoma-formation potential from the poorly 
differentiated hESC cultures. Thus demonstrating experimentally it is possible to deplete 
undifferentiated teratoma-forming cells from cells that have been differentiated from hESCs. 
This report shows promise for hiPSC-derived cellular therapies in the future. 
Finally, in order to make hiPSC-derived cellular therapies clinically relevant, 
investigations on what happens to iPSCs upon transplant into a recipient need to be determined 
in a large animal model. A recent report discussed the first autologous transplantation of 
undifferentiated iPSCs in a large animal model through the generation of canine iPSCs and 
subsequent transplantation into the canines from which the iPSCs were made [157]. Fate of the 
undifferentiated iPSCs autologously transplanted to the canine heart and flank was tracked in 
vivo using clinical positron emission tomography, computed tomography, and magnetic 
resonance imagining. Transplanted cells were tracked using these methods after induction with a 
reporter gene. Although canine hearts were immediately explanted after transplant, they were 
confirmed to have cells in them by ex vivo microPET imaging and histological analysis. This 
report shows that iPSCs have the ability to be tracked once transplanted, further helping to 
provide evidence that one day they may be proven to be useful in a clinical setting. 
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1.24 EPIGENETIC MEMORY, DONOR DIFFERENCES AND CELL SOURCE 
INFLUENCING IPSC DIFFERENTIATION POTENTIALS 
It has recently been discovered that many iPSC lines show ability to differentiate to one lineage 
more efficiently and reproducibly than other lines. This experimental observation prompted 
researchers to begin to determine why there are these differentiation differences among cell lines. 
This information will allow researchers to determine the best characteristics of iPSC lines to 
differentiate to the hepatocyte lineage to use for drug discovery or regenerative medicine 
applications. 
It has been determined that background mutations in parental cells account for most of 
the genetic heterogeneity of iPSCs [161]. This was determined by sequencing the genome of ten 
mouse iPSC clones derived from 3 independent experiments and comparing them to the parental 
cell genomes. This group detected hundreds of single nucleotide variants in every clone, with an 
average of 11 in coding regions. In two of the experiments all variants were unique for each 
clone and did not cluster in pathways, but in the third all four clones contained 157 shared 
genetic variants, which could also be detected in rare cells within the parental cell pool. In short, 
these researchers concluded that most of the genetic variation in iPSC lines is not caused by 
reprogramming, but is rather a consequence of cloning individual cells within the parental pool 
and “capturing” that single reprogrammed cells unique genetic mutational history. These 
genetically unique iPSC lines could be the reason why some lines will differentiate to one 
lineage more efficiently and reproducibly than others. This is especially true if a line has a 
unique mutation in a coding region of a protein essential for specification to a certain lineage. 
For example lines that have mutations in the HNF4α gene could potentially have difficulty 
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differentiating to hepatocytes, since HNF4α is an important transcription factor that controls 
expression of many key hepatocyte specific genes. 
Another group has determined that aberrant silencing of the Dlk1-Dio3 gene cluster on 
chromosome 12qF1 in mouse iPSCs leads to poor developmental potential of the clones when 
comparing genetically identical iPSCs [162]. This is consistent with the developmental role that 
this gene cluster is known to be involved in. More specifically, it was shown that when this gene 
cluster is silenced the iPSC clones contributed poorly to chimeras and failed to support the 
development of entirely iPSC-derived animals. In comparison, iPSCs that had normal expression 
of this locus had the ability to form high-grade chimeras and generated viable all-iPSC mice. 
Furthermore, treatment of a clone that had silencing of the locus with a histone deacetylase 
inhibitor, such as valproic acid, reactivated the locus and rescued the lines developmental 
capabilities. This report is important because it can allow investigators to screen each developed 
iPSC line for silencing of this gene locus. If the line has silencing then it can be discarded due to 
its lack of developmental potential. 
Evidence has recently been generated that show mouse iPSCs contain epigenetic memory 
of the donor cell from which they were made from [163] and cell type of origin influences in 
vitro differentiation potentials [111].  It was shown that iPSC lines have DNA methylation 
signatures that are characteristic of their somatic tissue of origin, which in turn favors the 
differentiation of that cell line to lineages related to the original cell source.  Therefore, 
according to this data, if hepatocytes were the target cell, iPSCs generated from hepatocytes 
would represent the best cell source to generate stem cell-derived hepatocytes that most closely 
resemble their primary cell counterparts. However it was shown that continuous passing of iPSC 
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lines largely attenuated the differentiation differences, suggesting that early passage iPSCs have 
superior re-differentiation capacity. 
Recently, a group has looked into donor-dependent variations in hepatic differentiation of 
hiPSCs to see if they could determine the best hiPSC to differentiate to a hepatocyte [164]. They 
differentiated and compared 28 hiPSC lines originating from various somatic cells. The hiPSCs 
were also derived from various methods including retroviruses, Sendai viruses or episomal 
plasmids. This comparison concluded that the origins, not the derivation methods, may be a 
major determinant of variation in hepatic differentiation. Specifically it was determined that 
clones derived from peripheral blood cells consistently showed efficient differentiation, whereas 
many clones from adult dermal fibroblasts showed poor differentiation. When they compared 
lines from peripheral blood and dermal fibroblasts from the same individual they found that 
variations in hepatic differentiation were attributable to donor differences, rather than to the cell 
type of origin of the iPSC line. 
A second group has experimental evidence, like the previously discussed report, that 
regardless of cell origin the different human iPSC lines all showed the same ability to 
differentiate into hepatic cells in vitro [158]. They differentiated iPSCs derived from 
hepatocytes, fibroblasts and keratinocytes, all of which showed the same ability to differentiate 
into hepatic cells.  
In short, it has been shown experimentally that both donor differences as well as the cell 
type of origin of the created iPSC contribute to the developmental potential and differentiation 
capacities of clonally expanded iPSCs. This means both factors must be taken into account when 
determining the best iPSC to be differentiated to a hepatocyte. 
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1.25 MOUSE FETAL LIVER-DERIVED IPSCS – INCREASED REPROGRAMMING 
CAPACITY AND SUPERIOR RE-DIFFERENTIATION? 
Recently, a group has determined that there is an increased reprogramming capacity of mouse 
liver progenitor cells, compared with differentiated liver cells [112]. Specifically, adult and fetal 
liver cells from mice were enriched for their progenitor cells and it was determined that 
enriching for these cells dramatically increased reprogramming efficiencies. Enriching fetal liver 
cells for progenitor cells resulted in a 275-fold higher reprogramming efficiency compared with 
unsorted fetal cells. It was determined that this reprogramming efficiency increase was 
associated with endogenous expression of reprogramming factors and members of the BAF-
complex, which mediate epigenetic changes during reprogramming.  
Also, a group demonstrated that there is a contribution of hepatic lineage stage-specific 
donor memory to  the differentiation potential of mouse iPSCs [113]. Specifically, iPSCs derived 
from fetal liver cells retain superior hepatic re-differentiation compared to iPSCs derived from 
adult liver cells. However once again, continuous passaging negated the differentiation 
differences. 
Taken together, and if translated to humans, human fetal hepatocytes should have a 
superior reprogramming capacity and re-differentiation potential compared to adult hepatocytes. 
Therefore fetal hepatocyte-derived iPSCs may represent the easiest, most efficient and cost 
effective source to generate iPSC-derived hepatocytes that can be used for drug discovery, 
molecular biology disease research and regenerative medicine for liver-based diseases. 
 66 
1.26 PROPOSAL SUMMARY 
Here, we propose to isolate human adult and fetal hepatocytes, with and without various liver-
based metabolic diseases, and examine their ability to become fully reprogrammed hiPSCs under 
entirely feeder-free conditions. Furthermore, to investigate if there are reprogramming efficiency 
differences between adult and fetal hepatocytes and perform preliminary differentiation 
experiments to see if the resulting hiPSC lines have the ability to become hepatocyte-like in vitro 
and in vivo. 
1.27 MAJOR SIGNIFICANCE 
This research, once completed, will serve as proof of principle that iPSCs derived from primary 
human adult and fetal hepatocytes represent the best cell source for making unlimited amounts of 
stem cell-derived hepatocytes that most closely resemble primary cells.  Furthermore a bank of 
human hepatocytes with various liver-based metabolic diseases will be established that can be 
used for countless numbers of reprogramming experiments in order to generate disease-specific 
hiPSCs that represent the best source for generating disease-specific hiPSC-derived hepatocytes. 
Fetal hepatocytes will be shown to represent a source of hiPSCs that can be generated in a highly 
efficient and cost effective manner. This will be in direct contrast to human adult hepatocytes, 
where iPSC generation will be low efficiency and labor intensive. In either case, hiPSCs derived 
from adult and fetal hepatocytes can be an unlimited source for countless numbers of in vitro 
experiments to understand liver cell biology, if an efficient and reproducible hepatic 
differentiation protocol can be established.  Transplantation medicine can utilize these 
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differentiated cells to stabilize a patient or even potentially correct a defect.  Moreover, these 
stem-cell derived hepatocytes can be generated from disease patients, corrected for their genetic 
defect, and then transplanted back into the patient to correct the disorder without the need for 
immunosuppression. Investigators utilizing a pharmaceutical approach to therapy can use these 
cells for in vitro drug screens or use disease-specific cells for in vitro or in vivo disease 
modeling.  These iPSC-derived hepatocytes theoretically have countless real-life applications in 
basic and clinical research; the data just needs to be generated to make the theory a reality. 
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2.0  INCREASED REPROGRAMMING OF HUMAN FETAL HEPATOCYTES 
COMPARED WITH ADULT HEPATOCYTES IN FEEDER-FREE CONDITIONS* 
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2.1 ABSTRACT 
Hepatocyte transplantation has been used to treat liver disease.  The availability of cells for these 
procedures is quite limited.  hESCs and hiPSCs may be a useful source of hepatocytes for basic 
research and transplantation if efficient and effective differentiation protocols were developed 
and problems with tumorigenicity could be overcome.  Recent evidence suggests that the cell of 
origin may affect hiPSC differentiation. Thus, hiPSCs generated from hepatocytes may 
differentiate back to hepatocytes more efficiently than hiPSCs from other cell types. We 
examined the efficiency of reprogramming adult and fetal human hepatocytes.  The present 
studies report the generation of 40 hiPSC lines from primary human hepatocytes under feeder-
free conditions. Of these, 37 hiPSC lines were generated from fetal hepatocytes, 2 hiPSC lines 
from normal hepatocytes and 1 hiPSC line from hepatocytes of a patient with Crigler-Najjar 
Syndrome, Type-1.  All lines were confirmed reprogrammed and expressed markers of 
pluripotency by gene expression, flow cytometry, immunocytochemistry, and teratoma 
formation. Fetal hepatocytes were reprogrammed at a frequency over 50-fold higher than adult 
hepatocytes. Adult hepatocytes were only reprogrammed with 6 factors, while fetal hepatocytes 
could be reprogrammed with 3 (OCT4, SOX2, NANOG) or 4 factors (OCT4, SOX2, NANOG, 
LIN28 or OCT4, SOX2, KLF4, C-MYC). The increased reprogramming efficiency of fetal cells 
was not due to increased transduction efficiency or vector toxicity. These studies confirm that 
hiPSCs can be generated from adult and fetal hepatocytes including those with genetic diseases. 
Fetal hepatocytes reprogram much more efficiently than adult, although both could serve as 
useful sources of hiPSC-derived hepatocytes for basic research or transplantation. 
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2.2 INTRODUCTION 
Hepatocyte transplantation has been proposed as a cellular therapy for metabolic liver disease 
and acute liver failure. Primary hepatocyte transplantation has been used to partially correct 
patients with Crigler-Najjar, urea cycle, glycogen storage disorders and other metabolic liver 
diseases [40, 43, 53] and this therapy shows promise despite continuing issues with cell 
engraftment and proper immunosuppression. The availability of transplantable hepatocytes 
remains an ongoing problem.   
Stem cell-derived hepatocytes from human embryonic stem cell (hESC) [67] and induced 
pluripotent stem cell (hiPSC) [88, 89]  technology has the potential to provide a nearly unlimited 
source of hepatocytes for basic research, or in vitro drug discovery if efficient protocols were 
developed to produce mature hepatocytes; however issues concerning tumorigenicity still limit 
the clinical application of hESCs or hiPSCs.  Furthermore, hiPSC generation is limited by low 
reprogramming efficiency as well as long duration from induction to cell line establishment. 
hiPSCs have been derived from multiple cell types including fetal lung and neonatal foreskin 
fibroblasts, mesenchymal stem cells [105], mouse adult and fetal hepatocytes [90, 112, 113], 
amnion epithelial [103, 108] and mesenchymal cells from the umbilical cord matrix or amnion 
[109] and even one report with human adult hepatocytes [107]. Furthermore, hiPSCs have also 
been derived from fibroblasts from patients with different genetic disorders, including inherited 
metabolic disorders of the liver [126]. These disease-specific cell lines potentially serve as an 
unlimited source of disease-specific cells if they could be differentiated back to a phenotype that 
faithfully recreates the disease. Theoretically, disease-specific cells could be genetically 
corrected and used for autologous cell transplantation to correct the phenotype. The idea of 
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patient specific therapy has recently been put into question with a report that differentiated 
mouse iPSCs induce T-cell-dependent immune responses in syngeneic recipients [159].  
Several groups have tried to increase reprogramming efficiencies by using all six 
transcription factors [131], by combination of transcription factors and chromatin modulation 
[165, 166] or by addition of chemical compounds [167]. However, if populations of cells are 
more easily reprogrammed, methods to increase reprogramming may not be necessary, and these 
cell populations could be useful for translational research and could also be good models for 
understanding the mechanisms of the reprogramming process. 
Recently, an increased reprogramming capacity of mouse liver progenitor cells compared 
with differentiated liver cells was reported [112]. There is evidence that mouse iPSCs retain 
epigenetic markings providing “memory” of the cell from which they were made [163] and that 
cell type of origin influences in vitro differentiation potential [111]. A recent report demonstrated 
hepatic lineage stage-specific donor memory in mouse iPSCs, and interestingly, fetal hepatocyte-
derived iPSCs demonstrated superior capacity for hepatic re-differentiation [113]. Therefore, 
iPSCs from fetal human hepatocytes might be a particularly useful source of stem cell-derived 
hepatocytes. 
There are no reports describing derivation of hiPSCs from human fetal hepatocytes or 
from hepatocytes from patients with an inborn error in metabolism. Here, we provide a method 
to generate hiPSCs from adult and fetal human hepatocytes under entirely feeder-free conditions 
and report that reprogramming of fetal hepatocytes was over 50-fold more efficient than adult 
hepatocytes and can be accomplished with only 3 reprogramming factors. 
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2.3 MATERIALS AND METHODS 
2.3.1 Human Adult Hepatocyte Isolation 
All human tissues were collected with informed consent following ethical and 
institutional guidelines. Liver tissues were obtained either from liver resections or organ donors 
whose livers were not used for orthotopic liver transplantation. Residual tissue not needed for 
diagnostic purposes was transported to the laboratory from the operating rooms in cold Eagle’s 
Minimum Essential Medium (EMEM) (Lonza, Walkersville, MD, cat no. 12-136Q) within 30 
minutes of removal. Organs not used for orthotopic liver transplantation were obtained 3-24 
hours after cross-clamp and in situ perfusion. When whole organs were obtained, they were 
surgically reduced to smaller size for more effective perfusion. The left lateral segment was 
processed first after anatomical dissection from the right lobe, 2-3 cm from the falciform 
ligament. If necessary, the right lobe was divided in two parts and processed as separate tissues. 
From this point forward, the procedure for hepatocyte isolation was the same for organ donor 
and liver resection tissues. Silicone catheters were inserted into the major portal and/or hepatic 
vessels and the tissue was perfused with Hank’s Balanced Salt Solution (HBSS; without calcium, 
magnesium and phenol red; Lonza) to determine which vessel(s) provide the most uniform 
perfusion of the tissue. After the best vessels were identified, purse string sutures were used to 
encircle each vessel with its accompanying catheter and the sutures were drawn tight to prevent 
the leakage of buffer around the catheter during the perfusion. Excess suture material was tied to 
the catheters to further secure them to the liver. Perfusion proceeded once all remaining major 
vessels on the cut surfaces were closed with sutures or surgical grade super glue. The liver tissue 
was then placed in a sterile plastic bag and connected to a peristaltic pump with flow rate 
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dependent on the number of catheters and size of tissue (35 to 240 ml/min). The bag containing 
the tissue was placed in a circulating water bath at 37°C and the tissue was perfused with HBSS 
supplemented with 0.5 mmol/L ethylene glycol tetraacetic acid (EGTA) (Sigma Chemical Co., 
St. Louis, MO) without recirculation. Chelation of calcium by EGTA aids in the dissolution of 
intercellular junctions between hepatocytes and in the washing of hematopoietic cells. A second, 
non-recirculating perfusion with HBSS without EGTA was performed to flush residual EGTA 
from the tissue since calcium is essential for tissue dissociation enzyme activity. Finally, tissues 
were perfused with a third buffer composed of EMEM supplemented with VitaCyte’s Clzyme™ 
Collagenase MA (MA) and recirculated as long as needed to complete the digestion. Enzyme 
was reconstituted per manufacturerer’s recommendations, filtered, and added to the EMEM just 
prior to perfusion. Clzyme™ collagenase MA (VitaCyte) concentration was 100 mg/L with 24 
mg Clzyme™ BP Protease (VitaCyte) in 1 L of EMEM immediately before perfusion. In 
general, hepatocyte isolations from organ donor required 1L of each buffer solution for each 
lobe, while those from liver resections, utilized half this volume. The duration that the tissue was 
exposed to the different buffers was dependent upon flow rate of the peristaltic pump, number of 
catheters and quality of the tissue; but perfusion of the first two buffers usually resulted in 
sufficient rinsing and warming of the tissue within 20-30 minutes. Perfusion times for the 
EMEM-collagenase solution varied among the tissue specimens and were determined 
subjectively by continual monitoring of the tissue integrity. Perfusion was stopped when the liver 
tissue beneath the capsule surface was visibly digested and separated from the capsule, which 
normally took about 25-35 minutes, thus, the total time of perfusion needed for cell isolation 
ranged from 40-65 minutes. The tissue was then transferred to a sterile plastic beaker that 
contained ice-cold EMEM and was gently chopped with sterile scissors to release hepatocytes. 
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The cell suspension was filtered through sterile gauze-covered funnels to remove cellular debris 
and clumps of undigested tissue. Hepatocytes were enriched by three consecutive centrifugation 
steps at 80g for 6 min each at 4°C. After three washes in EMEM, hepatocytes were suspended in 
cold Hepatocyte Maintenance Medium® (HMM, Lonza). Cell viability was assessed by mixing 
an aliquot of the final suspension with an equal volume of 0.4% (w/v) trypan blue in phosphate 
buffered saline and counting the number of viable (unstained) and dead (blue) hepatocytes with a 
hemacytometer. Viabilities were expressed as a percentage of the total cell number. Cultures 
were changed out with fresh media 2 hours after plating and washed extensively 18-24 hours 
post plating to remove dead and unattached cells. Primary human hepatocytes were cultured in 
HMM (Lonza) and supplemented with 1X penstrep (Invitrogen, Carlsbad, CA) and 10-7M insulin 
and 10-7M dexamethasone (Lonza). 5% bovine calf serum (Atlanta Biologicals, Norcross, GA) 
was supplemented to the above mentioned media for the first 2 hours of plating to help facilitate 
hepatocyte attachment. Table 13 summarizes the various liver-based metabolic disorders where 
human hepatocytes have been isolated and cryopreserved to establish a cell bank where disease-
specific hiPSCs can be derived from. 
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Table 13. Human Hepatocyte Bank of Various Liver-based Metabolic Disorders 
This table summarizes the various liver-based metabolic disorders where human hepatocytes have been isolated and 
cryopreserved to establish a cell bank where disease-specific hiPSCs can be derived from. Table outlines the 
metabolic disease and the number of donors where disease-specific cells have been isolated from. 
 
Metabolic Disease # of Donors 
Crigler-Najjar Syndrome Type-1 2 
Ornithine Transcarbamylase Deficiency 2 
Carbamoyl Phosphate Synthetase-1 Deficiency 2 
Alpha 1-antitrypsin Deficiency 2 
Maple Syrup Urine Disease 3 
Familial Hypercholesterolemia 1 
Oxalosis 1 
Biliary Atresia 1 
Progressive Familial Intrahepatic Cholestasis Type-2 3 
Alagille Syndrome 1 
 
 
2.3.2 Human Fetal Hepatocyte Isolation 
HBSS supplemented with 1 mM EGTA was warmed to 37°C and 10 ml was added to the 
fetal liver tissue in a petri dish. The tissue was held with sterile forceps and gently chopped with 
a sterile cell scraper. After the tissue was chopped the biliary tree was removed and discarded. 10 
ml of warm HBSS with EGTA was added to the chopped tissue. This solution was pipetted into a 
new 50 ml conical tube(s) using a 25 ml pipette and the volume in the tube was brought up to 50 
ml using the warmed HBSS with EGTA. The tube(s) were gently inverted several times to mix 
the tissue inside well and centrifuged at 80g for 5 minutes at 4°C. The subsequent supernatant 
was poured off and a pellet formed containing a band of red cells and a band of buffy colored 
fibroblasts on top. The red cells and fibroblasts were aspirated carefully by holding the tube in 
the near horizontal position and rotating the tube while using an aspirating pipette along the edge 
of the pellet. The resulting pellet was washed by inversion using 50 ml of warmed HBSS 
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(without EGTA) and centrifuged at 80g for 5 minutes at 4°C. If red cells were present in the 
pellet they were carefully aspirated again. The resulting pellet was resuspended using warmed 
EMEM supplemented with 0.5 mg/ml collagenase-Type XI (Sigma Chemical Co.) and 0.2 
mg/ml DNase (Sigma Chemical Co.) to a final volume of 50 ml. The tubes were placed on a lab 
quake shaker/rotisserie (Barnstead Intl., Dubuque, IA) in a 37°C incubator (5% CO2/ambient O2) 
for 40 minutes. After the incubation the tube(s) were inverted several times and centrifuged at 
80g for 5 minutes at 4°C. The subsequent supernatant was poured off and the pellet was 
resuspended in 20 ml of warm EMEM. The pellet was resuspended by pipetting up and down 
several times using a 25 ml pipette and shaking the tube vigorously to break up the remaining 
tissue pieces. An aliquot of this cell suspension was used for total cell count and viability. This 
was assessed by mixing the aliquot with an equal volume of 0.4% (w/v) trypan blue in phosphate 
buffered saline and counting the number of viable (unstained) and dead (blue) hepatocytes with a 
hemacytometer. Viabilities were expressed as a percentage of the total cell number. The 
remaining cells were spun at 80g for 5 minutes at 4°C. The subsequent supernatant was poured 
off and the cells were resuspended in warm DMEM supplemented with 10% FBS (PAA 
Laboratories, Pasching, Austria), 10-7M insulin, 1X penstrep, and 10 ng/ml EGF (BD 
Biosciences). Cultures were changed out with fresh media 2 hours after plating and washed 
extensively 18-24 hours post plating to remove dead and unattached cells as well as red blood 
cells. 
2.3.3 hESC and hiPSC Cell Culture 
The H1 hESC and all hiPSC lines were maintained on hESC-qualified matrigel (BD 
Biosciences, San Jose, CA) and cultured in mTeSR™1 medium (Stem Cell Technologies, 
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Vancouver, BC, Canada) in a HERAcell150 incubator at 37°C and ambient O2 / 5% CO2. Cells 
were passaged using 1 mg/ml dispase (Gibco, Carlsbad, CA) using conventional stem cell 
culture techniques. All cell lines used for data collection were passage 30 or under. The H1 
hESC line was obtained from the WiCell Research Institute, Inc. The hiPSC inductions and cell 
line establishment section describes the cell culture process in detail. 
2.3.4 Matrigel Coating of 6-well Plates 
6-well plates were coated with hESC-qualified matrigel by diluting an aliquot of cold 
matrigel in 25 ml of cold DMEM/F12. The volume of the matrigel aliquot was noted on the 
specification sheet that came with the matrigel. 1 mL of matrigel diluted in DMEM/F12 was 
placed in each well of a 6-well plate. The plates were left undisturbed in the tissue culture hood 
for at least 1 hour. After an hour the plates were washed once with DMEM/F12. Plates were used 
immediately or could be stored in the 4°C refrigerator for up to 14 days. Stored plates contained 
2 mL of DMEM/F12 per well and were wrapped in plastic wrap to ensure sterility. 
2.3.5 hiPSC Inductions and Cell Line Establishment 
Primary human adult and fetal hepatocytes were added to matrigel-coated 6-well plates at 
100,000 cells/well in their respective media and allowed to attach overnight. The following day 
transduction media was given to the cells that consisted of each cell type’s respective culture 
medium supplemented with 6 µg/ml polybrene and lentiviruses delivering up to six 
reprogramming factors OCT4, SOX2, KLF4, C-MYC, NANOG, and LIN28, (Thermo Fisher 
Scientific) each at a targeted MOI of up to 10 (Day 0). After 24 hours the cells were washed with 
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DMEM/F12 (Thermo Fisher Scientific) 3X. Cells were cultured in their respective media and 
media was changed to mTeSR™1 on days 1-7. Media was refreshed every 2-3 days. Large 
hiPSC colonies appeared between days 16 and 21 and individual colonies were selected for 
expansion between days 25 and 35.  
The following describes the colony selection process and resulting hiPSC line culture 
techniques: Colonies for selection have well defined borders, a high nucleus to cytoplasm ratio 
and were morphologically indistinguishable from hESCs. Once these colonies were seen, the 
inverted microscope was placed into the tissue culture hood and the colonies were picked up 
manually using a P20 pipetman. hiPSCs were scratched gently off the culture dish and aspirated 
into the P20 pipet tip.  Each aspirated colony was plated into one well of a 6-well plate on hESC-
qualified matrigel in mTeSR.  hiPSC clones attached 24 hours after initial selection and retained 
the morphology observed prior to the selection.  Once the one well of a 6-well plate became 
about 80% confluent with hiPSCs the cells were passaged.  Briefly, the hiPSCs were washed 2X 
with DMEM/F12 and given 1 mg/ml dispase (Gibco) for about 5 minutes, or until the edges of 
the colonies folded up.  The cells were washed 2X with DMEM/F12 and then given mTeSR.  
The hiPSCs were gently scraped with a cell scraper to remove all the colonies off the bottom of 
the well.  The floating colonies were aspirated 2 to 3 times with a pipet in order to break the 
colonies up into smaller ones more suitable for passage. Colonies for passaging were smaller 
than those used for freezing, however not smaller than 20 cells. The colonies in the one well of a 
6-well plate were then transferred to another well of a 6-well plate coated with hESC-qualified 
matrigel in mTeSR. The splitting ratio was based on how confluent the well was prior to dispase 
treatment.  This splitting procedure was repeated until each individually picked clonally 
expanded colony could be established in a completely undifferentiated state with a normal 
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proliferation rate (passaging every 7-10 days). Figure 2 outlines the hiPSC induction protocol 
with examples of developing and selected colonies harvested into hiPSC lines. 
 
 
Figure 2. Protocol for hiPSC Inductions 
This figure summarizes the hiPSC induction protocol to establish hiPSCs derived from adult and fetal hepatocytes in 
entirely feeder-free conditions. Accompanied photographs show a timeline for the hiPSC induction experiment that 
lead to the formation of the AH-CN hiPSC line. Scale bars are 100 µM. 
 
 
Multiple vials of each established cell line were cryopreserved in mFreSR (Stem Cell 
Technologies) to establish a bank of human adult and fetal hepatocyte-derived hiPSC lines. 
Table 14 summarizes all of the established hiPSC lines, their associated Strom lab donor 
numbers and how many vials have been cryopreserved in mFreSR. 
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Table 14. Adult and Fetal Hepatocyte-derived hiPSC Bank 
This table summarizes the various hiPSC lines that have been derived from both adult and fetal hepatocytes, the 
associated Strom lab donor numbers and the number of vials that have been cryopreserved. 
 
Cell Line Name Strom Lab Donor # # Vials Cryopreserved 
AH-CN HH1655 80 
AH1 HH1591 26 
AH2 HH1591 NA 
FH1 HH1781f 70 
FH2 HH1795f 60 
FH3 HH1795f 6 
FH4 HH1791f 1 
FH5 HH1791f 4 
FH6 HH1791f 3 
FH7 HH1791f 3 
FH8 HH1791f 3 
FH9 HH1791f 3 
FH10 HH1902f 3 
FH11 HH1902f 4 
FH12 HH1902f 18 
FH13 HH1902f 4 
FH14 HH1902f 18 
FH15 HH1902f 12 
FH16 HH1902f 4 
FH17 HH1902f 4 
FH18 HH1902f 4 
FH19 HH1902f 5 
FH20 HH1902f 3 
FH21 HH1902f 3 
FH22 HH1902f 3 
FH23 HH1902f 4 
FH24 HH1902f 5 
FH25 HH1902f 4 
FH26 HH1902f 4 
FH27 HH1902f 4 
FH28 HH1902f 3 
FH29 HH1902f 16 
FH30 HH1902f 3 
FH31 HH1902f 4 
FH32 HH1986f 1 
FH33 HH1986f 1 
FH34 HH1986f 3 
FH35 HH1986f 2 
FH36 HH1986f 2 
FH37 HH1986f 1 
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Table 15 outlines each individually performed hiPSC induction experiment. It outlines 
the donor #, age, sex, viability, days in culture prior to induction, days into induction mTeSR™1 
was started, viruses used, MOI of viruses and what hiPSC lines were formed (if any). 
 
Table 15. Details of hiPSC Induction Experiments on Adult and Fetal Hepatocytes 
Information includes donor #, age, sex, viability, days in culture prior to induction, days into induction mTeSR™1 
was started, viruses used, MOI of viruses and what hiPSC lines were formed (if any). 
 
Donor # Age Sex Viability 
(%) 
hiPSC 
lines 
formed 
Days in 
culture 
prior to 
induction 
Days into 
induction 
mTeSR™1 
started 
Viruses 
used 
MOI 
(of 
each 
virus) 
HH1655 3 
mos 
F 83.4 AH-CN 4 7 OSKMNL 10 
HH1705 9 
yrs 
M 96.0 No 3 1 OSKMNL 10 
HH1758 6 
yrs 
F 78.0 No 1 7 OSKMNL 5 
HH1758 6 
yrs 
F 78.0 No 1 7 OSKMNL 10 
HH1764 10 
yrs 
M 76.0 No 2 7 OSKMNL 10 
HH1806 1 
mos 
M 70.5 No 1 7 OSKMNL 10 
HH1813 1 
yrs 
M 91.0 No 2 7 OSKMNL 10 
HH1815 13 
mos 
F 90.0 No 1 7 OSKMNL 10 
HH1815 
(thawed) 
13 
mos 
F UND No 1 2 OSKMNL 10 
HH1843 12 
yrs 
F 94.0 No 2 1 OSKMNL 10 
HH1892 1 
yrs 
M 88.0 No 1 3 OSKMNL 10 
HH1901 4 
mos 
M 89.0 No 2 3 OSKMNL 10 
HH1904 8 
mos 
M 84.0 No 1 3 OSNLM 10 
HH1591 12 
yrs 
F 76.0 AH1-2 3 6 OSKMNL 1.67 
HH1995 
(thawed) 
3 
yrs 
F 70.0 No 1 1 OSNL 10 
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HH1995 
(thawed) 
3 
yrs 
F 70.0 No 1 1 OSNL 5 
HH1996 
(thawed) 
14 
yrs 
M 70.0 No 1 1 OSNL 10 
HH1996 
(thawed) 
14 
yrs 
M 70.0 No 1 1 OSNL 5 
HH1781f 20 
wks 
UN
D 
95.0 FH1 3 2 OSN 10 
HH1782f 15 
wks 
M 98.5 No 2 1 OSNL 10 
HH1791f 12.
7 
wks 
M 91.0 FH4-9 1 1 OSNL 10 
HH1794f 18 
wks 
UN
D 
91.0 No 1 1 OSNL 10 
HH1795f 21 
wks 
M 91.0 FH2-3 1 1 OSNL 10 
HH1902f 22 
wks 
M 95.0 FH10 1 3 OSKM 10 
HH1902f 22 
wks 
M 95.0 FH11-
31 
1 3 OSNL 10 
HH1986f 24 
wks 
M 96.0 FH32-
37 
1 1 OSNL 10 
 
Colony formation was determined by counting total number of individual hESC-like 
colonies formed in all wells. Reprogramming efficiency was determined by the following 
equation: (total number of hESC-like colonies/total number of cells plated) X 100. Details of 
each individual experiment (n=18 adult and n=8 fetal) can be found in Table 15. 
2.3.6 Freezing of hESCs and hiPSCs 
The freezing procedure was the same procedure for splitting the cells, however instead of 
splitting the cells to a new matrigel coated plate the cells were centrifuged in mTeSR at 1000 
RPM for 5 minutes. The resulting cell pellet was resuspended in mFreSR, placed into a 
CoolCell® alcohol-free cryopreservation container (BioCision) and placed in the -80°C freezer 
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overnight. After 24 hours the frozen cell vials were permanently stored in liquid nitrogen. The 
ratio of mFreSR for each cell pellet was generally 2 80%-confluent wells of a 6-well plate per 1 
mL of mFreSR. 
2.3.7 Thawing of hESCs and hiPSCs 
A vial of cells was quickly taken out of liquid nitrogen and placed on dry ice and 
transported to a 37°C water bath for rapid thawing. Once the vial was completely thawed the 
solution of cells was gently aspirated using a pipet, put into mTeSR and centrifuged at 1000 
RPM for 5 minutes. The resulting cell pellet was resuspended in mTeSR supplemented with 10 
µM rock inhibitor (Sigma-Aldrich), being careful not to break up the colonies too much. Larger 
colonies generally plated better after thawing than smaller ones. Cells were plated onto 6-well 
matrigel coated plates according to how they were frozen. For example, if 2-wells of a 6-well 
plate were frozen in one vial, the thawed colonies were plated back to 2-wells of a 6-well plate. 
24-hours after thawing the attached colonies were similar in size to what the colonies looked like 
24-hours after normal passaging. 
2.3.8 Gene Expression 
RNA was isolated using TRIZOL® reagent (Life Technologies, Carlsbad CA) according 
to the manufacturer’s protocol. RNA integrity and purity were confirmed. DNase-I treated RNA 
of each sample were reverse-transcribed by PCR with RT-PCR reagents (Promega, Fitchburg, 
WI) according to manufacturer’s protocol. The resulting cDNA was analyzed by quantitative 
real-time PCR using specific TaqMan® assays and TaqMan® Gene Expression Master Mix 
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(Applied Biosystems, Carlsbad, CA) according to the manufacturer’s protocol. Ct values were 
entered into the following equation to determine the arbitrary unit value: 1 x 109 x e(-0.6931 x 
Ct) [168] then normalized to cyclophilin A. All samples were run and analyzed on a ABI Prism 
7000 Sequence Detection System. Table 16 summarizes the TaqMan® assays that were used: 
 
Table 16. TaqMan® Assays Used for Chapter 2 Experiments of this Dissertation 
Table summarizes the TaqMan® assays used for Chapter 2 experiments and the associated gene symbols, gene 
name and assay ID numbers. 
 
Gene Symbol Gene Name Assay ID # 
CYCA (PP1A) Cyclophilin A (peptidylprolyl isomerase A) Hs99999904_m1 
OCT4 Octamer 4 Hs03005111_g1 
SOX2 SRY (sex determining region Y)-box 2 Hs01053049_s1 
NANOG Nanog homeobox Hs02287400_g1 
GDF3 Growth differentiation factor Hs00220998_m1 
hTERT Human telomerase reverse transcriptase Hs00972656_m1 
DNMT3B DNA (cytosine-5-)-methyltransferase 3 beta Hs00171876_m1 
c-MYC Myelocytomatosis viral oncogene homolog Hs00905030_m1 
KLF4 Kruppel-like factor 4 Hs00358836_m1 
BAF155 (SMARCC1) SWI/SNF related, matrix associated, actin 
dependent regulator of chromatin, subfamily c, 
member 1 
Hs00268265_m1 
BRG1 (SMARCA4) SWI/SNF related, matrix associated, actin 
dependent regulator of chromatin, subfamily a, 
member 4 
Hs00231324_m1 
 
 
2.3.9 Flow Cytometry 
After a 3-5 minute exposure to accutase (Gibco), cells were counted and viability was 
determined. The cells were resuspended at a concentration of 107/ml in PBS enriched with 
human albumin and EGTA. We characterized the cells according their expression of nuclear and 
surface markers: NANOG, OCT3/4, SOX2, SSEA-3, SSEA-4, TRA1-60 and TRA 1-81 (all from 
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BD Biosciences). The staining procedure was the same for both type of markers: a minimum 
number of 0.5 x 106 viable cells per tube were incubated for 45 minutes at 4°C with appropriate 
amount of monoclonal antibodies directly conjugated with six fluorochromes: fluorescein 
isothiocyanate (FITC), phycoerythrin (PE), cyanine chrome 5 (Cy5), allophycocyanine (APC), 
Alexa 466 (Al.466) and Alexa 667 (Al.667) (according to manufacturer dilutions). After 
staining, the samples were fixed with 2% paraformaldehyde for 10 min at room temperature. The 
evaluation of nuclear markers required a fixation-permeabilization procedure (Perm/Wash 
Buffer), as described in the manufacture protocol (BD Biosciences, San Jose, CA), before the 
staining procedure. Appropriate non-specific fluorescence-conjugated antibodies of identical 
isotype were used as negative controls in order to evaluate positive cells for each specific 
antibody used. Four color flow-cytometry acquisition was performed by dual laser 
FACSCalibur® equipped with CellQuest® software (BD Biosciences). To analyze and 
immunophenotype different cell subpopulations, at least 0.3 x 106 cells per tube were acquired. 
Sequential gating was implemented based on negative-control staining profiles. All samples were 
analyzed by FlowJo® software (Tree Star Inc., OR). 
2.3.10 Immunofluorescence  
hiPSCs were plated on matrigel-coated coverslips in 24-well plates. Cells were washed 
3X with PBS and fixed using 4% PFA for 20 minutes. Cells were permeabilized with 0.1% 
Triton X made in PBS for 15 minutes for Oct4, Sox2, and Nanog. Cells were not permeabilized 
for SSEA4. Cells were rehydrated with 3 washes of PBS and 5 washes of 0.5% BSA in PBS.  
Blocking was performed in 2% BSA for 45 minutes followed by 5 washes of 0.5% BSA.  
Primary antibody was diluted in 0.5% BSA and incubated for 60 minutes followed by 5 washes 
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of 0.5% BSA. Secondary antibody was diluted in 0.5% BSA and incubated for 60 minutes 
followed by 5 washes of 0.5% BSA and 5 washes of PBS. Nuclei were stained using Hoechst for 
1 minutes followed by 2 washes with PBS. Cells were mounted using gelvatol mounting media 
consisting of PVA (Sigma-Aldrich, Cat. # P-8136), glycerol (Sigma-Aldrich, Cat. # G-9012) and 
sodium azide (Thermo Fisher Scientific, Cat. # S227-100) and refrigerated until images were 
captured on an Olympus Provis AX70 fluorescent microscope with Magnafire 2.1B software. 
The following primary antibodies were used: Rabbit anti-Oct3/4 (Santa Cruz sc-9081) 1:250, 
Rabbit anti-Sox2 (Millipore AB5603) 1:300, Rabbit anti-Nanog (Abcam ab-80892) 1:100, 
SSEA-4-Alexa Fluor 555 (BD Bioscience 560218) 1:100. The following secondary antibodies 
were used: Goat anti-rabbit Alex Fluor 488 (Invitrogen) 1:500 and Donkey anti-rabbit TR (Santa 
Cruz sc-2784) 1:250. 
2.3.11 Alkaline Phosphatase Staining 
hiPSCs were plated on matrigel in 24-well plates. Cells were fixed with 4% PFA in PBS 
and stained using the Vector Blue Alkaline Phosphatase Substrate Kit III (Vector Laboratories) 
using manufacturer’s protocol. 
2.3.12 Teratoma Formation 
hiPSCs were grown in 6-well plates to about 85% confluence. The entire 6-well plate was 
treated with 1 mg/ml dispase and cells were centrifuged at 200 x g for 5 minutes in a 50 mL 
conical tube. Cells were resuspended in 1 mL of mTeSR™1 and 1 mL of undiluted matrigel and 
equal volumes were transplanted subcutaneously between the scapulas of 3 NOD/SCID IL2γ-
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chain receptor knockout mice (dorsal injection). All animals were housed and euthanized 
according to University of Pittsburgh Animal Husbandry protocols. Tumors were excised from 
euthanized animals and fixed with 10% formalin overnight at 4°C. Tumor sections were 
processed and sections were made and stained for hematoxylin and eosin y. A pathologist from 
Children’s Hospital of Pittsburgh confirmed cell types from all 3 germ layers were present. 
2.3.13 Transduction Efficiency 
Primary human adult and fetal hepatocytes were plated on matrigel in 6-well plates at 
100,000 cells/well in their respective media and allowed to attach overnight. The following day 
transduction media was added to the cells that consisted of each cell type’s respective culture 
medium supplemented with 6 µg/ml polybrene (Millipore, Billerica, MA) and GFP lentivirus 
(Thermo Fisher Scientific, Waltham, MA) at an MOI of 5, 10, 25, and 50 in triplicate wells (Day 
0). After 24 hours the cells were washed with DMEM/F12 (Thermo Fisher Scientific) 3X and 
cells were given new cell culture media (Day 1). On Day 3 fluorescent images of the cells were 
taken using a Nikon Eclipse Ti inverted fluorescent microscope and Elements software (Nikon, 
Melville, NY). Ten random areas of each well from each MOI were taken for a total of 10 
pictures per MOI. Transduction efficiency was determined by the following equation: (GFP+ 
cells/total cells) X 100. 
2.3.14 Toxicity Assays 
Adult and fetal hepatocytes were isolated as described earlier. Ten thousand cells/well 
were plated on 96-well plates coated with matrigel in their respective cell culture media and 
 88 
allowed to attach overnight. The next day each respective cell type’s media was supplemented 
with 6 µg/ml polybrene and a lentivirus delivering GFP (Thermo Fisher Scientific) at an MOI of 
0-60. The next day the cells were washed and given their respective cell culture media. Cells for 
the 24 and 72 hour time points were analyzed for total double strand DNA using the Quanti-iT™ 
assay (Invitrogen), caspase activity by Caspase-Glo® 3/7 assay (Promega) and CellTiter-Glo® 
cell viability assay (Promega) according to manufacturer’s instructions. 
2.3.15 Statistical Analysis 
Reprogramming efficiency and gene expression analysis were analyzed using a two-
tailed student’s t-test. The incidence of hESC-like colony formation was analyzed using a 
Fisher’s Exact Test where colony formation in an individual experiment was scored either as a 
yes or a no. All toxicity assays were analyzed using a two way ANOVA with a Bonferroni 
posttest. A p-value of <0.05 was determined as significant. 
2.3.16 Use of Animal- and Human-derived Tissue 
All animal experiments were performed in accordance with the University of Pittsburgh’s 
Institutional Animal Care and Use Committee. Furthermore all human tissue was obtained and 
approved by the University of Pittsburgh’s Institutional Review Board and appropriate measures 
were taken to insure patient privacy. Informed consent was given for the human material. 
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2.4 RESULTS 
2.4.1 Establishing a Bank of Human Adult and Fetal Hepatocyte-derived hiPSCs in 
Entirely Feeder-Free Conditions 
Donor characteristics for the hepatocyte cases used in these studies are presented in Table 
15. For clarity, adult hepatocytes are defined here as any hepatocytes isolated from postnatal 
livers.  Fetal hepatocytes were isolated from tissue ranging from 89 – 168 days of gestation.  
Adult and fetal hepatocytes were freshly isolated and seeded on matrigel in their respective 
culture media and allowed to attach overnight (Figure 3). The average viability according to 
trypan blue exclusion was 83% and 94% for adult and fetal cells, respectively. The cells were 
transduced with lentiviruses delivering the reprogramming factors for 24 hours and media was 
changed every 2 to 3 days until hESC-like colonies appeared (see Experimental Procedures). 
Large hESC-like colonies appeared between days 16 and 21 and individual colonies were 
selected for expansion between days 25 and 34 and were seeded onto new matrigel-coated plates 
in mTeSR™1 medium. Fully reprogrammed colonies were easily distinguishable by their 
similarity to hESC colonies (Figure 3, 5-10). All selected colonies had high nuclei to cytoplasm 
ratio, well defined borders and were otherwise morphologically indistinguishable from hESCs 
(Figure 3, 5-10). In contrast, transformed / not fully reprogrammed colonies did not grow in well 
defined borders and the individual cells growing within the colonies were distinguishable from 
each other (Figure 4).  Colonies, like the one pointed out by the green arrow (Figure 4), were 
selected for and expanded into cell lines when the original colony was big enough to be 
harvested with a pipet under a microscope placed in the tissue culture hood to ensure sterility. 
Three hiPSC lines were isolated from 2 different adult hepatocyte cases; one of which was from 
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a 13 month old patient diagnosed with CN-1 syndrome and 2 lines were derived from a 12 year 
old female organ donor. Attempts at reprogramming 12 other adult and pediatric cases failed to 
generate hiPSC colonies (n=18 total experiments with adult hepatocytes). These cases ranged 
from 4 months to 39 years. In contrast, 37 hiPSC lines were isolated from 5 different fetal 
hepatocytes cases.  Importantly, one line was reprogrammed with only 3 factors (OCT4, SOX2, 
and NANOG; FH1). Attempts at reprogramming 2 other fetal hepatocyte cases failed to generate 
hiPSC colonies (n=8 total experiments with fetal hepatocytes). 
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Figure 3. Generation of hiPSCs from Adult and Fetal Hepatocytes in Entirely Feeder-Free Conditions 
Adult or fetal hepatocytes were exposed to lentiviruses delivering the reprogramming factors in their respective 
culture media overnight (Day 0). The culture medium was changed to mTeSR1 on Days 1-7. The pictures are 
representative images of starting cells and hiPSC lines grown on matrigel in mTeSR1. The hiPSC lines are 
morphologically indistinguishable from the H1 hESC line and grow in colonies with well defined borders and high 
nuclei to cytoplasm ratio. Scale bar is 100 µM. (A) Fetal hepatocytes in culture on Day 0 of hiPSC induction. (B) 
Representative colony of fetal hepatocyte-derived hiPSC clone FH1. FH1 was derived using only OCT4, SOX2 and 
NANOG. (C) Adult hepatocytes in culture on Day 0 of hiPSC induction. (D) Representative colony of adult 
hepatocyte-derived hiPSC clone AH1. (E) Representative colony of adult hepatocyte-derived hiPSC clone made 
from cells of a patient diagnosed with CN-1. Clone AH-CN (F) Representative colony of H1 hESC. 
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Figure 4. Distinguishing Between Transformed vs. Fully Reprogrammed Colonies 
This figure denotes the morphology of transformed (red arrows) and fully reprogrammed (green arrows) colonies. 
Fully reprogrammed colonies grow with well defined borders and individual cells are not distinguishable from each 
other. In contrast, transformed colonies do not have well defined borders and individual cells within the growing 
colony are distinguishable from each other. Scale bars are 100 µM. Colonies like the one pointed out by the green 
arrow were selected for and expanded into cell lines when the original colony was big enough to be harvest with a 
pipet under a microscope placed in the tissue culture hood to ensure sterility. 
 
 
Of the 40 lines generated, 8 were selected and examined for characteristics of fully 
reprogrammed cells. Two adult (AH1 and AH-CN) and 6 fetal (FH1, FH2, FH12, FH14, FH15 
and FH29) hepatocyte-derived hiPSC lines were further characterized for pluripotency for this 
report. All 8 of these hiPSC lines were characterized by morphology (Figure 3, 5-7, 9), gene 
expression, flow cytometry and ICC of pluripotency markers and teratoma formation. All other 
hiPSC lines established (both adult and fetal-derived) were expanded, cryopreserved and banked 
for later use. All of the characterized cell lines were carried out to at least passage 35 and 
maintained characteristic hESC-like morphology and a consistent proliferation rate. Please refer 
to Table 14 above for the established bank of hiPSCs derived from adult and fetal hepatocytes. 
Figures 5-10 shows the morphology of all other established hiPSC lines (AH2 line not shown). 
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Figure 5. Morphology of hiPSCs FH2-7 (A-F) 
Established hiPSC lines FH2-7 are morphologically indistinguishable from hESCs in culture. Scale bar is 100 µM. 
 
 
 
Figure 6. Morphology of hiPSCs FH8-13 (A-F) 
Established hiPSC lines FH8-13 are morphologically indistinguishable from hESCs in culture. Scale bar is 100 µM. 
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Figure 7. Morphology of hiPSCs FH14-19 (A-F) 
Established hiPSC lines FH14-19 are morphologically indistinguishable from hESCs in culture. Scale bar is 100 
µM. 
 
 
Figure 8. Morphology of hiPSCs FH20-25 (A-F) 
Established hiPSC lines FH20-25 are morphologically indistinguishable from hESCs in culture. Scale bar is 100 
µM. 
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Figure 9. Morphology of hiPSCs FH26-31 (A-F) 
Established hiPSC lines FH26-31 are morphologically indistinguishable from hESCs in culture. Scale bar is 100 
µM. 
 
 
Figure 10. Morphology of hiPSCs FH32-37 (A-F) 
Established hiPSC lines FH32-37 are morphologically indistinguishable from hESCs in culture. Scale bar is 100 
µM. 
 96 
2.4.2 Gene Expression Analysis of Pluripotency Genes of hiPSC Lines from Adult and 
Fetal Hepatocytes 
Quantitative RT-PCR was performed using human specific TaqMan® assays.  The hESC 
line, H1, was used as a positive control and the IMR90 fibroblast line was used as a negative 
control. All hiPSC lines expressed OCT4, SOX2, NANOG, GDF3, hTERT and DNMT3B at 
levels comparable to H1 hESCs, although the latter 2 were the most variable between different 
hiPSC clones (Figure 11). All analyzed cell lines were passage 35 or under. 
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Figure 11. Gene Expression Analysis of Pluripotency Marker Expression of Selected Clonally Expanded hiPSC 
Lines from Both Adult and Fetal Hepatocytes 
This figure displays the characterized hiPSC line gene expression. The H1 hESC line is used for a positive control 
an the IMR90 fibroblasts line is used for a negative control of expression levels. All expression level values are 
normalized to the cyclophilin housekeeping gene. All characterized cell lines express the pluripotency markers 
OCT4, SOX2, NANOG, hTERT, GDF3 and DNMT3B. All analyzed cell lines were passage 35 or under. 
 
2.4.3 Flow Cytometry Analysis of Pluripotency Marker Expression of hiPSC Lines From 
Adult and Fetal Hepatocytes 
Flow cytometry analysis indicated that every hiPSC line analyzed expressed the 
pluripotency surface markers SSEA-3, SSEA-4, TRA1-60, and TRA1-81 and nuclear markers 
OCT4, SOX2, and NANOG at levels comparable to H1 hESCs (Figure 3). IMR90 fibroblasts 
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were completely negative for all markers analyzed. The expression of TRA1-60 and 1-81 were 
the most variable between the different lines examined. All analyzed cell lines were passage 35 
or under. 
 
 
Figure 12. Flow Cytometry Analysis of Pluripotency Marker Expression of Selected Clonally Expande4d hiPSC 
Lines from Both Adult and Fetal Hepatocytes 
This figure displays the characterized hiPSC line protein expression. The H1 hESC line is used for a positive control 
and the IMR90 fibroblasts line is used for a negative control of expression levels. All characterized cell lines express 
the pluripotency markers SSEA3, SSEA4, TRA1-60, TRA1-81, OCT4, SOX2 and NANOG. All analyzed cell lines 
were passage 35 or under. 
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2.4.4 Alkaline Phosphatase Activity of hiPSC Lines from Adult and Fetal Hepatocytes 
Alkaline phosphatase activity, a property of pluripotent cells, was detected in adult and 
fetal-derived hiPSCs and H1 hESC; IMR90 fibroblasts were negative (Figure 13-14). A blue 
staining denotes a positive alkaline phosphatase signal. All analyzed cell lines were passage 35 
or under. 
 
 
Figure 13. Alkaline Phosphatase Activity of Adult Hepatocyte-derived hiPSCs 
Established hiPSC lines have alkaline phosphatase activity denoted by the blue stain. (A) Both AH1 and (B) AH-CN 
are alkaline phosphatase positive. (C) H1 hESC and (D) IMR90 fibroblasts were used as positive and negative 
controls respectively. All analyzed cell lines were passage 35 or under. Scale bar is 100 µM. 
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Figure 14. Alkaline Phosphatase Activity of Fetal Hepatocyte-derived hiPSCs 
Established hiPSC lines have alkaline phosphatase activity denoted by the blue stain. (A) FH1, (B) FH2, (C) FH12, 
(D) FH14, (E) FH15 and (F) FH29 are alkaline phosphatase positive. H1 hESC and IMR90 fibroblasts were used as 
positive and negative controls respectively and can be seen in Figure 13. All analyzed cell lines were passage 35 or 
under. Scale bar is 100 µM. 
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2.4.5 Immunofluorescence Staining of hiPSC Lines from Adult and Fetal Hepatocytes 
Nuclear OCT4 and SOX2 were observed in AH-CN and FH1 shown by the green 
staining (Figure 15). IMR90 fibroblasts were negative and H1 hESCs were positive (data not 
shown). Nuclear NANOG and cell surface SSEA4 were also observed in AH-CN and FH1 
shown by the red staining (Figures 16 and 17). Again, IMR90 fibroblasts were negative and H1 
hESCs were positive (data not shown). IF staining for OCT4, SOX2, NANOG and SSEA-4 were 
also performed on all other characterized adult and fetal-derived hiPSCs (AH1, FH2, FH12, 
FH14, FH15 and FH29). All lines were positive denoted by the red staining. OCT4, SOX2 and 
NANOG were nuclear and SSEA4 was found on the surface (Figures 18-29). All analyzed cell 
lines were passage 35 or under. 
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Figure 15. OCT4 and SOX2 Immunofluorescence Staining of AH-CN and FH1 
The adult hepatocyte line depicted is AH-CN and the fetal hepatocyte line depicted is FH1. The H1 hESC line is 
used for a positive control and the IMR90 fibroblast line is used for a negative control of expression (data not 
shown). Scale bar is 100 µM. Positive protein staining is found in green and nuclei are stained with DAPI, seen in 
blue. The merge panel shows that both AH-CN and FH1 colonies express OCT4 and SOX2 entirely in the nucleus. 
CTRL panels depict colonies that did not receive primary antibody. As expected these colonies did not stain for 
OCT4 and SOX2 protein. All analyzed cell lines were passage 35 or under. 
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Figure 16. NANOG and SSEA4 Immunofluorescence Staining of AH-CN 
The AH-CN line is positive for NANOG and SSEA4 denoted by the red stain. CTRL panels depict colonies that did 
not receive primary antibody. All analyzed cell lines were passage 35 or under. Scale bar is 100 µM. 
 
 
 
Figure 17. NANOG and SSEA4 Immunofluorescence Staining of FH1 
The FH1 line is positive for NANOG and SSEA4 denoted by the red stain. CTRL panels depict colonies that did not 
receive primary antibody. All analyzed cell lines were passage 35 or under. Scale bar is 100 µM. 
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Figure 18. OCT4 and SOX2 Immunofluorescence Staining of AH1 
The AH1 line is positive for OCT4 and SOX2 denoted by the red stain. CTRL panels depict colonies that did not 
receive primary antibody. All analyzed cell lines were passage 35 or under. Scale bar is 100 µM. 
 
 
 
 
 
 
Figure 19. NANOG and SSEA4 Immunofluorescence Staining of AH1 
The AH1 line is positive for NANOG and SSEA4 denoted by the red stain. CTRL panels depict colonies that did not 
receive primary antibody. All analyzed cell lines were passage 35 or under. Scale bar is 100 µM. 
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Figure 20. OCT4 and SOX2 Immunofluorescence Staining of FH2 
The FH2 line is positive for OCT4 and SOX2 denoted by the red stain. CTRL panels depict colonies that did not 
receive primary antibody. All analyzed cell lines were passage 35 or under. Scale bar is 100 µM. 
 
 
 
 
 
 
Figure 21. NANOG and SSEA4 Immunofluorescence Staining of FH2 
The FH2 line is positive for NANOG and SSEA4 denoted by the red stain. CTRL panels depict colonies that did not 
receive primary antibody. All analyzed cell lines were passage 35 or under. Scale bar is 100 µM. 
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Figure 22. OCT4 and SOX2 Immunofluorescence Staining of FH12 
The FH12 line is positive for OCT4 and SOX2 denoted by the red stain. CTRL panels depict colonies that did not 
receive primary antibody. All analyzed cell lines were passage 35 or under. Scale bar is 100 µM. 
 
 
 
 
Figure 23. NANOG and SSEA4 Immunofluorescence Staining of FH12 
The FH12 line is positive for NANOG and SSEA4 denoted by the red stain. CTRL panels depict colonies that did 
not receive primary antibody. All analyzed cell lines were passage 35 or under. Scale bar is 100 µM. 
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Figure 24. OCT4 and SOX2 Immunofluorescence Staining of FH14 
The FH14 line is positive for OCT4 and SOX2 denoted by the red stain. CTRL panels depict colonies that did not 
receive primary antibody. All analyzed cell lines were passage 35 or under. Scale bar is 100 µM. 
 
 
 
 
Figure 25. NANOG and SSEA4 Immunofluorescence Staining of FH14 
The FH14 line is positive for NANOG and SSEA4 denoted by the red stain. CTRL panels depict colonies that did 
not receive primary antibody. All analyzed cell lines were passage 35 or under. Scale bar is 100 µM. 
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Figure 26. OCT4 and SOX2 Immunofluorescence Staining of FH15 
The FH15 line is positive for OCT4 and SOX2 denoted by the red stain. CTRL panels depict colonies that did not 
receive primary antibody. All analyzed cell lines were passage 35 or under. Scale bar is 100 µM. 
 
 
 
Figure 27. NANOG and SSEA4 Immunofluorescence Staining of FH15 
The FH15 line is positive for NANOG and SSEA4 denoted by the red stain. CTRL panels depict colonies that did 
not receive primary antibody. All analyzed cell lines were passage 35 or under. Scale bar is 100 µM. 
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Figure 28. OCT4 and SOX2 Immunofluorescence Staining of FH29 
The FH29 line is positive for OCT4 and SOX2 denoted by the red stain. CTRL panels depict colonies that did not 
receive primary antibody. All analyzed cell lines were passage 35 or under. Scale bar is 100 µM. 
 
 
 
Figure 29. NANOG and SSEA4 Immunofluorescence Staining of FH29 
The FH29 line is positive for NANOG and SSEA4 denoted by the red stain. CTRL panels depict colonies that did 
not receive primary antibody. All analyzed cell lines were passage 35 or under. Scale bar is 100 µM. 
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2.4.6 Teratoma Formation of hiPSC Lines from Adult and Fetal Hepatocytes 
Teratoma formation is considered the definitive test of complete reprogramming to 
pluripotency. Each hiPSC line derived from either adult or fetal hepatocytes generated complex 
teratomas within 8-12 weeks in NOD/SCID IL2γ-chain receptor knockout mice. Representative 
pictures of structures resembling all three germ layer tissues, such as neural tissue and neural 
rosettes (ectoderm), chondroid tissue (mesoderm), and intestinal epithelium (endoderm) are 
shown in Figure 30. Figures 30-36 show teratoma formation capabilities of the rest of the 
characterized hiPSC lines. All analyzed cell lines were passage 35 or under. 
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Figure 30. Teratoma Formation of Selected Clonally Expanded hiPSC Lines from Both Adult and Fetal 
Hepatocytes 
The adult hepatocyte line depicted is AH1 and the fetal hepatocyte line depicted is FH1. The H1 hESC line is used 
for a positive control and the IMR90 fibroblast line is used for a negative control (data not shown). Cell lines were 
subcutaneously injected into the backs of NOD/SCID IL2γ-chain receptor knockout mice. Once tumors were large 
enough they were excised and processed for hematoxylin and eosin y staining. A pathologist then examined cross 
sections of tumors from different cell lines for evidence of cell types from all 3 germ layers. All characterized adult 
and fetal-derived hiPSC lines formed complex teratomas in vivo. FH1 and AH1 hiPSC lines display cell types 
ranging from neural tissue (ectoderm), chondroid tissue (mesoderm) and intestinal epithelium (endoderm). All 
analyzed cell lines were passage 35 or under. Scale bars are 50 µM. 
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Figure 31. Teratoma Formation of AH-CN 
Scale bars are 50 µM. 
 
 
Figure 32. Teratoma Formation of FH2 
Scale bars are 50 µM. 
 
 
Figure 33. Teratoma Formation of FH12 
Scale bars are 50 µM. 
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Figure 34. Teratoma Formation of FH14 
Scale bars are 50 µM. 
 
 
Figure 35. Teratoma Formation of FH15 
Scale bars are 50 µM. 
 
 
Figure 36. Teratoma Formation of FH29 
Scale bars are 100 µM. 
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2.4.7 Human Fetal Hepatocytes Reprogram More Efficiently than Human Adult 
Hepatocytes 
Only 3 hESC-like colonies were identified from 18 experiments with 14 different donors 
when adult cells were used for attempted reprogramming. A total of 19,950,000 adult 
hepatocytes were exposed to reprogramming factors, and that resulted in 3 hiPSC colonies that 
were identified by their morphology and collected, expanded and cryopreserved. Vastly different 
results were obtained when reprogramming was attempted with fetal hepatocytes.  A total of 80 
hESC-like colonies were identified from 8 experiments with 7 different donors when fetal cells 
were used for attempted reprogramming. A total of 4,900,000 fetal hepatocytes were exposed to 
reprogramming factors. Of the 80 total hiPSC colonies generated from fetal hepatocytes, 37 
hiPSC colonies were selected at random and were collected, expanded and cryopreserved. 
Reprogramming efficiency, defined as (number of hESC-like colonies formed/total number of 
cells exposed to the vectors) x 100, are 2.41 X 10-5 and 1.23 X 10-3, for adult and fetal 
hepatocytes, respectively (Figure 37A). This represents a highly significant, and over a 50-fold 
higher reprogramming efficiency of fetal hepatocytes as compared to adults (p=0.0015). 
Furthermore, 75% of the fetal hepatocyte cases yielded hESC-like colonies as compared to only 
11% of the adult hepatocyte isolations (Figure 37B). The incidence, or likelihood, of hESC-like 
colony formation in any given experiment from adult vs. fetal hepatocytes is also highly 
significant (Fisher’s Exact Test with a p-value of 0.0028). 
 
 115 
 
Figure 37. Fetal Hepatocytes Reprogram at Over a 50-fold Higher Rate as Compared to Adult Hepatocytes 
(A) A total of 19,950,000 adult hepatocytes were exposed to reprogramming factors as compared to only 4,900,000 
fetal hepatocytes. Reprogramming efficiency, defined as (number of hESC-like colonies formed/total number of 
cells exposed to the vectors) X 100, was more than 50-fold higher for fetal hepatocytes as compared to adult 
hepatocytes. *p = 0.0015 versus adult hepatocytes and data are SEM of n=18 adult experiments and n=8 fetal 
experiments. (B) When looking at individual hiPSC induction experiments of adult and fetal hepatocytes and 
scoring each experiment as a yes, hESC-like colonies formed, or no, hESC-like colonies did not form; fetal 
hepatocytes form hESC-like colonies at a higher incidence or likelihood than adult hepatocytes. This was highly 
statistically significant by Fisher’s Exact Test. *p = 0.0028 versus adult hepatocytes and data are SEM of n=18 adult 
experiments and n=8 fetal experiments. 
 
 
Because the fetal cells reprogrammed with a higher efficiency than the adult cells we 
examined the donor characteristics of the adult cases to determine if there was a consistent trend 
towards more efficient reprogramming in younger donors. As shown in Table 15, 
reprogramming was achieved with 2 donors, one 12 years and the other 13 months of age. 
Reprogramming efficiency does not appear to be related to donor age in the adult cells, as the 
youngest “adult” donor, 4 months of age, and 2 cases from 1 year old donor, also failed to 
reprogram. Many younger donors were examined and in total 11 of the 14 adult cases tested 
were from donors 12 years or under. Thus, from these 14 cases, there is no clear connection 
between donor age and reprogramming efficiency post birth. However, we did not specifically 
design the experiments to examine reprogramming efficiency in different age groups. 
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2.4.8 Human Fetal Hepatocytes’ Higher Reprogramming Efficiency is Not Due to 
Transduction Efficiency or Toxicity to Reprogramming Factor Viruses 
A trivial explanation for such large differences in reprogramming efficiency could be 
related to the infectivity of the cells with the lentiviruses.  To determine if there were differences 
between adult and fetal cells with respect to transduction efficiency, a lentivirus carrying GFP 
was used in place of the reprogramming vectors at an MOI ranging from 0-50 and the percentage 
of GFP-positive cells was determined 72 hours after viral exposure (Figure 38A). The percentage 
of GFP-positive cells increased with increasing MOI in both fetal and adult cells. The data from 
adult cells was consistently higher than that observed with fetal cells, however there were no 
significant differences between adult and fetal cells at any MOI. 
Large differences in reprogramming efficiency could also result if reprogramming viruses 
were more toxic to adult cells. To test this, a lentivirus carrying GFP was used in place of the 
reprogramming vectors at MOI ranging from 0 to 60. Apoptosis levels were measured by 
caspase 3/7 activity and cell viability was measured by ATP content and total double strand 
DNA content 24 hours after viral exposure. All data was normalized to MOI 0. Adult and fetal 
hepatocytes showed no statistical differences between caspase 3/7 activity (Figure 38B), cell 
viability measured by ATP content (Figure 38C) or total double strand DNA levels (Figure 38D) 
at all tested MOI, however fetal cells trended towards higher caspase activity and lower amounts 
of ATP. Total double strand DNA levels were consistent between adult and fetal cells at all 
tested MOIs. Similar data was obtained when toxicity was investigated 72 hours after viral 
exposure (data not shown). 
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Figure 38. Fetal Hepatocytes’ Higher Reprogramming Efficiency Not Due to Transduction Efficiency Differences 
or Toxicity to Reprogramming Factor Viruses 
(A) A transduction efficiency experiment was performed on adult and fetal hepatocytes where a lentivirus delivering 
GFP was given to the cells at increasing MOIs to determine if the fetal cells are infected more efficiently than the 
adult cells. Both adult and fetal hepatocytes were readily and efficiently infected with the lentivirus, however adult 
cells were more efficiently infected than fetal cells at all tested MOIs but this was not statistically significant. (B-D) 
Toxicity to a lentivirus delivering GFP was investigated at increasing MOIs and analyzed 24 hours after infection. 
Data was normalized to MOI 0. Toxicity was measured by caspase 3/7 activity (B), ATP content (C) and total 
double strand DNA (D). Data are SEM of n=3 adult and fetal experiments.  No statistical differences were seen 
between adult and fetal cells in the three assays at the different MOIs. 
 
2.4.9 Endogenous Gene Expression Analysis of Reprogramming Factors and BAF-
complex Members BAF155 and BRG1 in Cultured Adult or Fetal Hepatocytes 
It was previously shown in mouse that the increased reprogramming efficiency was 
associated with the endogenous expression of reprogramming factors (OCT4, SOX2, NANOG, 
KLF4 and C-MYC) and mediators of epigenetic changes during reprogramming (BAF-complex 
components BRG1 and BAF155) [112]. Therefore quantitative RT-PCR was performed using 
human specific TaqMan® assays to determine the endogenous levels of expression of these genes 
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in adult and fetal hepatocytes. Adult hepatocytes expressed higher levels of endogenous OCT4, 
SOX2, NANOG, and KLF4; while fetal hepatocytes showed higher expression of the two BAF 
factor complex members and C-MYC (Figure 39). Again, there were no statistical differences 
between expression of these genes in adult and fetal hepatocytes. 
 
 
Figure 39. Endogenous Gene Expression Analysis of Reprogramming Factors and BAF (Brg1/Brm associated 
factor)-complex Members BAF155 and BRG1 
Expression of these markers was performed in cultured primary adult and fetal hepatocytes. BAF155 and BRG1 are 
known to mediate epigenetic changes during reprogramming. All expression level values are normalized to the 
cyclophilin housekeeping gene. Adult and fetal hepatocytes expressed levels of all markers analyzed. Adult 
hepatocytes had a trend of higher expression of reprogramming factors while fetal hepatocytes had higher 
expression of the two BAF factor complex members. Data are SEM of n=4 adult and n=3 fetal samples. No 
statistical differences were seen between adult and fetal cells. 
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2.5 DISCUSSION 
Here, we report the generation of 40 new hiPSC lines; derived from adult hepatocytes, and fetal 
hepatocytes. To the best of our knowledge this is the first report of generation of human fetal 
hepatocyte-derived hiPSCs, the generation of a metabolic disease specific hiPSC line from an 
adult hepatocyte (CN-1), and also the generation of hiPSC lines in entirely feeder-free 
conditions. Furthermore, derivation of fetal-derived hiPSCs was possible without the use of the 
oncogene C-MYC (using only OCT4, SOX2, and NANOG). 
Although initial experiments with adult hepatocytes were conducted with 4 
reprogramming factors (n=4) and at 5 and 10 MOI for each factor, none of these experiments 
yielded reprogrammed colonies. Other investigators have reported that there is an enhanced 
efficiency of generating hiPSCs by a combination of six factors [131].  Successful 
reprogramming of adult cells was finally accomplished when six factors were transduced. Fetal 
hepatocytes were found to reprogram over 50-fold more efficiently than adult hepatocytes even 
though only 3 or 4 reprogramming vectors were transduced.  It was recently reported that 
increased reprogramming efficiency was obtained with a population of cells enriched for 
progenitor cells [112]. Even though an enriched progenitor cell population was not used in our 
experiments, human fetal cells at the hepatoblast stage of development still show over a 50-fold 
higher reprogramming efficiency as compared to adult, in this feeder-free system. 
Additional experiments demonstrated that the higher reprogramming efficiency of fetal 
cells was not due to a more efficient lentiviral infection of fetal hepatocytes than adult 
hepatocytes; as adult cells were actually transduced more efficiently than fetal cells (Figure 
38A). Likewise, the differences in reprogramming efficiency were not due to the lentivirus being 
more toxic to the adult hepatocytes because at all tested MOI and time points the adult and fetal 
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cells showed no statistical difference between levels of apoptosis, ATP content and total double 
strand DNA (Figure 38B-D). In fact, the trend was the viruses were more toxic to the fetal cells. 
It was recently shown that an increased reprogramming efficiency of mouse liver 
progenitor cells, compared with differentiated liver cells, was associated with endogenous 
expression of reprogramming factors and BAF-complex members BAF155 and BRG1, which 
mediate epigenetic changes during reprogramming [112]. The BAF-complex components 
achieve a euchromatic chromatin state and enhance reprogramming efficiencies by increasing the 
binding of reprogramming factors onto key pluripotency gene promoters [166]. However, when 
endogenous levels of expression of these markers in human adult and fetal hepatocytes were 
examined, adult hepatocytes trended to higher levels of expression of the reprogramming factors 
(Figure 39), although this was not statistically significant. Interestingly, fetal hepatocytes trended 
to higher expression levels of the BAF-complex members BAF155 and BRG1, although again, 
this was not statistically significant. This suggests that the increased reprogramming capacity of 
human fetal hepatocytes in a feeder-free system is not due to higher levels of expression of the 
reprogramming factors or known mediators of reprogramming. Future experiments will be 
needed to determine if there is a molecular basis for increased reprogramming capability of 
human fetal hepatocytes because it is not conserved from the mouse models currently published. 
Increased reprogramming efficiency in fetal cells could simply be due to the observation that 
fetal human hepatocytes replicate robustly in culture even in the absence of added growth factors 
and are more likely to be simple diploid cells. In contrast, adult cells are mainly polyploid (4, 8 
and 16 N) and proliferate poorly, in vitro, which together may make it more difficult to 
reprogram the adult hepatocytes. 
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Recent evidence suggests that at low passages numbers, mouse iPSCs may retain 
epigenetic “memory” of the donor cell from which they were made [163] and that cell type of 
origin influences in vitro differentiation potential [111]. This has since been corroborated in liver 
when a group demonstrated hepatic lineage stage-specific donor memory to mouse iPSCs [113]. 
More importantly these researchers showed that mouse fetal hepatocyte-derived iPSCs retained a 
superior capacity for hepatic re-differentiation, however this was lost after continuous passaging. 
Although, not studied here, future experiments will need to determine if human adult and fetal 
hepatocyte-derived hiPSCs differentiate efficiently to cells with mature hepatocyte 
characteristics and functions.  
Fetal hepatocytes have some advantages for making new hiPSC lines as compared to 
adults.  They can be generated in far fewer experiments, and at a lower expenditure of time and 
resources. With more clones to choose from, the best lines in terms of differentiation potential 
could be selected. Furthermore, fetal hepatocyte tissue serves as a potential source of tissue to 
generate disease specific hiPSCs; as many elective abortions are due to identification of genetic 
abnormalities. Moreover the fetal cells can be induced to pluripotency without the use of 
oncogenes such as C-MYC.  Taken together, these results demonstrate that human adult and fetal 
hepatocytes can be reprogrammed to pluripotency using entirely feeder-free conditions and the 
efficiency of reprogramming fetal hepatocytes is more than 50-fold higher than that observed 
with adult cells. Although less frequent, fetal hepatocytes can be reprogrammed using only 3 
factors, OCT4, SOX2, and NANOG. Human fetal and adult hepatocyte-derived hiPSCs may be a 
useful source for stem cell-derived hepatocytes that could be used for basic hepatic biology 
research, drug metabolism, and toxicology studies and possibly, as a cell source for hepatocyte 
transplants. 
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3.0  TRANSPLANTATION AND DIFFERENTIATION OF FETAL HEPATOCYTE-
DERIVED HIPSCS 
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3.1 ABSTRACT 
Since primary human hepatocytes do not proliferate in vitro, the cells isolated from a donor are 
all that one has to work with. To compound issues, primary cells cannot be cultured long term, as 
hepatocytes lose their activity and function as the time spent in culture increases. Moreover, 
tissues to isolate hepatocytes from are not readily available and are of marginal quality. It has 
recently been reported that mouse fetal hepatocyte-derived iPSCs have superior re-differentiation 
capacity. Here, we report the transplantation and differentiation of human fetal hepatocyte-
derived iPSCs. Specifically we show preliminary data that undifferentiated cells can engraft in 
mouse livers of FRG and NOD/SCID mice. Engraftment was based on human DNA being found 
in liver tissue. Furthermore we show that fetal hepatocyte-derived hiPSCs can be differentiated 
to definitive endoderm and this definitive endoderm can be transplanted to FRG mice and human 
DNA can be found in mouse livers and human albumin can be found in mouse serum. Finally, 
we differentiate these fetal hepatocyte-derived hiPSCs to hepatocyte-like cells. Although we 
show limited differentiation in terms of the cells’ ability to express liver specific genes and 
perform liver-specific metabolism, we believe this is due to the lack of definitive endoderm 
formation in the experiments where the cells were differentiated through the entire hepatic 
differentiation protocol. Taken together, this report demonstrates that fetal hepatocyte-derived 
hiPSCs can engraft in mouse livers, can form definitive endoderm in culture and show promise 
in being able to be fully differentiated to hepatocyte-like cells. Issues with finding the best 
differentiation protocol and engraftment being associated with tumorigenicity need to be 
overcome. 
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3.2 INTRODUCTION 
Since primary human hepatocytes do not proliferate in vitro, the cells isolated from a donor are 
all that one has to work with. To compound issues, primary cells cannot be cultured long term, as 
hepatocytes lose their activity and function as the time spent in culture increases. Moreover, 
tissues to isolate hepatocytes from are not readily available and are of marginal quality. 
Therefore, if a stem cell source can be identified that readily differentiates to hepatocytes 
efficiently and reproducibly; we would have a limitless supply of cells for transplantation and 
research purposes. 
If the cell source, techniques and protocols become available, hiPSCs will have countless 
numbers of real life applications if they can be differentiated to hepatocytes that are 
indistinguishable from primary cells. These stem cell-derived hepatocytes can be an unlimited 
source of cells for basic hepatic biology research and drug discovery. They could also be used 
for transplant to treat liver-based metabolic disorders or liver failure. This cell replacement 
therapy could be curative or used as a “bridge to transplant” to keep the patient alive until a 
donor liver becomes available for OLT. More importantly, disease-specific hiPSCs could be 
made to give researchers a limitless source of disease-specific hepatocytes to study new disease 
pathologies or to come up with drug interventions to treat underlying disease symptoms. Patient 
specific cells could be created and corrected for their genetic defect and transplanted back to the 
patient without the need for immunosuppression since the transplant is autologous. 
Three recent publications have suggested that hiPSCs derived from fetal hepatocytes may 
be a good source of cells to differentiate to hepatocytes. One issue with creating iPSCs is that it 
is very labor intensive, costly and time consuming. If a source of cells is readily reprogrammable 
though, this is not an issue. Investigators have determined that there is an increased 
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reprogramming capacity of mouse liver progenitor cells, compared with differentiated liver cells 
[112]. Specifically, adult and fetal liver cells from mice were enriched for their progenitor cells 
and it was determined that enriching for these cells dramatically increased reprogramming 
efficiencies. Enriching fetal liver cells for progenitor cells resulted in a 275-fold higher 
reprogramming efficiency compared with unsorted fetal cells. It was determined that this 
reprogramming efficiency increase was associated with endogenous expression of 
reprogramming factors and members of the BAF-complex, which mediate epigenetic changes 
during reprogramming. This finding was reproduced in human fetal hepatocytes in entirely 
feeder-free conditions (Hansel et al. 2012; IN PRESS September 2012). Although fetal 
hepatocytes were not enriched for progenitor cells, they still were shown to reprogram at more 
than a 50-fold rate as compared to adult hepatocytes. Although it was shown that this increase in 
reprogramming efficiency was not mediated by BAF-complex members, investigators 
demonstrated that human fetal hepatocytes can be reprogrammed very efficiently and cost 
effectively compared to their adult cell counterparts.  
There is also evidence that there is hepatic lineage stage-specific donor memory to  the 
differentiation potential of mouse iPSCs [113]. Specifically, iPSCs derived from fetal liver cells 
retain superior hepatic re-differentiation compared to iPSCs derived from adult liver cells. 
Taken together, mouse and human fetal hepatocytes are efficiently reprogrammed in a 
timely and cost efficient manner and mouse fetal hepatocyte-derived iPSCs have superior re-
differentiation back to hepatocytes compared to mouse adult hepatocytes. Therefore it needs to 
be determined if human fetal hepatocyte-derived iPSCs contain this superior re-differentiation 
capacity. 
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Many protocols have been established to differentiate ESCs [75-84] and iPSCs [126-128, 
150-155] to hepatocytes in culture. Here, we use a modified protocol established by Si-Tayeb 
and colleagues to differentiate our fetal hepatocyte-derived hiPSCs to the hepatocyte lineage. We 
characterize our stem cell-derived hepatocytes by liver-specific gene expression and metabolic 
activity. Furthermore, although very preliminary, we transplant undifferentiated and endoderm 
differentiated fetal hepatocyte-derived hiPSCs into two different mouse models and demonstrate 
potential engraftment and differentiation in vivo.  
3.3 MATERIALS AND METHODS 
3.3.1 Transplantation of Undifferentiated Fetal Hepatocyte-derived hiPSCs in FRG Mice 
Cells were transplanted to recipient animals as described previously with the following 
modifications [32]: Fetal hepatocyte-derived hiPSCs were maintained in a pluripotent state by 
methods previously described in this thesis. Undifferentiated cells were lifted off the tissue 
culture plates through a 5 minute accutase (Gibco) digestion at 37°C. Cells were centrifuged at 
1000 RPM for 5 minutes, re-suspended in HBSS, counted by trypan blue exclusion and diluted 
to 10 X 106 viable cells/mL. 43 to 78 days old Fah-/-/Rag2-/-/Il2rg-/- mice (FRG mice) were 
injected intrasplenically with 200 µL of the cell suspension (2 X 106 cells/animal). Animals were 
not pretreated with adenoviral vector expressing human urokinase. 4 FRG mice were 
transplanted with FH1 and 4 mice were transplanted with FH2. 
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3.3.2 Transplantation of Undifferentiated Fetal Hepatocyte-derived hiPSCs in 
NOD/SCID Mice 
Fetal hepatocyte-derived hiPSCs were maintained in a pluripotent state by methods 
previously described in this thesis. Undifferentiated cells were lifted off the tissue culture plates 
through a 5 minute accutase digestion at 37°C. Cells were centrifuged at 1000 RPM for 5 
minutes, re-suspended in HBSS, counted by trypan blue exclusion and diluted to 10 X 106 viable 
cells/mL.  19 day old NOD/SCID Il2rg-/- mice (NOD/SCID mice) were directly injected with 100 
µL of the cell suspension into the left and right sides of their liver (1 X 106 cells/side of liver) 
and 200 µL of cells were delivered by an intraperitoneal (IP) injection (2 X 10 cells/IP). 
Transplants were performed by puncturing each animal’s skin with a 27-gauge needle and 
administering each side of the liver with 100 µL of cell suspension and 200 µL IP. 3 mice were 
transplanted with FH1 and 3 mice were transplanted with FH2. 
3.3.3 Detection and Quantification of Human DNA in Transplanted Mouse Liver Tissue 
After transplantation, mouse livers (and tumors) were dissected from animals and snap 
frozen using liquid nitrogen. Tumor tissue was carefully dissected away from tumor adjacent 
tissue and snapped frozen separately. Total DNA in tumor and tumor adjacent tissue was isolated 
with DNeasy blood and tissue kit following manufacturer’s instructions (Qiagen). Human DNA 
was detected and quantified by the human TaqMan® RNase P detection reagents kit according to 
manufacturer’s instructions (Applied Biosystems, Cat. # 4316831). A standard curve was made 
by spiking known amounts of human DNA in mouse DNA at different concentrations. The 
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percentage of unknown amounts of human DNA in tumor and tumor adjacent tissue was 
interpolated using this standard curve. 
3.3.4 Differentiation of Fetal Hepatocyte-derived hiPSCs to Definitive Endoderm 
Fetal hepatocyte-derived hiPSCs were maintained in a pluripotent state by methods 
previously described in this thesis. Undifferentiated cells were lifted off the tissue culture plates 
through a 5 minute accutase digestion at 37°C. Cells were counted, plated in 6-well plates on 
BDESMG and allowed to attach overnight. Differentiation was initiated once the wells were ≈ 
85% confluent. Cells were maintained in mTeSR™1 media until differentiation was initiated 
followed by culturing in RPMI media (Gibco) supplemented with complete B27 (Gibco), Activin 
A (Peprotech) and LY294002 (Cell Signaling Technology). Figure 40 outlines the definitive 
endoderm differentiation protocol. 
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Figure 40. Definitive Endoderm Differentiation Protocol 
This figure outlines the definitive endoderm differentiation protocol. 
 
 
3.3.5 Transplantation of Definitive Endoderm derived from hiPSCs into FRG Mice 
hiPSCs derived from fetal hepatocytes were differentiated to definitive endoderm as 
previously described. Definitive endoderm cells were lifted off the tissue culture plates through a 
5 minute accutase digestion at 37°C. Cells were centrifuged at 1000 RPM for 5 minutes, re-
suspended in HBSS, counted by trypan blue exclusion and diluted to 10 X 106 viable cells/mL. 
FRG mice (17 days old) were directly injected with 100 µL of the cell suspension into the left 
and right sides of their liver (1 X 106 cells/side of liver). Transplants were performed by 
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puncturing each animal’s skin with a 27-gauge needle and administering each side of the liver 
with 100 µL of cell suspension. 7 mice were transplanted with endoderm derived from FH2. 
3.3.6 Detection of Human-specific Albumin in Transplanted FRG Mouse Serum 
Blood samples were collected from the mice via the vascular bundle located at the rear of 
the jaw bone and serum was prepared using a microtainer serum separator tube (BD) according 
to manufacturer’s protocol. Human albumin secretion was determined by ELISA according to 
manufacturer’s protocols (Bethyl Laboratories). 
3.3.7 Differentiation of Fetal Hepatocyte-derived hiPSCs to Hepatocyte-like Cells 
Fetal hepatocyte-derived hiPSCs were maintained in a pluripotent state by methods 
previously described in this thesis. Differentiation protocols used were modified versions of the 
protocol published by Si-Tayeb and colleagues [153]. Briefly, undifferentiated cells were lifted 
off the tissue culture plates through a 5 minute accutase digestion at 37°C. Cells were plated in 
6-well plates on BDESMG and allowed to attach overnight. Differentiation was initiated once 
the wells were ≈ 85% confluent (unless otherwise specified). Cells were maintained in 
mTeSR™1 media until differentiation was initiated. Six unique differentiation experiments were 
performed and are outlined in Figures 41-46. These figures denote the cell line that was 
differentiated along with the growth factors and viruses given to the cells to differentiate them to 
the hepatocyte lineage. Each differentiation protocol is named by the date on which the 
undifferentiated cells were lifted off the tissue culture plate by a 5 minute digestion with 
accutase. Protocol variations included: plating (low seeding and growing to ≈ 85% confluence or 
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high seeding and initiating differentiation the next day), the use of an adeno-associated virus 
expressing human HNF4α (on Day 1 of the hepatic specification stage or Day 1 of the hepatic 
induction stage) and different hepatic maturation media (HMM+ or HBM). Inductions on the last 
3 days of the hepatic maturation stage were carried out as follows: Cells were incubated for 72 
hours in the presence of specific inducers Rifampicin (RIF; 10 µM; CYP3A4; Sigma-Aldrich), 
Phenobarbital (PB; 1 µM; CYP3A4; Sigma-Aldrich) or β-naphthoflavone (BNF; 25 µM, 
CYP1A1/1A2; Sigma-Aldrich) in HMM media used to culture primary human hepatocytes. 
DMSO was used as vehicle control for all 3 specific inducers (0.1%; Sigma-Aldrich). Media was 
refreshed every 24 hours. 
 
Figure 41. 012012 Differentiation of FH1 to Hepatocyte-like Cells 
Outline of the 012012 differentiation to stem cell-derived hepatocytes. Figure includes cell line used and its passage 
number and media components used to differentiate the cells. 
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Figure 42. 012512 Differentiation of FH2 to Hepatocyte-like Cells 
Outline of the 012512 differentiation to stem cell-derived hepatocytes. Figure includes cell line used and its passage 
number and media components used to differentiate the cells. HNF4 AAV was given overnight (O/N) on Day 1 of 
the hepatic induction stage in half of the wells being differentiated. 
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Figure 43. 013112 Differentiation of FH1 to Hepatocyte-like Cells 
Outline of the 013112 differentiation to stem cell-derived hepatocytes. Figure includes cell line used and its passage 
number and media components used to differentiate the cells. HNF4 AAV was given overnight (O/N) on Day 1 of 
the hepatic induction stage in half of the wells being differentiated. 
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Figure 44. 022112 Differentiation of FH1 to Hepatocyte-like Cells 
Outline of the 022112 differentiation to stem cell-derived hepatocytes. Figure includes cell line used and its passage 
number and media components used to differentiate the cells. HNF4 AAV was given overnight (O/N) on Day 1 of 
the hepatic specification stage. 
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Figure 45. 030212 Differentiation of FH1 to Hepatocyte-like Cells 
Outline of the 030212 differentiation to stem cell-derived hepatocytes. Figure includes cell line used and its passage 
number and media components used to differentiate the cells. HNF4 AAV was given overnight (O/N) on Day 1 of 
the hepatic specification stage. 
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Figure 46. 031312 Differentiation of FH1 to Hepatocyte-like Cells 
Outline of the 031312 differentiation to stem cell-derived hepatocytes. Figure includes cell line used and its passage 
number and media components used to differentiate the cells. HNF4 AAV was given overnight (O/N) on Day 1 of 
the hepatic specification stage. 
 
 
3.3.8 Gene Expression 
RNA was isolated using TRIZOL® reagent (Life Technologies, Carlsbad CA) according 
to the manufacturer’s protocol. RNA integrity and purity were confirmed. DNase-I treated RNA 
of each sample were reverse-transcribed by PCR with RT-PCR reagents (Promega, Fitchburg, 
WI) according to manufacturer’s protocol. The resulting cDNA was analyzed by quantitative 
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real-time PCR using specific TaqMan® assays and TaqMan® Gene Expression Master Mix 
(Applied Biosystems, Carlsbad, CA) according to the manufacturer’s protocol. Ct values were 
entered into the following equation to determine the arbitrary unit value: 1 x 109 x e(-0.6931 x 
Ct) [168] then normalized to cyclophilin A. All samples were run and analyzed on a ABI Prism 
7000 Sequence Detection System. Table 17 summarizes the TaqMan® assays that were used: 
 
Table 17. TaqMan® Assays Used for Chapter 3 Experiments of this Dissertation 
Table summarizes the TaqMan® assays used for chapter 3 experiments and the associated gene symbols, gene name 
and assay ID numbers. 
 
Gene Symbol Gene Name Assay ID # 
OCT4 Octamer 4 Hs03005111_g1 
SOX2 SRY (sex determining region Y)-box 2 Hs01053049_s1 
NANOG Nanog homeobox Hs02287400_g1 
SOX17 SRY (sex determining region Y)-box 17 Hs00751752_s1 
CXCR4 Chemokine (C-X-C motif) receptor 4 Hs00607978_s1 
HNF4A Hepatocyte nuclear factor 4, alpha Hs00230853_m1 
CYP1A1 Cytochrome P450, family 1, subfamily 
A, polypeptide 1 
Hs00153120_m1 
CYP1A2 Cytochrome P450, family 1, subfamily 
A, polypeptide 2 
Hs01070374_m1 
CYP3A4 Cytochrome P450, family 3, subfamily 
A, polypeptide 4 
Hs00430021_m1 
CYP3A7 Cytochrome P450, family 3, subfamily 
A, polypeptide 7 
Hs00426361_m1 
ALB Albumin Hs00609411_m1 
AFP Alpha-fetoprotein Hs00173490_m1 
CYP2B6 Cytochrome P450, family 2, subfamily 
B, polypeptide 6 
Hs03044634_m1 
HNF3B (FOXA2) Hepatocyte nuclear factor 3-beta 
(Forkhead box A2) 
Hs00232764_m1 
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3.3.9 Drug Metabolism Studies 
Each metabolite was measured in culture after three days of exposure to specific 
prototypical inducers (if applicable). Cells were incubated for 72 hours in the presence of 
specific inducers Rifampicin (RIF; 10 µM; CYP3A4; Sigma-Aldrich), Phenobarbital (PB; 1 µM; 
CYP3A4; Sigma-Aldrich) or β-naphthoflavone (BNF; 25 µM, CYP1A1/1A2; Sigma-Aldrich) in 
HMM media used to culture primary human hepatocytes. DMSO was used as vehicle control for 
all 3 specific inducers (0.1%; Sigma-Aldrich). Media was refreshed every 24 hours. Results are 
expressed as product mole/min and normalized per mg total cellular protein. Protein content was 
determined with the Bio-Rad Protein Assay kit (Bio-Rad) according to manufacturer’s 
instructions. 
3.3.10 Luminescent Cytochrome P450 Assays 
Cells were lifted off of the tissue culture plates by a 5 minute accutase digestion and 
counted on a hemacytometer. Thirty thousand viable cells were added to each well of a 96-well 
plate and subsequent cytochrome P450 assays were performed in triplicate (P450-Glo™ Assays, 
Promega). The following assays were performed on hepatocytes in HBSS solution: CYP1A1 and 
CYP1A2. The following assays were performed on cells in HMM only solution: CYP2B6, 
CYP2C9, CYP3A4 and CYP3A7. 10 µL of each Cyp-Glo reagent was added to the each well of 
a 96-well plate that contained cells. The plate was incubated on a rocker in the incubator at 37°C 
for 30 minutes. After 30 minutes 50 µL of luciferase detection reagent without esterase 
(premixed with cysteine) was added to the wells that received CYP1A1, CYP1A2, CYP2B6, 
CYP2C9 and CYP3A7 specific compounds. 50 µL of luciferase detection reagent with esterase 
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was added to the wells that received CYP3A4 specific compound.  The plate was incubated at 
room temperature for 30 minutes. After 30 minutes, the luminescent signal was read on a 
luminescent spectrometer (Synergy HT, Biotek Instruments, Inc., U.S.A.) equipped with Gen5 
software. Results were normalized to total double strand DNA using Quanti-iT™ assay 
according to manufacturer’s instructions. Luciferase detection reagents only were used as the 
negative control for assays. 
3.3.11 EROD Assay – CYP1A1/1A2 Metabolism 
Cytochrome P450-1A1/1A2 phase I activity was assessed by the conversion of 7-
ethoxyresorufin to resorufin as described previously in HMM only [169]. EROD activity was 
measured in cells in culture after treatment for three days with specific 1A1/1A2 inducer BNF or 
vehicle control (DMSO). Briefly, cells are incubated for 1 hour at 37°C with 7-ethoxyresorufin 
solution (20 µM; Sigma Aldrich) and salicylamide (1.5 mM; Sigma-Aldrich). Salicylamide was 
added to prevent conjugation of the fluorescent product. After 1 hour incubation, the media was 
collected, clarified by centrifugation and frozen. 100 µL of each sample, analyzed in triplicate, 
was added to a 96-well white plate and analyzed on a fluorescent spectrometer (Synergy HT, 
Biotek Instruments, Inc., U.S.A.) equipped with Gen5 software at an excitation wavelength of 
535 nm and an emission wavelength of 581 nm. Resorufin concentration was quantified by 
interpolating the A581 values for the unknowns from a standard curve of resorufin prepared in 
HMM (resorufin [µg/ml] = 617844 * A581 + 171.23; R2 = 0.9996). Following sampling period, 
cells were harvested in phosphate buffer (0.1 M, pH 7.4) and stored at -20°C until protein 
content was determined. Results are expressed as picomoles of product formed/min normalized 
to total protein content. 
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3.3.12 Testosterone Metabolism – CYP3A4 Metabolism 
Testosterone 6β-hydroxylase activity catalyzed by CYP3A4 was determined in cells in 
culture that were induced by RIF, PB or vehicle control (DMSO) as described above and 
previously [170]. Briefly, cells were exposed to testosterone (250 µM; Sigma-Aldrich) for 50 
minutes at 37°C in HMM only. The media was collected, centrifuged to remove cells and 
fragments and stored at -20°C until analyzed by HPLC. Metabolite was identified by comparing 
retention times with 6β-hydroxytestosterone standard prepared in HMM. Results are expressed 
as picomoles of product/min normalized to protein content. 
3.3.13 Ammonia Metabolism 
Ammonia metabolism was determined in vitro through a colorimetric assay as described 
previously [171]. Differentiated cells were treated with 1 mM ammonium chloride and 1 mM 
ornithine for 2 hours in HMM only and one well was immediately centrifuged and the 
supernatant retained at “time 0” and then stored frozen. After 2 hours, each sample was 
collected, centrifuged and stored frozen until read. Each sample was read and prepared in 
triplicate on a spectrometer (Synergy HT, Biotek Instruments, Inc., U.S.A.) equipped with Gen5 
software at a wavelength of 560 nm and results were compared to a linear calibration curve. The 
metabolism of ammonia was expressed as a percentage of ammonia metabolized after 2 hours 
and as picomoles/min normalized to total protein content. 
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3.3.14 Phase II Metabolism – Resorufin Metabolism 
Phase II metabolism was determined by the metabolism of the fluorescent compound 
resorufin after incubation for 30 minutes at 37°C and measurement of the decrease in fluorescent 
signal in HMM only. A 50 ng/mL solution of resorufin was added to differentiated cells, and one 
well was immediately centrifuged and the supernatant retained at “time 0” and then stored 
frozen. Subsequent time point samples were centrifuged to remove cells and debris and then 
stored frozen until analyzed with the same conditions described for the EROD assay. Resorufin 
metabolism was quantified by comparing the fluorescent signal after 30 minutes to the “time 0” 
value. All the results are expressed as percentage of resorufin metabolized or as picomoles of 
product formed/min and normalized to total protein content. 
3.4 RESULTS 
3.4.1 Transplantation of Undifferentiated Fetal Hepatocyte-derived hiPSCs into FRG 
Mice 
Undifferentiated fetal hepatocyte-derived hiPSCs were transplanted intrasplenically into 
(43-78 days old) FRG mice. Each animal was transplanted with 2 million cells and 4 mice were 
transplanted for each cell line. Survival was investigated and potential engraftment was analyzed 
by the human RNase P assay looking for human DNA in the mouse livers.  
3 out of 4 mice transplanted with FH1 developed tumors (Figures 47 and 48). Tumor 
tissue (Figure 47; red arrow) and tumor adjacent tissue (Figure 47; green arrow) were carefully 
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dissected away from each other and snap frozen for DNA isolation.  The animals that developed 
tumors lived for an average of 75 days post transplant (a range of 50-93 days) (Figure 48). 
Animals were sacraficed due to tumor burden. The one animal that did not develop a tumor lived 
for the duration of the study (150 days). Human DNA was detected in one transplanted animal’s 
tumor adjacent tissue (≈ 0.9%) (Figure 48), which fell within the assays standard curve. Human 
DNA was found in all tumors, which consisted of 79.7-138.2% human DNA (data not shown). 
 
 
Figure 47. Tumor and Tumor Adjacent Tissue 
This figure denotes the difference between tumor and tumor adjacent tissue. This figure is applicable to all 
in vivo transplants where tumors occurred. Tumor adjacent tissue is indicated by the green arrow and tumor 
tissue is indicated by the red arrow. 
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Figure 48. Tumor Prevalence, Animal Survival and Human DNA in FRG Mice Transplanted with Undifferentiated 
FH1 
This figure summarizes the transplant data collected for undifferentiated FH1 intrasplenic transplantation to FRG 
mice. 
 
 
0 out of 4 mice transplanted with FH2 developed tumors and all mice lived for the 
duration of the study (150 days). The animals’ liver tissue was snap frozen and no human DNA 
was found (Figure 49). 
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Figure 49. Tumor Prevalence, Animal Survival and Human DNA in FRG Mice Transplanted with Undifferentiated 
FH2 
This figure summarizes the transplant data collected for undifferentiated FH2 intrasplenic transplantation to FRG 
mice. 
 
 
3.4.2 Transplantation of Undifferentiated Fetal Hepatocyte-derived hiPSCs into 
NOD/SCID Mice 
Undifferentiated fetal hepatocyte-derived hiPSCs were transplanted both IP and directly 
into the liver of 19 day old NOD/SCID mice. Each animal was transplanted with 2 million cells 
IP and 1 million cells to the left and right sides of the liver (2 million total). 3 mice were 
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transplanted for each cell line. Survival was investigated and potential engraftment was analyzed 
by the human RNase P assay looking for human DNA in the mouse livers.  
0 out of 3 mice transplanted with FH1 developed tumors and all mice lived for the 
duration of the study (150 days). The animals’ liver tissue was snap frozen and no human DNA 
was found (data not shown). 
1 out of 3 mice transplanted with FH2 developed tumors. Tumor tissue (Figure 47; red 
arrow) and tumor adjacent tissue (Figure 47; green arrow) were carefully dissected away from 
each other and snap frozen for DNA isolation.  All animals, even the one that developed a tumor, 
lived until the end of the study (150 days). The one animal that developed a tumor was sacrificed 
due to tumor burden. Human DNA was detected in one transplanted animal’s tumor adjacent 
tissue (≈ 0.4%; data not shown), which fell within the assays standard curve. This animal’s tumor 
consisted of > 100% human DNA (data not shown). 
3.4.3 Transplantation of Definitive Endoderm derived from hiPSCs into FRG Mice 
Undifferentiated FH2 cells were differentiated to definitive endoderm, the embryonic 
derivative of hepatocytes, using a step-wise protocol in vitro that consisted of RPMI medium 
supplemented with B27, non-essential amino acids, antibiotic-antimycotic, Activin A and the 
PI3K inhibitor LY294002. Over the course of the 5 day differentiation, the FH2 cells 
morphology changed dramatically. Undifferentiated FH2 cells grew in tight, compact colonies 
with high nuclei to cytoplasm ratio (Figure 50A). After accutase digestion, plating and growing 
to ≈ 85% confluence the cells resulted in colonies with a more distinct cytoplasm (Figure 50B). 
After 5 day differentiation to definitive endoderm the cells are much larger and their nuclei to 
cytoplasm ratio are drastically reduced (Figure 50C). Furthermore, the cells are no longer 
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growing in colonies. Cells that did not receive Activin A or LY294002 (RPMI basal medium 
only) did not display a characteristic definitive endoderm morphology as their nuclei to 
cytoplasm ratio remained constant and the well became over-grown with cells (Figure 50D). 
 
 
Figure 50. Morphology of FH2 Differentiated to Definitive Endoderm 
This figure denotes the cellular morphology of FH2 throughout the course of differentiation to definitive endoderm. 
(A) Undifferentiated FH2. (B) FH2 after accutase digestion, plating and growing to ≈ 85% confluence. (C) 
Definitive endoderm. (D) Cells receiving only RPMI basal media. Scale bar is 100 µM. 
 
 
 
When investigating gene expression, definitive endoderm highly expresses SOX17 and 
CXCR4 [74]. FH2-derived definitive endoderm saw 870 and 48 fold increases in SOX17 and 
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CXCR4 expression respectively compared to undifferentiated cells (Figure 51). Adult and fetal 
hepatocytes and IMR90 fibroblasts were negative controls of mRNA expression levels. 
 
 
Figure 51. Definitive Endoderm-specific Gene Expression of FH2 Differentiated to Definitive Endoderm 
This figure denotes definitive endoderm-specific gene expression of the definitive endoderm (Endo) derived from 
FH2. The differentiated cells showed 870 and 48 fold increases in SOX17 and CXCR4 expression respectively 
compared to undifferentiated cells. Adult and fetal hepatocytes and IMR90 fibroblasts were negative controls of 
expression levels. Levels are normalized to cyclophilin A. 
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When investigating pluripotency marker gene expression, over the course of 
differentiation to definitive endoderm the cells should decrease markers for pluripotency. FH2-
derived definitive endoderm saw decrease in both OCT4 and SOX2 gene expression compared to 
undifferentiated cells (Figure 52). Adult and fetal hepatocytes and IMR90 fibroblasts were 
negative controls of expression levels. 
 
 
Figure 52. Pluripotency Marker Gene Expression of FH2 Differentiated to Definitive Endoderm 
This figure denotes the pluripotency marker gene expression of the definitive endoderm (Endo) derived from FH2. 
The differentiated cells showed decreases in OCT4 and SOX2 expression respectively compared to undifferentiated 
cells. Adult and fetal hepatocytes and IMR90 fibroblasts were negative controls of expression levels. Levels are 
normalized to cyclophilin A. 
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FH2 cells were differentiated to definitive endoderm and 1 million cells were 
transplanted to each side of the livers of 19 day old NOD/SCID mice (n=7; 2 million cells total). 
Survival was investigated and potential engraftment was analyzed by the human RNase P assay 
looking for human DNA in the mouse livers as well as human albumin in the mouse serum.  
3 out of 7 mice transplanted with FH2-derived definitive endoderm developed tumors. 
Tumor tissue (Figure 47; red arrow) and tumor adjacent tissue (Figure 47; green arrow) were 
carefully dissected away from each other and snap frozen for DNA isolation.  Animals with 
tumors lived an average of 69 days (the range was 57-80). Animals that did develop tumors were 
sacrificed due to tumor burden. Animals that did not develop tumors lived until the end of the 
study (100 days). Human DNA was detected in one transplanted animal’s tumor adjacent tissue 
(≈ 0.2%; Figure 53), which fell within the assays standard curve. This animal’s tumor consisted 
of > 100% human DNA (data not shown). The animal that had human DNA in the tumor 
adjacent tissue also had 1 µg/mL of human albumin in its serum (Figure 53). 1 mg/mL albumin 
correlates with ≈ 20% repopulation of human cells within the mouse liver, therefore 1 µg/mL 
correlates with 0.2% repopulation with human hepatocytes derived from FH2-derived definitive 
endoderm. 
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Figure 53. Human DNA Prevalence and Human Albumin in FRG Mice Transplanted with Definitive Endoderm 
Derived from FH2 
This figure summarizes the human DNA prevalence and human albumin in FRG mice transplanted with definitive 
endoderm derived from FH2. Although preliminary, data suggests repopulation of MS #142. 
 
 
3.4.4 Differentiation of FH2, FH12, FH14 and FH15 to Definitive Endoderm 
FH2, FH12, FH14 and FH15 were differentiated to definitive endoderm in vitro. They 
show characteristic decrease in nuclei to cytoplasm ratio and increase in cell size that is 
consistent with definitive endoderm morphology (data not shown). They have also been shown 
to have definitive endoderm gene expression with large inductions of SOX17 and CXCR4 
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expression when compared to their undifferentiated counterparts. Table 18 summarizes each cell 
line’s fold change from their undifferentiated cell counterparts in terms of SOX17 and CXCR4 
expression. Adult and fetal hepatocytes and IMR90 fibroblasts were used as controls for gene 
expression (data not shown). All data in the table was normalized to cyclophilin A expression.  
 
 
Table 18. Cell Lines Differentiated to Definitive Endoderm and their Associated Fold Changes in SOX17 and 
CXCR4 Gene Expresssion Compared to their Undifferentiated Cell Counterparts 
 
Cell Lines Fold Δ SOX17 Fold Δ CXCR4 
FH2 870 48 
FH12 32 6 
FH14 71 10 
FH15 538 13 
 
 
3.4.5 Differentiation of Fetal Hepatocyte-derived hiPSCs to Hepatocyte-like Cells 
6 unique differentiation protocols were used to differentiate fetal hepatocyte-derived 
hiPSCs to hepatocyte-like cells. This was done because after each protocol was completed only 
limited liver specific gene expression and function of hepatocyte-like cells resulted. Here we 
describe the data for one of the six experiments, 012512 differentiation, which is representative 
of each of the other five not shown. Briefly, the differentiation protocol entailed the following: 
FH2 cells were lifted off the tissue culture plates by a 5 minute digestion with accutase and 
plated in mTeSR™1 and allowed to come to ≈ 85% confluence after six days. This followed a 5 
day endoderm induction with Activin A and LY294002, a 5 day hepatic specification with 
BMP4 and FGF2, a 5 day hepatic induction with HGF (half the cells received an AAV 
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expressing human HNF4α on day 1 of this stage) and finally a 5 day hepatic maturation in 
HMM+ (adult hepatocyte media). Throughout the induction cell morphology changed as 
expected. The differentiating cells became larger and their nuclei to cytoplasm ratio decreased. 
By the end of the protocol the cells had a hepatocyte-like morphology with a cobblestone like 
morphology, however the cells were still relatively small compared to a primary hepatocyte. 
Some areas of the plate even had cells that had bile canalicular-like structures with neighboring 
cells (data not shown). 
Real time gene expression analysis was performed to look at the ability of the 
differentiating cells to form definitive endoderm in culture. Therefore gene expression of SOX17 
and CXCR4 was analyzed. For this experiment, there were 30 and 4 fold increases in SOX17 and 
CXCR4 gene expression compared to undifferentiated cells (Figure 54). This is a drastic 
reduction from a previous experiment with this cell line that showed 870 and 48 fold inductions 
respectively at this stage in differentiation (Figure 51). 
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Figure 54. 012512 Differentiation Experiment Endoderm Marker Gene Expression 
This figure denotes the endoderm marker gene expression for the 012512 differentiation experiment of FH2. The 
differentiated cells show an increase in endoderm marker expression at the endoderm stage; however this increase is 
not what is seen in pervious differentiation experiments. IMR90 fibroblasts were used as a negative control of 
expression levels. Levels are normalized to cyclophilin A. 
 
 
Liver-specific gene expression at the end of the differentiation protocol was investigated 
on both the cells that received HNF4α AAV and the cells that did not. When looking at HNF4α 
gene expression, cells that received HNF4α AAV on Day 1 of the hepatic induction stage had a 
251% increase in HNF4α gene expression compared to primary adult hepatocytes (Figure 55). In 
contrast, cells that did not receive the HNF4α AAV only had a 0.4% HNF4α gene expression 
compared to primary adult hepatocytes, thus demonstrating that the HNF4α AAV was “jump 
starting” HNF4α gene expression in the cells that were exposed to the virus (Figure 55). 
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Figure 55. 012512 Differentiation Experiment HNF4α Gene Expression 
This figure denotes the HNF4α gene expression at the end of the differentiation protocol for the 012512 
differentiation experiment of FH2. Cells that received HNF4α AAV had a significant increase in HNF4α gene 
expression compared to cells that did not receive the virus. Adult and fetal hepatocytes were used as positive 
controls of expression and IMR90 fibroblasts were used as a negative control. Levels are normalized to cyclophilin 
A. 
 
 
 
Other liver-specific gene expression was investigated on the differentiated cells at the end 
of the protocol. Table 19 summarizes the liver-specific gene expression of the differentiated cells 
that did or did not receive HNF4α AAV at the end of the differentiation protocol. Each marker is 
broken down by percentage compared to primary adult hepatocyte expression levels. There was 
limited expression of liver-specific markers in the differentiated cells in all markers analyzed. 
 
Table 19. Liver-Specific Gene Expression of the Differentiated Cells at End of 012512 Differentiation Protocol 
Each marker is broken down by percentage compared to primary adult hepatocyte expression levels and whether or 
not the cells received HNF4α AAV. 
 
Liver Marker Percent Adult w/HNF4α 
AAV 
Percent Adult w/out 
HNF4α AAV 
CYP1A1 16% 20% 
CYP1A2 0.1% 0.1% 
CYP3A4 0.02% 0.002% 
CYP3A7 0.1% Undetected 
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Albumin 0.0007% 0.001% 
AFP 11,588% 17,225% 
CYP2B6 0.3% 0.3% 
HNF3β 4.6% 3.2% 
 
 
Gene expression of the pluripotency markers was analyzed throughout the course of the 
differentiation and, as expected, OCT4, SOX2 and NANOG expression decreased throughout the 
course of the protocol (data not shown). 
The differentiated cells were also investigated to see if they would have characteristic 
hepatocyte drug-specific inductions. Some inductions were seen with the hepatocyte-like cells; 
however none of the inductions seen were on the same order of magnitude as primary adult 
hepatocytes (data not shown). 
The differentiated cells were also investigated for metabolic activity capabilities in 
various metabolic activity assays: ammonia metabolism, EROD metabolism, testosterone 
metabolism, resorufin metabolism and luminescent cytochrome P450 assays. As was seen in the 
gene expression analysis, differentiated cells showed limited or no metabolic activity in all 
assays performed. If there was activity, it was not on the same order of magnitude as a primary 
adult hepatocyte (data not shown). 
Each protocol was ranked based on liver specific-gene expression to determine the most 
efficient differentiation protocol out the six performed. For example, each protocol was ranked 1 
through 8 for ability to express CYP1A1. The experiment yielding highest expression of 
CYP1A1 was given a score of 1 and the lowest received a score of 8. This was done for each 
liver-specific marker analyzed. Each protocol’s score was added together for each marker to get 
an overall score. Table 20 summarizes the total scores for each specific protocol. The protocol 
with the lowest score was determined to be the most efficient protocol for differentiation of fetal 
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hepatocyte –derived hiPSCs to stem cell derived hepatocytes in terms of ability of the 
differentiated cells to express liver-specific markers. 013112 Differentiation with HNF4α AAV 
was determined to be the most efficient protocol to date using this scoring method. 
 
Table 20. Comparing Every Performed Differentiation Experiment for its Ability to Differentiate Fetal Hepatocyte-
derived hiPSCs to Stem Cell-derived hepatocyte-like cells 
Each protocol was ranked based on liver specific-gene expression to determine the most efficient differentiation 
protocol out the six performed. 
 
Experiment Hepatocyte Markers Rank (total score) 
013112 – w/ HNF4α 1 (38) 
012512 – w/ HNF4α 2 (41) 
012012 3 (53) 
022112 3 (53) 
012512 – w/out HNF4α 4 (54) 
013112 – w/out HNF4α 5 (58) 
030212 6 (67) 
031312 7 (68) 
 
 
3.5 DISCUSSION 
Two different mouse models were used to investigate whether undifferentiated fetal hepatocyte-
derived hiPSCs could engraft within mouse livers (FRG and NOD/SCID models). Although 
extremely preliminary, undifferentiated hiPSCs could be transplanted into mice and human DNA 
could be found in liver tissue in both models. However engraftment was always associated with 
tumorigenesis. Furthermore, an alternative explanation for human DNA being found in tumor 
adjacent tissue is that when dissecting away the tumor tissue from the tumor adjacent tissue, 
some of the tumor tissue contaminated the tumor adjacent samples thus resulting in the tiny 
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amount of human DNA in the tumor adjacent samples. Although beyond the scope of this thesis, 
future experiments should be performed to see if transplantation of undifferentiated cells results 
in human albumin in the mouse serum, which would further support that undifferentiated cells 
can engraft in the mouse liver and differentiate to hepatocytes expressing albumin. Furthermore, 
upon animal sacrifice, one can analyze human albumin in tissue sections to provide direct 
evidence of cell differentiation in terms of the ability of the transplanted cells to produce human 
albumin. 
Fetal hepatocyte-derived hiPSCs were differentiated to endoderm and subsequently 
transplanted to FRG mice to investigate if the endoderm can engraft within the mouse liver. 
Once again human DNA was found in the tumor adjacent tissue. However in this same animal 
human albumin was found in the blood serum that correlated to 0.2% repopulation. Although, 
once again, engraftment was associated with tumorigenesis, these data suggest that differentiated 
fetal hepatocyte-derived hiPSCs have the ability to engraft in mouse livers. 
Taken together, these three transplant experiments show that engraftment of fetal 
hepatocyte-derived hiPSCs in the liver is possible, albeit at the cost of tumorigenesis in the 
animal. These results agree with other published work reporting poor engraftment of stem cell-
derived hepatocytes and undifferentiated iPSCs. These data also suggest that if these hiPSCs 
were differentiated to stem cell-derived hepatocytes, these fully differentiated cells would have 
the potential to engraft within the mouse liver and therefore be useful for regenerative medicine 
purposes if issues of tumorigenicity can be overcome. 
Fetal hepatocyte-derived hiPSC lines FH2, FH12, FH14 and FH15 were differentiated to 
definitive endoderm in vitro. SOX17 and CXCR4 gene expression levels were induced among 
these lines, however induction levels were different when comparing all lines. Importantly, and 
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as expected, higher SOX17 inductions correlated with higher CXCR4 inductions. These results 
agree with the current literature that says different hiPSC lines have better abilities to 
differentiate than others. Since these fetal hepatocyte-derived hiPSC lines can be differentiated to 
definitive endoderm in culture, it is expected that these cells can be further differentiated to 
hepatocyte-like cells. 
When full differentiation of fetal hepatocyte-derived hiPSCs was performed limited 
results were obtained. A total of 6 unique experiments were performed that generated limited 
hepatocyte-like characteristics of the cells in terms of their ability to express liver-specific 
markers or perform liver-specific metabolism. It has been determined that HNF4α can be 
induced in these hiPSCs by giving the cells an AAV expressing HNF4α, however this HNF4α 
expression alone is not enough to jumpstart “full differentiation”. All differentiation protocols 
outlined in the methods section resulted in data trends similar to the ones outlined in Table 19. 
Furthermore all performed metabolic activity assays in all differentiations showed the same 
trends as the gene expression data found in Table 19.  
In order to get full hepatic differentiation of hiPSCs, proper definitive endoderm 
formation is critical. An explanation for why none of these differentiation protocols efficiently 
formed hepatocyte-like cells is that each full differentiation experiment resulted in limited 
endoderm formation, in terms of SOX17 and CXCR4 mRNA expression. All endoderm 
formation in all hepatocyte differentiation experiments was similar to the one found in Figure 54. 
Future experiments should be performed to show the large definitive endoderm inductions as 
seen in Figure 51. Cells that achieve this large induction should be able to be differentiated more 
efficiently to hepatocyte-like cells. 
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4.0  CONCLUSIONS AND FUTURE RESEARCH 
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4.1 DISCUSSION AND SUMMARY 
Cell therapy has a chance to take a huge burden off the liver transplant waiting list. If we can 
identify which diseases can be treated with cell replacement therapies then we can concentrate on 
performing OLTs on those not corrected by cellular therapy. Therefore all other diseases can be 
treated with cell therapy, where theoretically one organ donor can treat multiple patients if 
enough cells can be isolated from the tissue, thus further taking the burden off the transplant 
waiting list. Moreover, if hESC and hiPSC technology can become clinically relevant doctors 
would not have to rely on organ donors to treat patients with cell therapy. Furthermore, hiPSC 
technology allows for the creation of patient-specific cells for autologous transplants that offers 
the potential of not needing immunosuppression. 
If the cell source, techniques and protocols become available, hiPSCs will have countless 
numbers of real life applications if they can be differentiated to hepatocytes that are 
indistinguishable from primary cells. These stem cell-derived hepatocytes can be an unlimited 
source of cells for basic hepatic biology research and drug discovery. They could also be used 
for transplant to treat liver-based metabolic disorders or liver failure. This cell replacement 
therapy could be curative or used as a “bridge to transplant” to keep the patient alive until a 
donor liver becomes available for OLT. More importantly, disease-specific hiPSCs could be 
made to give researchers a limitless source of disease-specific hepatocytes to study new disease 
pathologies or to come up with drug interventions to treat underlying disease symptoms. Patient 
specific cells could be created and corrected for their genetic defect and transplanted back to the 
patient without the need for immunosuppression since the transplant is autologous. 
Recent reports in mice have determined that fetal hepatocyte-derived iPSCs contain 
superior re-differentiation capacity and fetal hepatocytes have superior reprogramming capacity 
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when enriched for progenitor cell populations. Therefore if human fetal hepatocytes can be 
reprogrammed to iPSCs, then this cell source may represent the best cell source to generate 
human stem cell-derived hepatocytes. 
Here, we report for the first time the derivation of hiPSCs from human fetal hepatocytes 
in entirely feeder-free conditions. Furthermore derivation of fetal hepatocyte-derived hiPSCs can 
be done using only OCT4, SOX2 and NANOG. Fetal hepatocytes reprogram significantly more 
efficiently and reproducibly than adult hepatocytes and are a potential new source of disease 
specific cells, since many terminated pregnancies are done so because of genetic defects. Finally 
we have reported for the first time the generation of a metabolic disease specific hiPSC from an 
adult hepatocyte. The established hiPSC cell lines from both fetal (n=37) and adult (n=3) 
hepatocytes will be an invaluable source for all of the reasons stated above. 
We also have preliminary data showing that undifferentiated fetal hepatocyte-derived 
hiPSCs and hiPSCs differentiated to endoderm can engraft within mouse livers; although 
engraftment is always associated with tumorigenesis. This suggests that if successful hepatic 
differentiation is performed on these hiPSCs then they should have the ability to engraft within 
mouse livers and therefore be useful for regenerative medicine applications if issues with 
tumorigenesis can be solved. 
Finally, full hepatic differentiation was performed on these fetal hepatocyte-derived 
hiPSCs however limited differentiation was observed in culture. Differentiated cells showed 
limited expression of liver-specific markers and performed poorly in different liver-specific 
metabolism assays. It has been concluded that the limited differentiation was most likely due to 
lack of good endoderm formation in the experiments where differentiation was carried out the 
entire way. Since there are a total of 40 distinct cells lines (n= 37 and 3 derived from fetal and 
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adult hepatocytes respectively) the best lines in terms of hepatic differentiation potential could be 
selected. 
4.2 FUTURE RESEARCH RECOMMENDATIONS 
Here we have reported that human fetal hepatocytes reprogram more efficiently and reproducibly 
than adult hepatocytes, however we have not determined the mechanism for this phenomenon. 
We know that it is not transduction efficiency or virus toxicity related. Furthermore we know it 
is not due to reprogramming factor stochiometry differences or differences in expression of BAF 
factor complex members. However it could be due to other known important pathways in 
reprogramming. These pathways include: p53 and its various downstream targets [129, 133, 
136], innate immune response pathways and regulators [130], pathways downstream of hypoxia 
inducible factors [135], MEK-ERK and TGFβ pathways [132], retinoic acid signaling [134],  
AID-dependent DNA demethylation [137], downstream targets of the orphan nuclear receptor 
Esrrb [138], and up-regulation of epithelial cell adhesion molecule complex proteins [139]. Any 
one of these pathways could be responsible for why human fetal hepatocytes reprogram more 
efficiently than adult and should be subsequently investigated. 
We only investigated engraftment of undifferentiated hiPSCs and hiPSCs differentiated 
to definitive endoderm. Although preliminary, potential engraftment was always associated with 
tumorigenesis. In repopulated animals we can investigate whether there is human hepatocyte-
specific gene expression in the tumor adjacent tissue to determine if the cells contributing to the 
human serum albumin and human DNA are also expressing other liver genes, thus suggesting the 
transplanted cells have differentiated to a hepatic phenotype. The tumors from these animals 
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have been fixed and stored in paraffin blocks. H & E’s should be made to determine the type of 
tumor it is; whether it is a teratoma or not. Furthermore, experiments should be performed to see 
if hiPSCs, when fully differentiated, can engraft in our various mouse models without 
tumorigenesis. If they still do then differentiated cells can be separated based on SSEA-5 
expression. Recently, a group has discovered a monoclonal antibody against SSEA-5, and 
separation based on SSEA-5 expression through FACS greatly reduced teratoma-formation 
potential of poorly differentiated hESC cultures [160]. Therefore, if transplantation of 
differentiated hiPSCs still leads to tumor formation, differentiated cells can be separated using 
this antibody to see if engraftment can occur without tumor formation. In repopulated animals 
engraftment can be assessed by human DNA found in the liver tissue as well as human albumin 
in the serum. In highly repopulated animals, serial liver sections can be stained with a human 
specific cytokeratin-18 antibody to identify human derived cells that have engrafted within the 
recipient mouse liver. This would be the direct evidence needed to say that hiPSC-derived 
hepatocytes can engraft in recipient livers. 
Finally, transplantation of undifferentiated or differentiated hiPSCs can be accompanied 
with transplantation of primary non-parenchymal cells. The idea here is that these primary non-
parenchymal cells will provide support to the undifferentiated or differentiated cells. This may 
help increase differentiation or engraftment of the recipient animal. 
One issue with the current hepatic differentiation of fetal hepatocyte-derived hiPSCs is 
that every full differentiation experiment resulted in poor induction of definitive endoderm. Full 
differentiation experiments should be repeated to ensure high quality definitive endoderm 
induction. If this occurs, more efficient and reproducible hepatic differentiation of fetal 
hepatocyte-derived hiPSCs should be obtained. This will result in differentiated cells having 
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higher expression of liver-specific genes and metabolism that is equivalent to primary adult cells 
in culture in the various metabolic assays we investigated. 
Finally, there are multiple reports of hepatic differentiation protocols for both hiPSCs and 
hESCs. We based our differentiation on a modified protocol from Si-Tayeb and colleagues 
[153]. However future differentiation experiments can utilize other published protocols or other 
modifications to current protocols. Ideas include the use of: TRA1-60 microbeads to purify the 
starting cell population, various extracellular matrices to provide extracellular support during the 
differentiation process, viruses delivering important liver specific transcription factors (like the 
HNF4α AAV) or human liver non-parenchymal cell co-culture. Undifferentiated hiPSCs could 
also be treated with valproic acid or other histone deacetylase inhibitors to reactivate important 
silenced genes that are necessary for true developmental potential of the hiPSC lines. For 
example reactivating the 12qF1 locus increases mouse iPSC developmental potentials [162]. 
Finally, we have generated a disease specific hiPSC line from hepatocytes of a patient 
diagnosed with CN-1 syndrome. Experiments should be undertaken to see if this hiPSC line can 
form stem cell-derived hepatocytes in vitro that contain both normal hepatocyte activity as well 
as disease specific activity. These cells once differentiated should be able to metabolize 
ammonia, however should be defective in generating bilirubin glucuronides. An important 
control in demonstrating this disease specific behavior is differentiating a hiPSC without CN-1 
and showing that when differentiated it can generate bilirubin glucuronides. Once this is 
established, the hiPSCs can be corrected for their genetic defect in the UGT1A1 enzyme using 
zinc finger nucleases. Once corrected for their defect one should be able to differentiate them 
back to hepatocytes that have the ability to form bilirubin glucuronides in culture. This data, 
once generated, would pave the way for patient specific therapies. These therapies would be 
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based on generating patient-specific hiPSCs, correcting them for their defect and differentiating 
them to hepatocytes that can be used for autologous transplant back to the patient without the 
need for immunosuppression or an invasive OLT to correct the metabolic defect. 
Furthermore this CN-1 hiPSC line can be differentiated to the hepatic lineage and 
transplanted to our FRG mouse model. Animals that are highly repopulated with disease specific 
cells should display CN-1 symptoms, like inability to conjugate bilirubin. This mouse model of 
CN-1 disease would be a superior animal model to those currently available because underlying 
disease pathologies are due to the presence of human cells. These repopulated animals would 
provide the microenvironment milieu to support the tissue’s physiological function within the 
context of the whole organism, enabling greater understanding of disease pathogenesis and 
providing a platform for preclinical testing of CN-1 drug candidates. 
It is obvious that a multidisciplinary approach is going to be needed to differentiate these 
fetal hepatocyte-derived hiPSCs to hepatocyte-like cells that resemble primary adult hepatocytes 
in gene expression and metabolic activity. The fact that there is a bank of 40 hiPSC lines shows 
there is promise that one of the lines will be useful in forming a stem cell-derived hepatocyte that 
can be used for drug discovery or regenerative medicine purposes. 
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